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Abstract 
Glioma  are among the most deadly types of cancer. In spite of the enormous 
improvements made in neurosurgery, chemotherapy, and radiotherapy the 
prognosis of malignant glioma has remained poor over the last decade. Such bad 
efficacy in the management of glioma is largely attribuitable to resistance to 
therapeutic drugs and to the highly invasive nature of glioma cells capable of 
diffusely infiltrating and widely migrating in the surrounding brain tissue, leading 
to restricted and incomplete surgical resection and, thus, high recurrence rates. 
MicroRNAs (miRNA) represent a novel class of small RNAs that function as 
negative regulators of gene expression, deeply involved in the pathogenesis of 
several types of cancer. Different evidences indicate that miRNAs might play a 
fundamental role in tumorigenesis, cell proliferation, migration and apoptosis. The 
objective of this study is the identification and the functional characterization of 
microRNAs and their targets involved in resistance to therapeutics drugs (TRAIL, 
temozolomide) and in tumorigenesis of glioma cells. 
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1. BACKGROUND 
 
1.1 Central nervous system tumours 
 
Tumours of the central nervous system (CNS) or gliomas are a large collection of 
primary brain tumours that have characteristics similar to glia, astrocytes and 
oligodendrocytes (and their precursors) which together support the function of 
neurons in the brain. Because these tumours arise in the central nervous system 
and affect the surrounding brain structure, patients affected commonly develop 
symptoms that include headaches, local neurologic alteration or languages 
disturbance. CNS tumours are usually detected by computed tomography (CT) 
and magnetic resonance imaging (MRI) scans (Tran and Rosenthal; 2010).  
Malignant gliomas may manifest at any age including congenital and childhood 
cases. Peak incidence is, however, in adults older than 40 years. Males are more 
frequently affected then females (Ohgaki and Kleihues; 2005, Ohgaki and 
Kleihues; 2005).  
Excepted for inherited tumour syndromes (10% of all brain tumours) the etiology 
is still largely unknown. The only unequivocal risk factor is therapeutic ionizing 
irradiation in fact children receiving prophylactic CNS irradiation for acute 
lymphatic leukemia (ALL) may develop malignant glioma. No association of 
exposure to electromagnetic fields or viral infection or diet and glioma has been 
proven so far (Ohgaki and Kleihues; 2005).   
Classification of brain tumours is based on histology and prognosis. The most 
recent classification of brain tumours is the World Health Organization (WHO) 
classification which was first formalized in 1979 and updated in 2007 (Louis et al; 
2007). In addiction to a morphological grouping of brain tumours on the basis of 
presumed histogenesis, the WHO schemes have been notable for their grading of 
individual tumour classes (I, II, III and IV) as a means of reflecting anticipated 
biological behaviour. In this way higher grade tumours, are expected to follow a 
more aggressive clinical course than their lower grade counterparts (Huse and 
Holland; 2010). The WHO scheme divides the brain tumours into astrocytic, 
oligodendroglial and mixed categories. Additionally, the presence of histological 
features such as nuclear atypia, increased proliferation, microvascular 
proliferation and necrosis typically result in higher grade classification as either 
anaplstic glioma or gliobalstoma (Figure 1).  
Grossly, glioblastoma multiforme are heterogeneous intraparenchymal masses 
that show evidence of necrosis and haemorrhage. Microscopically they consist of 
several cell types: the glioma cells proper, hyperproliferative endothelial cells, 
macrophages and trapped cells of the normal brain structures that are overrun by 
the invading glioma. The blood vessels both within and adjacent to the tumour are 
hypertrophied. Furthermore, the nuclei of tumour cells are extremely variable in 
size and shape, a characteristic called nuclear pleomorphism. Tumours cells 
characteristically invade the adjacent normal brain parenchyma, migrating through 
the white matter tracts to collect around blood vessels and neurons. The extent to 
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which these tumours invade adjacent structures is variable, at its extreme, large 
portion of the brain are diffusely infiltrated by individual tumour cells with no 
clear focus of tumour. Glioblastoma may develop from diffuse low grade or 
anaplastic astrocytomas (secondary glioblastoma), but more frequently, they 
manifest de novo, without a less malignant precursor lesion (primary 
glioblastoma) (Figure 1).  
Low grade gliomas are divided into two histological variants: astrocytomas and 
oligodendrogliomas. 
Anaplastic astrocytoma arise from low grade astrocytomas, but are diagnosed at 
first biopsy without a less malignant precursor lesion. This kind of tumor consist 
of cell with a large amounts of cytoplasm and which express the astrocyte-
spercific marker gene GFAP (GLIAL FIBRILLARY ACIDIC PROTEIN).This 
tumours tend to progress to glioblastoma. 
Anaplastic oligodendroglioma is a diffusely infiltrating tumour composed of 
oligodendroglia-like tumour cells which have small rounded nuclei a minimal 
cytoplasm and do not express GFAP, with focal or diffuse histological features of 
malignancy (Huse and Holland; 2010).  
 
 
 
Figure 1-Current World Health Organization classification for diffuse glioma and 
medulloblastoma. Adapted from (Huse and Holland; 2010) 
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1.2 Pathogenic Pathway involved in gliomagenesis 
 
Neoplastic disorders are in general genetic disease. The genetic alterations are 
associated with alteration of cell proliferation, apoptosis, senescence, migration, 
and cell-to-cell communication. Genetic alterations in malignant gliomas are 
extremely complex and diverse. However, distinct molecular pathways show 
frequent alterations: 
 
1.2.1 Altered growth factor signalling 
The genes that encode growth factors and their receptors frequently have elevated 
expression in gliomas. All grade gliomas usually display an overproduction of 
growth factor such as FGF2, CNTF and PDGF and their receptors (Noble and 
Mayer-Pröschel; 1997, Ekstrand et al; 1991). These phenomena usually happen in 
the same cell inducing an autocrine stimulation of the pathway controlled by those 
receptors. It seems that the pathways activated by these growth factors have a 
significant role in gliomagenesis. Mutations (amplification or activating mutation) 
of the gene encoding for EGF receptor have been found in most malignant 
gliomas. These mutations usually produce a constitutively active receptor in the 
absence of EGF ligand (Wong et al; 1992).  
In glioma these growth factor receptors activate several common signalling 
pathways including RAS and AKT pathway.  
The RAS pathway is one of the best-studied pathways. RAS is indirectly activated 
by tyrosine kinase receptor and is active when bound to GTP but inactive when 
the GTP is hydrolysed to GDP. In the active form RAS activates many pathways 
such as RAL, RAC and RAF pathways, which lead to the mitogen-activated 
protein kinases (MAPKs) ERK, Jun Kinase (JNK) and p38. This activated 
pathways enhance proliferation, progression through cell cycle and inhibition of 
apoptosis (Hunter; 1995).  
The pathway of AKT is also activated by tyrosine kinase receptors and is involved 
in glial differentiation. AKT is activated through phosphosohatidylinositol-3-OH 
kinase (PI(3)K) and is modulated by tumour suppressor protein PTEN. Active 
AKT enhance metabolism by activating glycogen synthase kinase 3 (GSK) and 
alter translation by activating the kinase called mammalian target of rapamycin 
(mTOR). AKT is also capable to inactivate apoptosis through inactivation of 
BAD, causing caspase activation to be inhibited. Most gliomas show mutation and 
frequent loss of expression of the PTEN gene and elevated AKT activity but the 
specific effect of AKT signalling on glial differentiation have not yet been 
investigated (Sano et al; 1999) (Figure 2A).  
 
1.2.2 Altered cell cycle arrest 
The second group of mutations found in gliomas includes those that disrupt the 
pathways involved in the control of G1 cell-cycle arrest. The retinoblastoma (Rb)  
tumour suppressor pathway has been shown to be defective in a significant 
number of high grade glioma, whether by inactivating mutations in RB1 gene 
itself or amplification of its negative regulators cyclin-dependent kinase 4 (CDK4) 
and, less frequently, CDK6. Analogously, amplification of the p53 antagonists 
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MDM2 and MDM4 have also been found in distinct subsets of TP53-intact 
glioblastomas. These tumours have mutation and/or deletion in the CDKIN2A 
locus that encodes for both INK4A and ARF, which are crucial positive regulators 
of Rb and p53 respectively. Mouse models have provide further evidence in the 
importance of the perturbance of p53 and Rb pathway in glioma pathogenesis 
demonstrating that functional loos of either Rb and p53 can directly drive glioma 
formation, decrease disease free latency and or increase tumour grade (He et al; 
1994). 
 
 
 
 
Figure 2- Schematic representation of genetic alterations occurring in glioblastoma in 
RAS/PI3K, p53 and RB signalling pathway. 
 
 
1.2.3. Invasion and cell motility 
All glial tumours are invasive. The degree of invasiveness does not necessarily 
correlate with the grade of malignancy. Low-grade astrocytomas often show 
extensive infiltration of normal brain, which limits surgical resection and 
eventually leads to recurrence and progression of the disease. The invasion of 
high-grade gliomas follows similar anatomic structures, but the dynamics of this 
process seem to be more rapid. After surgical removal of a malignant glioma, 
invariably a recurrent tumour will manifest; in more than 95% of the cases and 
frequently immediately adjacent to the resection cavity. Distant  lesions far away 
from the site of the initial tumour may also be found (Giese et al; 2003). 
The advent of gene-expression profiling has opened up the opportunity to gain 
insight into the underlying genetic basis of glioma invasion and motility (Sallinen 
et al; 2000). Because the elimination of malignant cell with an invasive phenotype 
remains an elusive therapeutic target, dedicated understanding of migratory and 
invasive molecular pathologies may be especially supportive for a new treatments 
of gliomas (Claes et al; 2007). 
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Invasion is a complex multistep process (Dear and Kefford; 1990). The initial step 
requires receptor-mediated adhesion of tumour cells to matrix proteins, followed 
by the degradation of matrix by tumour-secreted proteases and accompanied by 
biochemical processes supportive of active cell movement. Cell motility is not a 
de novo feature of cancer cells. Several cell types exhibit active movement during 
various stages of embryonic development, during wound healing, and in the 
inflammatory response. This motile behaviour is strictly controlled for this it can 
be hypothesized that the reappearance of a motile phenotype in cancer cell can be 
due by the lost of this control (Gressens; 2000).  To migrate, the cell body must 
modify its shape and stiffness to interact with the surrounding extracellular 
matrix. Cell movement necessitates a change in cell morphology: the cell becomes 
polarized and membrane protrusions develop, including the extensions of 
pseudopodia, lamellipodia and filopodia. These extensions contain filamentous 
actin and various structural and signalling proteins necessary for attachment to the 
ECM. The formation of membrane anchors allows cytoskeletal contraction, which 
finally advances a cell forward. 
 The proteolytic activity of matrix-metalloproteinases has been correlated with 
invasiveness in tumours of various tissue types and may be an important mediator 
of glioma invasion. Protease degradation of extracellular matrix creates an 
intercellular space into which invading cells can migrate by an active mechanism 
that requires membrane synthesis, receptor turnover, and rearrangement of 
cytoskeletal elements. This process also requires dissociation from adjacent cells 
and detachment from previous matrix adhesion sites.  
Glioma cells in vitro are highly migratory cells, and the migration rate of these 
cells can be profoundly regulated by extracellular matrix components. Motility 
rates positively correlate with substrate adhesion, demonstrating that matrix 
receptors, which link the cellular membrane to the extracellular space, facilitate 
migration by providing adhesion and traction on a given matrix substrate. 
Recently, a study was presented by Mariani et al who harvested 20,000 glioma 
cells by a laser-capture micro dissection technique from invaded brain as well as 
the highly cellular tumour mass of a human glioblastoma specimen. Differential 
gene-expression profiles of invading and non-invading tumour cells were 
analyzed, and some 60 candidate genes differentially expressed in invasive cells 
were identified. One gene over expressed in invasive cells was identified as P311, 
which localizes to focal adhesion areas and serves a structural function by linking 
the F-actinin bundles through a chain of linking proteins to the cell membrane. 
This process plays a critical role in cell motility. Over expression of this gene was 
confirmed in a number of glioblastoma specimens, and antisense oligonucleotide 
treatment decreased motility of glioma cells in a monolayer-migration assay. This 
demonstrates that mechanisms regulating cell motility contribute to the invasive 
phenotype of malignant gliomas (Mariani et al; 2001).  
Recently work suggest an important role in glioma cell migration and invasion 
also for protein tyrosine phosphatase (Mori et al; , Blanquart et al). 
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1.3. Protein tyrosine phosphatase in glioma 
 
As indicated before, gliomas are characterized by diffuse infiltrative growth in the 
surrounding brain parenchyma. This characteristic precludes curative treatment by 
surgery or radiotherapy alone, and together with their relative resistance to 
common chemotherapy place these tumours among the most incurable human 
malignancies (Claes et al; 2007). As described before, most of the alteration in 
glioma tumorigenesis leads to aberrant growth factor signalling and deregulation 
of cell cycle control in which, the phosphorylation of proteins on tyrosine residues 
plays a fundamental role. This reliance on protein tyrosine kinase (PTK) activity 
requires a closer look on the role played by protein tyrosine phosphatases (PTPs) 
in glioma biology. The opposing actions of PTK and PTP enzymes provide the 
cell with a functional dial that regulates the activity of mutual substrates through 
phosphorylation of tyrosine residue in a reversible manner. This phosphorylation 
itself may regulate the activity of PTKs and PTPs themselves.   
The PTP enzyme family has emerged as an important regulator of developmental 
and disease-related signalling pathways, and multiple members are directly linked 
to malformation syndromes and tumorigenesis (Hendriks et al; 2008).  Reversible 
tyrosine phosphorylation of proteins plays an important role in the regulation, 
proliferation and differentiation of cells (Tonks; 2006).  There are 107 genes in 
the human genome that belong to the PTP super family of enzymes. These super 
families have been divided into four different classes basing on the sequence 
homology of their catalytic domains. Class I comprises 38 so called ‘classical’ 
PTPs (enzymes that exclusively dephosphorylate phosphotyrosine residues, as 
well as 61 dual-specificity PTPs (DSPs). DSPs can also dephosphorylate 
phosphoserine and phosphothreonine residues. The 38 classical PTPs can be 
further subdivided into transmembrane, receptor-like (RPTPs) and non-receptor-
type PTPs. In human genome, there is only a single class II gene that encodes the 
low-molecular weight PTP, termed LMPTP, that is specific for phosphotyrosine 
residues. Class III comprises three CDC23 homologs that dephosphorylate 
tyrosine and threonine residues within cyclin-dependent kinases, which participate 
in cell cycle regulation. Class IV consists of the eyes absent (Eya) proteins, which 
recognizes phosphorylated tyrosine, or dual serine and tyrosine residues and 
function as transcriptional regulators. Each PTP class  is believed to originate 
from a distinct ancestral gene and because of similarity in the dephosphorylation 
mechanism they provide an impressive example of convergent evolution (Alonso 
et al; 2004). 
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Figure 3-Signalling pathway by tyrosine phosphatase activity: opposing action of PTK 
(protein tyrosine phosphatase) and PTP (protein tyrosine phosphatase). 
 
 
 
A common feature of the PTP class I, II and III is the PTP signature motif 
(H/V)C(X)R(S/T) in their catalytic domain. The cysteine residue is essential for 
catalytic activity; the target phosphate group is transferred from the substrate onto 
this catalytic site, producing a thiol intermediate, and is subsequently released via 
hydrolysis. The Class IV uses a slight different mechanism, in which aspartate 
instead cysteine plays a crucial role in the reaction. Outside the catalytic domain, 
PTPs are very diverse in their structure (Tabernero et al; 2008). 
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Figure 4- Domain structure of the PTP super family members implicated in glioma 
biology. 
 
 
 
 
PTPs are been studied for their role in glioma development. 15 out of 107 PTP 
genes are implicated in some way. Between these a major attention in the last year 
has been acquired by the cell surface receptor RPTP. PTP is a member of the 
PTP-like subfamily which includes PTP, PTPk, PTPd and PCP-2. The 
extracellular segment of the PTP-like RPTPs contains motifs found in cell 
adhesion molecules including a MAM (Meprin/A5-protein/PTPMu) domain, an Ig 
domain, and four FNIII repeats. PTP mediates cell-cell aggregation via 
homophilic binding (Brady-Kalnay et al; 1993, Gebbink et al; 1993). These events 
happen when PTP on the extracellular surface of one cell binds to PTP on the 
surface of an adjacent cell, forming an adhesive contact. The intracellular segment 
of PTP contains a juxtamembrane sequence with homology to cadherins and two 
conserved phosphatase domains of which only the most membrane proximal is 
catalytically active. There are different evidences that both cell adhesion and 
tyrosine phosphorylation play a role in contact inhibition of cell movement.  
Brady-Kalnay and others (Hellberg et al; 2002, Burden-Gulley and Brady-Kalnay; 
1999)  have demonstrated that PTP interacts specifically with N-cadherin, E-
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cadherin and R-cadherin and that PTP is capable to regulate N-cadherin 
dependent neurite outgrowth of retinal ganglion cells. PTP is expressed in a 
gradient both in the retina and the tecum (Burden-Gulley et al; 2002). Since the 
axon of retinal ganglion cells form the optic nerve and are the sole output from the 
retina to the brain, the expression of PTP on these cells indicate a putative role of 
PTP in axonal migration and neurite outgrowth. In addition to PTP’s role in the 
regulation of cadherin function, PTP appears to either directly or indirectly 
regulate protein Kinase C. PTP was found to interact with the scaffolding protein 
RACK1 (receptor for activated c Kinase) and this interaction is required for both 
PTP mediated neurite outgrowth and PTP mediated axon guidance of retinal 
ganglion cells (Rosdahl et al; 2002). 
PTP is expressed as a 200kDa protein that is proteolytically cleaved in the fourth 
FNIII repeat, resulting in a 100KDa extracellular fragment (E-subunit) and 
intracellular portion (P-subunit). This cleavage is mediated by a furin like protease 
in the endoplasmic reticulum during intracellular trafficking. The intracellular 
fragment of PTP translocates to the nucleus. The overexpression of full length 
PTP in glioblastoma cells suppresses cell migration and growth factor 
independent survival. Recently, it was found that full-length PTP is 
downregulated in primary human glioblastomas (Burgoyne et al; 2009, Burgoyne 
a,b et al; 2009). While overexpression of full length PTP protein reduces glioma 
cell migration (Burgoyne et al; 2009), the presence of a proteolytically cleaved 
cytoplasmatic fragment of PTP, capable to translocate to the nucleus, increases 
glioma cell migration (Burgoyne et al; 2009). This consideration implies that the 
presence of full-length PTP suppresses migration. In a recent work Phillips-
Mason and colleagues identify PKCdelta and PLCgamma1 as PTP substrates in 
tumour cells involved in regulation of PTP cell motility (Phillips-Mason et al). 
 
Figure 5- PTP structure and mechanisms of activation. PTP is cleaved by secretases to 
generate a fragment that translocates to the nucleus. 
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1.4. Glioblastoma treatments 
 
Primary brain tumours are widely regarded as being particularly resistant to the 
most commonly used antineoplastic strategies. Although surgery plays a major 
role in removing some brain tumours, often the tumour cannot be effectively 
removed. Both radiation and chemotherapy are compromised because many glial-
derived tumours seem to be particularly resistant to apoptosis following DNA 
damage and are very difficult to reach by the chemoterapic. Recently, the 
strategies used to fight primary brain tumours are based on the use of alkylalting 
agent, TRAIL and antiagiogentetic molecules. 
 
 1.4.1. Alkylating agent: temozolomide 
A new alkylating agent, temozolomide (TMZ) has been recently introduced in 
clinical trials for treatment of primary or recurrent high grade gliomas (Plowman 
et al; 1994, Stupp et al; 2005). TMZ has several advantages over other existing 
alkylating agents because its characteristic: TMZ is a small lipophilic molecule 
and it can be administrated orally and it crosses the blood brain barrier. Moreover, 
temozolomide is less toxic to the hematopoietic progenitor cells than convential 
chemotherapeutic agent because it doesn’t result in chemical cross-linking of the 
DNA strands. For all this characteristics temozolomide is a promising agent for 
the treatment of malignant gliomas (Agarwala and Kirkwood; 2000, Friedman et 
al; 2000).  
There are different evidences which demonstrate that temozolomide improves 
median survival and increases the likelihood of long-term survival when given 
currently with radiotherapy and then following radiotherapy, instead of 
radiotherapy alone following by surgical resection (Stupp et al; 2005). The 
cytotoxicity of TMZ has been investigated and recent report suggest that cells 
treated with temozolomide underwent autophagy cell death and not apoptosis 
(Kanzawa et al; 2004).  
O6-methylguanine DNA methyltransferase (MGMT) is a key enzyme in the DNA 
repair network that remove mutagenic, cytotoxic adducts from O6-guanine in 
DNA, the preferred point of attack of alkylating agents. This transfer irreversibly 
inactivates MGMT. Accordingly, MGMT knockout mice are hypersensitive 
against alkylating drugs, including TMZ, and depletion of the enzyme by the 
substrate analog O8-benzylguanine increased the sensitivity of glioma cells 
against alkylating drugs (Bobola et al; 2004, Liu and Gerson; 2006, Friedman et 
al; 2002). A direct relationship between MGMT activity and resistance to 
alkylating agents has also been observed in cell lines and xenografts derived from 
a variety of human tumours, including gliomas (Esteller et al; 2001) .Therefore, 
adjuvant chemotherapy based on temozolomide is limited by the action of this 
enzyme, resulting in the very poor survival of glioblastoma patients. 
The loss of MGMT expression is commonly attributable to deletion, mutation, or 
rearrangement of MGMT gene or messenger MGMT instability. MGMT activity 
is frequently lost in the presence of CpG island hypermetylation in the promoter 
region of certain types of human primary neoplasma, including gliomas. 
Therefore, the methylation status of the MGMT promoter was considered to be 
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indicative of a good outcome in patients with malignant gliomas treated with an 
alkylating agent. The most concing data were provided by Hegi et al (Hegi et al; 
2005), who investigated the MGMT methylation status in a large cohort of 
glioblastoma by comparing patients receiving either radiotherapy alone or 
radiotherapy combined with concomitant and adjuvant TMZ. Patients with 
methylated MGMT tumours benefited the most from the addition of TMZ, while 
those with unmethylated MGMT tumours showed only a non significant 
improvement in survival with TMZ. 
 
 
 
1.4.2. Reactivation of apoptosis: TNF-related apoptosis-inducing ligand 
(TRAIL) 
In recent years, a variety of cancer-specific molecular aberration have been 
identified and explored as potential targets for treatment of patients with 
glioblastoma. A novel interesting therapeutic approach is the reactivation of 
apoptosis using member of TNF (tumor necrosis factor) -family, of which TRAIL 
hold the greatest interest.  TRAIL is a relatively new member of the TNF family 
known to induce apoptosis in a variety of cancers (Schaefer et al; 2007).   
TRAIL is an effector molecule involved in immune surveillance by T cell 
population and NK cells. TRAIL is important for the elimination of virally 
infected and cancer cells (Hayakawa et al; 2004, Janssen; 2003). 
TRAIL is normally expressed on both normal and tumour cells as a 
transmembrane protein. In addition, a soluble form of TRAIL can be generated 
due to alternative mRNA splicing or proteolytic cleavage of the membrane form. 
This molecule acts through four distinct membrane receptors, designed TRAIL-
R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4. Of these receptors, only TRAIL-R1 
and TRAIL-R2 are functional and transmit the apoptotic signal. These two 
receptors belong to a subgroup of the TNF receptor family called the death-
receptor, and contain the intracellular domain (DD). This domain is critical for the 
activation of apoptotic signalling of the receptor. 
TRAIL, binding one of the two receptors, activates the extrinsic pathway of 
apoptosis. The activate receptor recruit and activate caspase-8 or -10 through the 
adaptor protein Fas-associated death domain (FADD; also known as MORT1) at 
the cell surface. This protein complex is often called the DISC, or Death Inducing 
Signalling Complex. This recruitment causes subsequent activation of 
downstream (effector) caspases such as caspase-3, -6 or -7, without any 
involvement of the BCL-2 family. In some cells, most notably hepatocytes, the 
extrinsic pathway can intersect the intrinsic pathway through caspase-8 cleavage-
mediated activation of the pro-apoptotic BH3-only protein BID. The C-terminal 
truncated form of BID (tBID) translocates to mitochondria and promotes further 
caspase activation (caspase-9 and the effector caspases caspase-3, -6 and -7) 
through the intrinsic pathway. In these situations, loss of BID or overexpression of 
BCL-XL inhibits cell death (Walczak and Krammer; 2000). 
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Figure 6- The intrinsic and extrinsic pathway of apoptosis. These two major signalling 
pathways converge at the level of the effector caspase, 
 
 
 
Treatment with TRAIL induces programmed cell death in a wide range of 
transformed cells, both in vivo and in vitro, without producing significant effects 
in normal cells (Schaefer et al; 2007, Falschlehner et al; 2007), and for this reason 
TRAIL is in phase II/III clinical trials for different kinds of tumours. However, a 
significant proportion of human cancer cells are resistant to TRAIL-induced 
apoptosis, and the mechanisms of sensitization seem to differ among cell types. 
Different studies relate resistance to TRAIL-induced cell death to downstream 
factors. It has been shown that down-regulation of PED or cellular FLICE-like 
inhibitory protein (c-Flip) can sensitize cells to TRAIL-induced apoptosis 
(Garofalo et al; 2007, Zanca et al; 2008, Quintavalle et al; 2010). However the 
mechanism of TRAIL resistance is still largely unknown.  
 
1.4.3. Antiangiogenetic Therapy 
One of the prominent features of malignant gliomas is extensive 
neovascularisation, which is thought to provide oxygen and nutrients to rapidly 
dividing tumour cells in hypoxic tumour environments. This process is known as 
angiogenesis. Angiogenesis is regulated by several proteins that promote or 
prevent the process. During tumour progression, growth is sustained by nutrients 
and oxygen through passive diffusion. Once new blood vessels form, the tumour 
start to grow and spread faster.  In gliomas, angiogenesis is typically associated 
with an increase in vascular endothelial growth factor (VEGF), a protein that 
stimulates new blood vessel formation (Hanahan and Folkman; 1996).   
The majority of the anti-angiogenic drugs that have been evaluated in clinical 
trials to date interfere with the VEGF pathway by directly blocking ligand or 
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receptor. However, there is increasing interest in targeting proangiogenic 
molecules that function by alternative mechanisms. For example, the neuropilins 
are nontyrosine kinase receptors that are activated by VEGF binding and 
potentiate VEGFR signalling. Neuropilin-1 also facilitates HGF/SF signalling (Hu 
et al; 2007). The angiopoietins (Ang-1 and Ang-2) are involved in the stability 
and maintenance of the tumour vasculature. Binding of Ang-2 to its cognate 
receptor, Tie-2, serves to destabilize vessels, which is a requirement for 
angiogenesis to proceed. Ang-2 inhibitors are therefore of interest as therapeutic 
agents (Oliner et al; 2004). Notch inhibitors may also prove effective. Notch 
receptors on tumour endothelial cells are activated by transmembrane jagged and 
delta-like ligands on the surfaces of neighbouring cells. Inhibition of delta-like 
ligand 4 (Dll4) on endothelial cells in preclinical models promotes the growth of 
an abnormal neovasculature with reduced perfusion and tumour growth (Noguera-
Troise et al; 2006). Finally, tumour cells secrete chemokines that serve to recruit 
proangiogenic myeloid cells to the tumour. For this reason, inhibitors of specific 
chemotactic signalling may have therapeutic value. 
After bevacizumab was approved by the FDA for colon cancer, several neuro-
oncology centers began to use it to treat patients with recurrent malignant glioma, 
often in combination with irinotecan. Different reports demonstrated that 
bevacizumab therapy leads to rapid reductions in peritumoral edema, often 
permitting a decrease in dose or even cessation of corticosteroid use. These 
studies also indicated that bevacizumab treatment is well tolerated in most cases. 
The risk of intracranial haemorrhage is low. Common toxicities related to 
bevacizumab therapy in the malignant glioma population include hypertension, 
proteinuria, fatigue, thromboembolic events, and wound-healing complications 
(Pope et al; 2006, Poulsen et al; 2009, Narayana et al; 2009). 
In addition to VEGF inhibitors, small molecule inhibitors of VEGFR have been 
tested in recurrent malignant gliomas. Cediranib (AZD2171) inhibits all known 
subtypes of VEGFR and was evaluated in a phase 2 trial of patients with recurrent 
GBM. The drug was largely well tolerated, with hypertension, diarrhea, and 
fatigue as the most common adverse effects. Using dynamic contrast-enhanced 
magnetic resonance imaging (MRI) scans, the authors demonstrated that cediranib 
therapy reduced blood vessel size and permeability. In addition to VEGF or 
VEGFR inhibition, a variety of other approaches may have antiangiogenic 
activity. Because of its role in pericyte recruitment, inhibition of PDGFR may 
prove useful. Several trials of PDGFR and dually targeted VEGFR/PDGFR 
inhibitors are ongoing, as noted earlier. Although antiangiogenic therapies prolong 
PFS, further progression of disease is inevitable. Tumours that progress during 
antiangiogenic therapy cannot often be treated successfully thereafter, and most 
patients die of the disease within a few months 
Combining antiangiogenic therapy with anti-invasion therapy may therefore delay 
disease progression. Another potential mechanism of resistance to antiangiogenic 
therapies involves increased PDGF signalling. PDGF promotes stabilization of the 
neovasculature by recruiting pericytes and facilitating pericyte-endothelial cell 
interactions. 
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1.5. MicroRNAs  
 
In the last decade, many non-coding RNAs were found to regulate a wide variety 
of biological processes. Among these, microRNAs (miRNAs) are the best 
characterized. miRs are a class of endogenous non-coding RNA of 19-24 
nucleotides in length that play an important role in the negative regulation of gene 
expression blocking translation or directly cleaving the targeted mRNA. The 
biogenesis of miRNAs is a complex and coordinate process in which are involved 
different enzymes and proteins (Bartel; 2004).  
miRNAs gene encoded in the genome are transcribed into long primary miRNAs 
(pri-miRNAs) by polymerase II or in few rare case, by polymerase III (Lee et al; 
2002). Typically, pri-miRNAs display a 33bp stem and a terminal loop structure 
with flanking segment. Primary miRNA processing begins in the nucleus where 
an RNAseIII enzyme, Drosha, removes the flanking segments and 11 bp of the 
stem region, inducing the conversion of pri-miR into precursor miRNAs (pre-
miRs). Pre-miRs are 60-70nt long hairpin RNAs with 2-nt overhangs at the 3’ 
end. Pre-miRNAs are transported into the cytoplasm for further processing to 
become mature miRNAs. The transport occurs through a nuclear pore complexes 
and is mediated by the RanGTP-dependent nuclear transport receptor exportin-5 
(EXP5). EXP5 exports the pre-miRNA out of the nucleus, where hydrolysis of the 
GTP results in the release of pre-miRNA. In the cytoplasm the pre-miRNA is 
subsequently processed by Dicer, an endonuclease cypolasmic RNAse III enzyme, 
to create a mature miRNA. Dicer is a highly specific enzyme that cleaves pre-
miRNAs into 21-25 nt long miRNA duplex, of which each strand bears 5’ 
monophosphate, 3’ hydroxyl group and 3’ 2-nt overhang. Of a miRNA duplex, 
only one strand, designed the miRNA strand, is selected as the guide of the 
effector RNA-induced silencing complex (RISC). The core component of RISC is 
a member of Argonaute (Ago) subfamily proteins. During RISC loading, the 
miRNA duplexes are incorporated into Ago proteins. RISC loading is not a simple 
binding of the duplexes and Ago proteins, but also an ATP-dependent active 
process. After RISC loading, the duplex is unwound and in the complex is 
maintained only the miRNA strand (Bartel; 2004, Lee et al; 2002, Gregory and 
Shiekhattar; 2005).   
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Figure 7- Biogenesis of miRNA 
 
 
 
 
miRNA target sites lie in the 3’ untranslated region (UTR) because the movement 
of ribosome (the translation) counteracts RISC binding.  Typically, a target 
mRNA bears multiple binding sites of the same miRNA and/or several different 
miRNAs. Not all nucleotides of a miRNA contribute equally to RISC target 
recognition. The recognition of the target is largely determined by base pairing of 
nucleotides in the seed region and is enhanced by addional base-pairing in the 
middle of the 3’UTR region. The binding of RISC to 3’ UTR of mRNA, through 
the action of Ago protein, is capable of RNA cleavage, but this reaction requires 
extensive base-pairing between the miRNA strand and mRNA target. This is the 
same mechanisms used by siRNAs.  If the complementarity between the miRNA 
strand and the mRNA is limited, RISC is incapable to cleave target. In such case, 
Ago protein can recruit other factors required for translation repression and 
subsequently mRNA deadenylation/degradation (Lewis et al; 2003). To date, the 
exact mechanisms used by RISC to repress translation are subjects of debate. 
Between the mechanisms proposed at least six seems to be possible: RISC could 
induce deadenylation of mRNA which cause decrease the efficiency of translation 
by blocking mRNA circularization, RISC could block the cap at 5’ or the 
recruitment of ribosomal subunit 60S; RISC could block the initial step of 
elongation or could induce proteolysis of nascent peptides; RISC could recruits 
mRNA to processing bodies, in which mRNA is degradated or temporary stored 
in an inactive form. These models do not necessarily exclude each other (Kwak et 
al). 
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Figure 8-Various mechanisms of regulation of gene expression by RNA-induced 
silencing complex (RISC) 
 
 
 
1.6. Function of miRNA in animals 
 
1.6.1 Evolution and Physiological function 
miRNAs have key roles in the regulation of distinct processes in mammals. 
miRNAs play an evolutionarily conserved role in the development and in the 
physiological functions in animal.  
Knockout gene strategies have been used in different mammals to study the role 
of miRNAs in developmental processes. A dicer knockout was made in zebrafish 
(127) and this revealed a role of the family of miR-140 which plays a fundamental 
role in zebrafish neurogenesis. miRNAs can also control late-stage mouse 
development by miR-196 which acts upstream Hox B8 and Sonic hedgehog in 
limb development. miR-1 and miR-133 are important for muscle generation and 
differentiation of cardiomyocytes and myoblast (Chen et al; 2006). miR-181  is 
preferentially expressed in B-lymphocytes and regulates mouse hematopoietic 
lineage differentiation (Chen et al; 2004). miR-181 is also able to regulate 
homeobox proteins involved in myoblast differentiation (Naguibneva et al; 2006). 
miR-122a is highly expressed in adult livers and its expression is upregulated 
during mammalian liver development (Chang et al; 2004). miR-143 is strongly 
expressed in adipose fat tissue and is upregulated during the differentiation of 
human pre-adipocytes into adipocytes (Esau et al; 2004). MicroRna are also 
involved in skin morphogenesis for example, miR-134 acts in dendritic spine 
development (Schratt et al; 2006). 
Some miRNAs regulate diverse physiological processed, for example miR-375 is 
expressed in pancreatic islet and inhibits glucose-induced insulin secretion, or 
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miR-16 which controls the ARE-containing mRNAs. Recently, it has been found 
that some endogenous miRNAs participate in adenoviral defence mechanisms for 
example miR-32 protects human cells from retrovirus type 1. 
Some studies have established a role for miRNAs in cellular processes including 
apoptosis, proliferation, stress resistance, metabolism,  
 
1.6.2 Cancer 
Cancer is characterized by abnormally proliferative cells that undergo rapid and 
uncoordinated cell growth. Malignant cancer are able to invade adjacent tissues 
ad/or metastasize to more distant, and sometimes specific, tissues. Genes involved 
in cancer are generally classified into oncogenes or tumour suppressor genes.  
The first evidence for miRNA involvement in human cancer came from a study by 
Calin et al (Calin et al; 2002). Examining a recurring deletion at chromosome 
13q14 in the search for a tumour suppressor gene involved in chronic lymphocytic 
leukaemia (CLL). In this study was found that the region of deletion encodes two 
miRNA,miR-15a and miR-16-1.  Subsequent investigations have confirmed the 
involvement of these two miRNAs in the pathogenesis of CLL (Calin et al; 2005, 
Cimmino et al; 2005). 
To date, a lot of miRs have been characterizated for their function in cancer. 
Let-7 family contains miRNAs  that have been shown to regulate the RAS family 
of oncogenes (Johnson et al; 2005). 
Constinean et al reported, for the first time, that a miRNA by itself could induce a 
neoplastic disease (Costinean et al; 2006). In fact, by using a transgenic mouse 
model, they demonstrated that overexpression of miR-155 in B cells induce a 
lymphoma pre-B leukemia. Petrocca et al (Petrocca et al; 2008) have 
demonstrated that the miR-106b-25 cluster plays a key role in gastric cancer 
interfering with proteins involved both in cell cycle and apoptosis.  
miRNAs have an important role also in tumour metastasis. miR10-b was found to 
be highly expressed in metastatic breast cancer cells and Tavazoi et al found that 
miR-26 and miR-335, whose expression is lost in human breast cancer cells, 
modulate metastatic potential (Tavazoie et al; 2008). 
Deregulation of miRNA expression levels emerges as the main mechanism that 
triggers their loos or gain of function in cancer cells. The activation of oncogenic 
transcription factors such as MYC, represents an important mechanisms for 
altering miRNA expression. Genomic aberrations such amplification, 
chromosomal deletions, point mutations or aberrant promoter methylation might 
alter miRNA expressions. Chromosomal abnormalities can trigger oncogenic 
actions of miRNAs by modulating miRNA expression in the wrong cell type or at 
wrong time. 
Several examples of miRNAs whose expression is deregulated in human cancer 
have been reported. miR-155 is overexpressed in Hodgkin lymphoma, in pediatric 
Burkitt lymphoma and in diffuse large B-cell Lymphoma (Eis et al; 2005, Kluiver 
et al; 2005, Metzler et al; 2004) . miR-21  is upregulated in breast cancer and in 
glioblastoma, while miR-143 and miR-145 genes are significantly downregulated 
in colon cancer tissue compared with colonic mucosa (Michael et al; 
2003).Evidences now indicate that the involvement of miRNAs in cancer is much 
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more extensive than initially expected. Studies that investigated the expression of 
the entire microRNAome in various human solid tumours and hematologic 
malignancies have revealed differences in miRNA expression between neoplastic 
and normal tissues (Calin et al; 2005, Ciafrè et al; 2005, Pallante et al; 2006, 
Weber et al; 2006). These studies show that each neoplasia has a distinct miRNA 
signature that differs from that of other neoplasms and that of the normal tissue 
counterpart. Moreover, it has become clear that some miRNAs are recurrently 
deregulated in human cancer. In most case, miRNAs are upregulated or 
downregulated in all tumours suggesting a crucial role for these miRNA in 
tumorigenesis. However, there are some unusual situation: for example members 
of the miR-181 family are up-regulated in some cancers, such as thyroid (Pallante 
et al; 2006), pancreatic (He et al; 2005),and prostate carcinomas (Volinia et al; 
2006) but downregulated in others, such as glioblastomas and pituitary adenomas 
(Ciafrè et al; 2005, Bottoni et al; 2007). 
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 2. Aims of the study 
Glioblastoma are among the most deadly types of cancer. Advances in standard 
treatments for this tumour, such as surgery, radiotherapy, and chemotherapy, have 
not significantly increased patient survival. The most important issues that affect 
patient survival rate are the resistance to therapeutics drugs and the aggressive 
phenotype of glioblastoma cancer cells.  The present work aims at investigated the 
role of microRNAs in the malignancy of glioblastoma, especially the role that 
microRNAs have in regulation of proteins involved in glioma cell motility and 
tumorigenesis (Aim I) in TRAIL resistance (Aim II) and in temozolomide 
resistance (Aim III).  Therapeutic intervention, involving the use of microRNAs, 
should not only sensitize tumour cells to drug-inducing apoptosis but also inhibit 
their survival, proliferation, and invasive capabilities. It can be hypothesized 
therefore that the modulation of miRNAs might become a viable therapeutic 
strategy to sensitize cancer cells. 
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 3. Materials and Methods  
 
3.1. Cell culture and transfection. U87MG and T98G and U251 cells were 
grown in DMEM. Meg01 cells (human, chronic myelogenous leukaemia cells) 
were grown in RPMI 1640 + 2mM Glutamine + 10%FBS. Media were 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-
glutamine and 100 U/ml penicillin/streptomycin. LN229 and LN18 were grown in 
Advanced DMEM (invitrogen) + 2mM Glutamine + 5 %FBS. For miRs transient 
transfection, cells at 50% confluency were transfected using Oligofectamine 
(Invitrogen) with 100nM (final) of pre-miR-221, pre-miR-222, pre-miR-30c 
and/or miR-21, scrambled or Anti miR-222 and Anti miR-221 (Applied 
Biosystems). For PTP transient transfection, cells were transfected using 
Lipofectamine and Plus Reagent with 5g of PTP cDNA (Origene) for 24 hrs. 
To knock-down PTP gene, specific shRNA were obtained by Open Biosystems 
(Huntsville, AL, USA) and were transfected using lipofectamine 2000. After 24 
hrs the cells were treated for 24hr with 500 ng/ml of puromicine for selection of 
transfected cells. Two clones stably expressing shRNAi-PTP were obtained. 
TWEEN empty vector, TWEEN miR-221 or TWEEN miR-222 vectors, were 
obtained from Dr. Ruggero De Maria (Rome). 
 
3.2. Soft Agar Assay. 103 cells were plated in 60mm dishes in a solution 
containing DMEM 2X (Sigma), TPB Buffer (Difco), and 1,25% of Noble Agar 
(Difco). Briefly, cell were harvested and counted then a layer of 7 ml with the 
solution containing Noble Agar were left to polymerize on the bottom of the 
dishes. Then cells were resuspended in 2 ml of same solution and plated. Cells 
were left grown for 2 weeks in the incubator. 
 
3.3. Injection of glioma cells in nude mice.  Nude mice were provided by 
Charles River. 105 cells of T98G and U87MG were subcutaneously injected in 
one flank of the mice. Were injected 5 mice for each cell type. Mice were 
followed for 4 weeks and the tumours were measured and photographed. 
 
3.4. Virus production. We produced vector stocks by calcium phosphate 
transient transfection, cotransfecting three plasmids in 293 T human embryonic 
kidney cells, since these cells are good DNA recipients. The three plasmids are: 
the packaging plasmid, pCMVDR8.74 designed to provide the HIV proteins 
needed to produce the virus particle; the envelope-coding plasmid, pMD.G, for 
pseudotyping the virion with VSV-G and TWEEN miR-221 or miR-222 vector, 
the transgene coding plasmids. The calcium phosphate–DNA precipitate was 
allowed to stay on the cells for 14–16 h, after which the medium was replaced, 
collected 48 h later, centrifuged at 1000 rpm for 5 min at room temperature and 
filtered through 0.22 mm pore nitrocellulose filters. On the day of infection, the 
medium was removed and replaced with viral supernatant to which 4 mg/ml of 
Polybrene had been added. Cells were then centrifuged in their plate for 45 min in 
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a Beckman GS-6KR centrifuge, at 1800 rpm and 32°C. After centrifugation, cells 
were kept for either 1 h 15 min or ON in a 5% CO2 incubator at 32 or 37°C, 
respectively. After exposure, cells were washed twice with cold PBS and fresh 
medium added. At either 12 or 48 h after the infection, cells were washed with 
PBS, harvested with trypsin/EDTA and analyzed by FACS for GFP expression. 
The GFP positive were sorted by a FACSscan.   
 
 
3.5. Protein isolation and Western blotting. Cells were washed twice in ice-cold 
PBS, and lysed in JS buffer (50 mM HEPES pH 7.5  containing 150 mM NaCl, 
1% Glycerol, 1% Triton X100, 1.5mM MgCl2, 5mM EGTA, 1 mM Na3VO4, and 
1X protease inhibitor cocktail). Protein concentration was determined by the 
Bradford assay (BioRad) using bovine serum albumin as the standard, and equal 
amounts of proteins were analyzed by SDS-PAGE (12.5% acrylamide). Gels were 
electroblotted onto nitrocellulose membranes (Millipore, Bedford, MA). For 
immunoblot experiments, membranes were blocked for 1 hr with 5% non-fat dry 
milk in Tris Buffered Saline (TBS) containing 0.1% Tween-20, and incubated at 
4°C over night with primary antibody. Detection was performed by peroxidase-
conjugated secondary antibodies using the enhanced chemiluminescence system 
(Amersham-Pharmacia Biosciences). Primary antibodies used were: anti-PTP 
(SantaCruz), anti-Actin (Sigma), Ser P-AKT (Promega), and anti-p27, -AKT, 
and -PTEN (Cell Signaling), anti-PTEN (Cell Signalling), anti-p85 (Cell 
Signalling), anti-p53 (Cell Signalling) and anti-Caspase 3, -Tap63 and –Atg5 were 
from Santa Cruz. 
. 
 
3.6. miRNA Microarray experiments- 5 μg of total RNA from each sample was 
reverse transcribed using biotin end labelled random-octamer oligonucleotide 
primer.  Hybridization of biotinlabeled complementary DNA was performed on a 
new Ohio State University custom miRNA microarray chip (OSU_CCC version 
3.0), which contains 1150 miRNA probes, including 326 human and 249 mouse 
miRNA genes, spotted in duplicates. The hybridized chips were washed and 
processed to detect biotin-containing transcripts by streptavidin-Alexa647 
conjugate and scanned on an Axon 4000B microarray scanner (Axon Instruments, 
Sunnyvale, Calif ).  
Raw data were normalized and analyzed with GENESPRING 7,2 software 
(zcomSilicon Genetics, Redwood City, CA). Expression data were median-
centered by using both the GENESPRING normalization option and the global 
median normalization of the BIOCONDUCTOR package (www.bioconductor.org 
) with similar results. Statistical comparisons were done by using the 
GENESPRING ANOVA tool, predictive analysis of microarray (PAM) and the 
significance analysis of microarray (SAM) software (http://www-
stat.stanford.edu/~tibs/SAM/index.html).  
3.7. Glioma cancer samples- A total of 18 paraffined high grade glioma samples 
were collected at the Federico II University of Naples, Italy at the University 
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Hospital of Gregorio Marañon, Madrid, Spain. RNA was isolated with 
RecoverALLTM Total Nucleic Acid Isolation kit from Ambion (Ambion Inc, 
Austin Texas). The samples were stored at -80°C.  
3.8. RNA extraction and Real-Time PCR- Total RNAs (miRNA and mRNA) 
were extracted using Trizol (Invitrogen) according to the manufacturer’s protocol. 
Reverse transcription of total miRNA was performed  starting from equal amounts 
of total RNA/sample (1g) using miScript reverse Transcription Kit (Qiagen), for 
mRNA was used SuperScript® III Reverse Transcriptase (Invitrogen). For 
cultured cells, quantitative analysis of PTP, Caspase-3, MGMT, -Actin (as an 
internal reference), miR-221/222, and RNU5A (as an internal reference) were 
performed by RealTime PCR using specific primers (Qiagen), miScript SYBR 
Green PCR Kit (Qiagen), and iQTM SYBR Green Supermix (Biorad), respectively. 
The reaction for detection of mRNAs was performed as follow: 95°C for 15’, 40 
cycles of 94°C for 15’’, 60°C for 30’’ and 72°C for 30’’. The reaction for 
detection of miRNAs was performed as follow: 95°C for 15’, 40 cycles of 94°C 
for 15’’, 55°C for 30’’ and 70°C for 30’’.  All reactions were run in triplicate. The 
threshold cycle (CT) is defined as the fractional cycle number at which the 
fluorescence passes the fixed threshold. For relative quantization the 2(-CT) 
method was used as previously described (Livak and Schmittgen; 2001). 
Experiments were carried out in triplicate for each data point, and data analysis 
was performed by using software (Bio-Rad). 
     
3.9. Luciferase assay- The 3’ UTR of the human PTP, Caspase-3 and MGMT  
genes were PCR amplified using the following primers: PTP Fw: 5’-
TCTAGACGAGGTGGCCCTGGAATACTTGAATTCT-3’ , PTP Rv 5’-
TCTAGAGCATTTTGTGAATGAGTCCTCCCCCAA-3’, Caspase-3 Fw: 5’ 
TCTAGAAGGGCGCCATCGCCAAGTAAGAAA 3’, Caspase-3 Rv : 5’ 
TCTAGACCCGTGAAATGTCATACTGACAG 3’ ; MGMT Fw: 5’ 
TCTAGAGTATGTGCAGTAGGATGGATG 3’ , MGMT Rv: 5’ 
TCCAGAGCTACAGGTTTCCCTTCC 3’ and cloned downstream of the Renilla 
luciferase stop codon in pGL3 control vector (Promega). This construct were used 
to generate, by inverse PCR, the UTRmut-PTP plasmid (primers:  PTP -mut: 
Fw 5’-GCATAATATATGCTTGCTTTCCAGGACTAACAGATAAATGTG-3’; 
Rv 5-’ CACATTTATCTGTTAGTCCTGGAAAGCAAGCATATATTATGC-3’) 
and the UTRmut-MGMT (primers: MGMT-mut Fw  5’ 
CTATATCCAAAAGGGAAACCTGTAGCTCTTGC 3’ RV 5’ 
GCAGAGCTACACGTTTCCCTTTTGGATATAG 3’).  MeG01 cells were 
cotransfected with 1μg of each generated plasmid and 1 μg of a Renilla luciferase 
expression construct pRL-TK (Promega) with Lipofectamine 2000 (Invitrogen). 
Cells were harvested 24 h post-transfection and assayed with Dual Luciferase 
Assay (Promega) according to the manufacturer’s instructions. Three independent 
experiments were performed in triplicate.  
 
 
28
 
3.10 MiRNA locked nucleic acid in situ hybridization of formalin fixed, 
paraffin-embedded tissue section- In situ hybridization (ISH) was carried out on 
deparaffinized human glioma tissues using previously published protocol (Nuovo 
et al; 2009), which includes a digestion in pepsin (1.3 mg/ml) for 30 minutes.  The 
sequences of the probes containing the six dispersed locked nucleic acid (LNA) 
modified bases with digoxigenin conjugated to the 5’ end were: miR-221-(5’) 
GAAACCCAGCAGACAATGTAGCT; miR-222(5’) 
ACCCAGTAGCCAGATGTAGCT.  The probe cocktail and tissue miRNA were 
co-denatured at 60˚C for 5 minutes, followed by hybridization at 37°C overnight 
and a low stringency wash in 0.2X SSC and 2% bovine serum albumin at 4°C for 
10 minutes. The probe-target complex was seen due to the action of alkaline 
phosphatase on the chromogen nitroblue tetrazolium and bromochloroindolyl 
phosphate (NBT/BCIP). Negative controls included the use of a probe which 
should yield a negative result in such tissues.  No counter stain was used, to 
facilitate co-labelling for PTP  protein.  After in situ hybridization for the 
miRNAs, as previously described (Nuovo et al; 2009), the slides were analyzed 
for immunohistochemistry using the optimal conditions for PTP (1:200, cell 
conditioning for 30 minutes).  For the immunohistochemistry, we used the 
Ultrasensitive Universal Fast Red system from Ventana Medical Systems.  We 
used glioma tissues as controls for these proteins.  The percentage of tumour cells 
expressing PTP and miR-221 and -222 was then analyzed with emphasis on co-
localization of the respective targets. 
 
3.11. Migration assay- Transwell Permeable Supports, 6.5 mm diameter inserts, 
8.0 µM pore size, polycarbonate membrane (Corning Incorporate, Corning, NY, 
USA) were used to perform migration assay. T98G and U87MG cells were grown 
as indicated above, then harvested by TrypLETM Express (Invitrogen, Carlsbad, 
CA, USA) and 105 cells were washed three times and then resuspended in 1% 
FBS containing DMEM medium and seeded in the upper chamber. Lower 
chamber of the transwell was filled with 600 µl of culture medium containing 
10% FBS, 5 µg/ml fibronectin, as an adhesive substrate. Cells were incubated at 
37°C for 24 h. The transwell were then removed from the 24-well plates and 
stained with 0.1% Crystal Violet in 25% methanol. Nonmigrated cells were 
scraped off  the top of the transwell with a cotton swab. % of migrated cells was 
evaluated by eluting crystal violet with 1% SDS and reading the absorbance at λ 
570 nm.  
 
3.12. Cell death quantification. Cells were plated in 96-well plates in triplicate, 
stimulated and incubated at 37°C in a 5% CO2 incubator. TRAIL was used at final 
concentration of 100 ng/ml for 24hr. Temozolomide was use at final concentration 
of 300 Mol for 48 hrs. Apoptosis was analyzed via propidium iodide 
incorporation in permeabilized cells by flow cytometry. The cells (2 × 105) were 
washed in PBS and resuspended in 200 μl of a solution containing 0.1% sodium 
citrate, 0.1% Triton X-100 and 50 μg/ml propidium iodide (Sigma). Following 
incubation at 4°C for 30 min in the dark, nuclei were analyzed with a Becton 
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Dickinson FACScan flow cytometer. Cellular debris was excluded from analyses 
by raising the forward scatter threshold, and the DNA content of the nuclei was 
registered on a logarithmic scale. The percentage of elements in the hypodiploid 
region was calculated. Cell viability was evaluated with the CellTiter 96 AQueous 
One Solution Cell Proliferation Assay (Promega) according to the manufacturer's 
protocol. Metabolically active cells were detected by adding 20 μL of MTS to 
each well. After 2 h of incubation, the plates were analyzed in a Multilabel 
Counter (BioTek). 
 
3.13. Colony Assay. Cells were transfected with miR-scrambled, miR-30b and 
miR-21 for 24 hrs, then were harvested and 2.4 X 10*4 cells were plated in six 
well plates. After 24 hr, cells were treated with 50 and 100 ng/ml of superKiller 
TRAIL for 24 hr. Cells were transferred to 100 mm dishes and let grown for 6 
day. After these period the cells were coloured with 01%crystal violet dissolved in 
methanol 25% solution for 20 min at 4°C. Dishes were washed with water and 
then let dry on bench.  
 
3.14. Statistical analysis. Continuous variables are expressed as mean values ± 
SD. One-tailed Student's t test was used to compare values of test and control 
samples. P < 0.05 was considered significant    
 
 
 
 
  
. 
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4. Aim I: Identification and characterization of miRNAs involved in glioma 
tumorigenesis 
 
 
 
Results 
 
4.1. miRs expression in glioma cell lines-  T98G and U87MG glioma cells have 
been described as having a different tumorigenic behaviour (Cerchia et al; 2009). 
In fact, while T98G are not able to grow in nude mice and to form colonies, 
U87MG, LN18 and LN229 cells form tumours when injected in mice and form 
colonies in soft agar, even in the absence of serum. We confirmed these data using 
soft agar and xenograft growth in nude mice (figure 10). In order to investigate the 
involvement of miR in glioma tumorigenesis, we analyzed miR expression profile 
in the tumorigenic glioma cell U87MG versus non-tumorigenic T98G cell. The 
analysis was performed with a microarray chip containing 1150 miR probes, 
including 326 human and 249 mouse miRs, spotted in duplicates (He et al; 2005). 
Pairwise significance analysis (PAM) of the microarray indicated that five miR 
genes were significantly overexpressed in tumorigenic cells with a >2.5-fold 
change (Table 1). We focus our attention on miR-221 and miR-222, since we and 
others have already demonstrated that those miRs are frequently overexpressed in 
a number of human tumours (Pallante et al; 2006, Conti et al; 2009, Pineau et al; 
2010).  
In order of confirm the array results, we analyzed the levels of miR-222 and -221 
in T98G, U87MG, LN18 and LN229 cells with Real-time PCR. Accordingly with 
microarray data, we found an up-regulation of these two miRs in tumorigenic cells 
(U87MG, LN18 and LN229) compared to T98G cells (Figure 11A). As expected, 
the predicted miR-221 and -222 targets, p27kip1 and PTEN, were expressed at 
decreased levels in U87MG cells (Figure 11B) as compared to T98G cells. In 
order to verify the involvement of these miRs in glioma tumorigenesis we 
transfected the T98G cell lines with  pre-miR-221 and pre-miR-222 and with a 
scrambled sequence, and U87MG with anti-miR negative control and anti-miR-
221 and 222. As shown in figure 11B by soft agar assay we found that in non 
tumorigenic T98G cell lines overexpressing miR-221 and -222 there was an 
increase of colony number while in the tumorigenic U87MG overexpressing anti-
miR-221 and -222 there was a decrease of colony number. 
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miR Intensities of 
U87MG 
Intensities of 
T98G 
Fold change 
hsa-miR-221 11150.1 1763.5 6.323 
hsa-miR-125b 4697.4 1020.4 4.603 
hsa-miR-21 6236.3 1662.4 3.751 
hsa-miR-222 16685.8 6014 2.774 
hsa-miR-34a 319.1 26.7 11.951 
 
Table 1- All differentially expressed miRs have q <0.01 (false positive rate). T test 
p<0.05. These miRs were identified by PAM as predictor of glioma cells with the lowest 
misclassification error.  
 
 
Figure 9- Upper panel. U87MG and T98G were plated in soft agar for two weeks and 
photographed. Lower panel U87MG and T98G were injected in nude mice and tumors 
were monitored for 4 weeks.  
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Figure 10- Expression of miR-222 and -221 and their targets in T98G and U87MG 
glioma cells. (A) Real time PCR of miR-221 and -222 in glioma cells. Representative of 
at least three independent experiments. (B) Western blot analysis of the known miR-221 
and -222 targets, PTEN and p27kip1. As a consequence of decreased PTEN protein levels, 
p-AKT levels were increased, although total AKT levels were comparable. -Actin was 
used as the loading control. (C) Soft agar growth of T98G transfected with pre-miR-221 
and 222 or negative control and of U87MG transfected with Anti-miR-221 and 222 and 
with a negative control. 
 
 

4.2. Identification of PTP as a new target of miR-221 and -222- To find new 
miR-221 and -222 targets, we used bioinformatics analysis. Comparing the results 
obtained from the different searches, we found that the protein phosphatase PTP 
was predicted as a target of miR-222 by the miRanda algorithm. RNAhybrid also 
predicted a possible binding region of miR-221 and -222 in the 3’UTR of PTP 
(Figure 12A).  The most widely used approach for experimentally validating 
miRNA targets is to clone the predicted miRNA-binding sequence downstream of 
a luciferase reporter construct, and to cotransfect it with the miRNA of interest for 
luciferase assays. To this end, we cloned the 3’UTR sequence of human PTP 
into the luciferase expressing vector pGL3-control downstream of the luciferase 
stop codon; Meg01 cells were transiently transfected with this construct in the 
presence of pre-miR-221 and pre-miR222 or in the presence of a scrambled 
oligonucleotide acting as a negative control. As reported in Figure 12B, miR-221 
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and miR-222 significantly reduced luciferase activity compared to the scrambled 
oligonucleotide. This indicates that miR-221 and -222 bind to the 3’UTR of ptpm 
and impair its mRNA translation. In order to determine that the region was 
specific for the binding with miR-222 and -221, we generated a deletion mutant 
(Figure 12C) lacking the binding site, ATGTAGC.  The mutant was cloned into 
the 3’UTR of the luciferase gene and cotransfected with pre-miR-221 and -222 in 
Meg01 cells. As shown in Figure 12D, miR-221 and -222 did not significantly 
reduce luciferase activity in the presence of the 3’UTR PTP -mut sequence. This 
result indicates that miR-221 and -222 target PTP mRNA at the ATGTAGC 
sequence. 
 
 
 
 
 
Figure 11- Identification of target sites in the 3’-UTR of PTP. Complementary sites 
for miR-222 and -221 on wild type (A) or mutated (C) PTP 3′UTR. The capital letters 
identify perfect base matches according to  miRanda software. The bold letters identify 
the deleted regions. For luciferase activity, Meg01 cells were transiently cotransfected 
with the luciferase reporter containing wild type PTP3′UTR  or PTP-3′UTR mutant 
(D) in the presence of pre-miR-222, miR-221 or scrambled oligonucleotide. Luciferase 
activity was evaluated 24 h after transfection as described in Materials and Methods. 
Representative of at least three independent experiments. 
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4.3. Expression of PTP and miR-222 and -221 in glioma- To assess whether 
the expression of PTP was inversely correlated with miR-221 and -222 in glioma 
cells, we analyzed the levels of the protein phosphatase in U87MG, LN18, LN229 
and T98G cells. We found reduced PTPprotein (Figure 13A) and mRNA levels 
(Figure 13B) in U87MG, LN18 and LN229 cells overexpressing miR-221 and -
222 compared with T98G. In order to establish a causative link with miRs-222 
and -221 and PTP, we stably infected T98G cells with a Tween lentiviral 
construct expressing miR-221 and -222, and then analyzed PTP protein and 
mRNA levels. miR expression in infected cells were monitored by RT-PCR 
(Figure 13C). We observed decreased PTP protein (Figure 13D) and mRNA 
expression levels (Figure 13E) in miR-222 and -221 stably expressing cells. The 
same effect was observed in T98G cells transiently transfected with a synthetic 
pre-miR-222 and miR-221 (Figure 13 G,H). The efficiency of miR expression 
upon transfection was monitored by RT-PCR (Figure 13F). Consistently with 
these data, U87-MG cells transfected with the anti-miR-222 and -221 showed an 
increase of PTP protein (Figure 14 A) and RNA levels (Figure 14 B). The 
efficiency of miR down-regulation upon anti-miR transfection was monitored by 
RT-PCR (Figure 14 C).   
 
 
 
Figure 12- PTP and miR-222/221 expression levels are inversely correlated in 
glioma. PTP protein (A) and RNA (B) expression levels in T98G and U87MG cells. 
Cell lysates were immunoblotted with anti-PTP antibody. To confirm equal loading, the 
membrane was immunoblotted with anti–β-Actin antibody. Effect of miR transfection on 
PTP expression: miR-222 and -221 constitutive (C) or transient (F) expression in 
glioma cells induced a decrease of PTP protein (D, G) and RNA (E, H) expression 
levels. Relative expressions of mRNA and miR-221 were calculated using the 
comparative CT methods. Columns, mean of four different experiments; bars, SD.  
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Figure 13- Effects of Anti miR-222 and -221 on PTP expression levels in glioma. 
PTP protein (A) and RNA (B) expression levels in U87MG cells transfected with anti 
miR-222, -221 or control scrambled (scr). The Anti-miRs were able to increase PTP 
expression levels. (C) Anti-miR transfection reduced miR levels as analyzed by Real time 
PCR. Columns, mean of four different experiments; bars, SD. 
 
 
 
4.4. miR-221 and -222 regulates cell motility in glioma cells- We hypothesized 
that miR-221 and -222 promote cell migration by regulating PTPexpression. To 
this end, we analyzed cell motility through a transwell assay in U87MG,LN18. 
LnN229, T98G parental cells, and T98G transduced with control vector (T98G-
tween), or lenti-miR221 and -222 vector (T98G miR-221 and T98G miR-222). As 
shown in Figure 15A, U87MG, LN18 and LN229 cells have an higher migration 
rate than T98G. The up-regulation of miR-221/222 in T98G induces an increase 
of cell motility. The same result was obtained in T98G cells transiently transfected 
with miR-221/222 (Figure 15B). Conversely, expression of anti-miR-222 was 
able to reduce cell migration of U87MG (Figure 15B). We also tested the effects 
of miRs or anti-miR expression on cell adhesion, obtaining the same results (data 
not shown). Furthermore, transfection of specific  PTP shRNAi  in T98G cells 
induced a strong reduction of PTP expression levels and at the same time an 
increase of cell motility while overexpression PTP cDNA  in U87MG induced a 
decrease of cell motility (Figure 15C). This result demonstrates strongly that 
PTP protein is able to control cell motility in glioma cells, as reported by other 
authors (Burgoyne et al; 2009). miRs may target different proteins. In order to 
demonstrate that migration/adhesion effects observed were carried out by PTP, 
we transfected T98G tween, tween-221 and tween 222 with ectopic PTP cDNA 
lacking the miRNA binding site in its 3'UTR, before assaying migration and 
adhesion. Levels of transfected PTP were analyzed by western blot. 
Interestingly, transfection of PTP in miR-221 and -222 overexpressing U87MG 
cells was able to overcome the effects of both miRs (Figure 15 C). These rescue 
experiments proved the causative connection between miR-222, PTP and glioma 
cell motility. 
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Figure 14- Effects of miR-222 and-221 on cell migration and adhesion. T98G glioma 
cells showed lower migration compared to U87MG, LN18, LN229 cells (A), whereas 
T98G cells stably (A) or transiently (B) transduced with miR-222 and -221 exhibited 
increased migration levels. Transfection of PTP cDNA in miR-222 and -221 
overexpressing cells was able to rescue the effect of both miRs on invasion (C), whereas 
T98G transfected with two different PTPshRNAi (#1, #2) exhibited higher migration 
compared to control scrambled shRNA (shRNAi) (C). Each assay was performed three 
times in independent experiments (n=3). Error bars indicate standard deviation. 
 
 
 
 
 
4.5. miR-222 and PTP mRNA levels in glioma- To evaluate whether PTP 
downregulation in glioma was related to increased miR-222 and -221 levels also 
in vivo, we analyzed  PTP and miR-222 -221 expression levels in tumour tissue 
specimens collected from 18 glioblastoma grade IV patients. As shown in Figure 
16, we found an inverse correlation between miR-222 and -221 levels and PTP 
in all glioma samples analyzed.  To investigate the inverse relation between miR-
221/222 and PTPμ in vivo, in situ hybridization analysis was performed using 5’-
 
37
 
digoxigenin-labeled LNA (locked nucleic acid) probes on 66 glioma cancers 
(table 2), followed by immunohistochemical detection of co-expression of PTPμ. 
As shown in figure 17A, miR-222 was abundantly expressed in cancers and rarely 
found in normal cells. No co-expression was found with PTPμ. Same result was 
obtained for miR-221 (data not shown). Importantly, was evident that miR-
221/222 were abundantly expressed in the aggressive and metastatic cancers by 
comparing grade IV glioblastoma with oligodendroglioma, a slowly growing 
glioma (Figure17). Conversely, PTPμ was highly expressed in oligodendroglioma 
and normal brain compared to grade IV glioblastoma. 
. 
 
 
 
 
 
Figure 15 -Correlation of endogenous miR-222 and PTP mRNA expression levels 
in human glioma- Total RNA extracted from tissue specimens collected from 18 high 
grade glioma-affected individuals was used to analyze miR-222/221 and PTP mRNA 
expression by real-time PCR. In each sample, an inverse correlation between miR-221 
and -222 with PTPwas observed.  
 
 
 
 
 Grade I and II Astrocitomas 
N=26 
Grade III and IV 
Glioblastomas 
          N=40  
Total gliomas 
      N=66 
miR-222 + 13 (50%) 26 (65%) 39 (59%) 
PTP 9 (34%) 15 (37%) 24 (36%) 
Table 2-Results of miR-222 in situ hybridization  and PTP immunohistochemestry on 
66 gliomas (26 Grade I and II, 40 Grade III and IV). N= inicates the number of sample 
analyzed. 
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Figure 17- Correlation of miR-222/PTPμ co-expession analyses. (A) 66 glioma cancer 
tissues on a TMA were analyzed for miR-222 expression by in situ hybridization and then 
for PTPμ, respectively, by immunohistochemistry.  Panel A shows miR-222 signal 
(fluorescent blue) and panel B is the PTPμ signal (fluorescent red) in a grade IV 
glioblastoma.  Panel C shows the mixed signal in which fluorescent yellow is indicative 
of miR and protein co-expression; note the lack of miR-222 and PTPμ co-expression. 
Panel D shows the RGB image of the in situ hybridization/immunohistochemical reaction 
shown in panels b-d. (B) In the normal brain one sees the miR-222 signal (fluorescent 
blue) in panel e and the PTPμ image as fluorescent red (panel f). As described in the text, 
the majority of normal brain were negative for miR-222 (panel e) and positive for PTPμ 
(panel f). Panel g shows the mixed signal in which fluorescent yellow is indicative of miR 
and protein co-expression. Panel h shows the RGB image of the in situ 
hybridization/immunohistochemical reaction shown in panels e-g. (C) Finally, on 4 
oligodendrogliomas, only 1/4 was miR-222+ and 4/4 were PTP positive. Panel a shows 
miR-222 signal (fluorescent blue) and panel b is the PTPμ signal (fluorescent red). Panel 
c shows the mixed signal in which fluorescent yellow is indicative of miR and protein co-
expression; note the lack of miR-222 and PTPμ co-expression. Panel d shows the RGB 
image of the in situ hybridization/immunohistochemical reaction shown in panels b-d. 
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5. Aim II: identification of miRNAs involved in TRAIL resistance in human 
glioma 
 
5.1. Selection of TRAIL sensitive vs. TRAIL resistant glioma cell lines- We 
analyzed TRAIL sensitivity of different human glioma cell lines, as shown in 
Figure 18. Cells were exposed to TRAIL for 24 hours after which cell death was 
assessed using an MTT assay or by FACS with annexin V and propidium iodide 
staining. As shown in Figure 18, we can distinguish two set of cells: TB10, 
LN229, U251, U87 cells did not display sensitivity when exposed to soluble 
TRAIL, whereas T98G and LN18 cells underwent to TRAIL-induced cell death. 
 
 
 
Figure 16- Glioblastoma cell lines TRAIL sensitivity- Glioblastoma cell lines were 
treated for 24 hrs with superKiller-TRAIL then, cell vitality was assessed with MTT 
assay. 
 
 
5.2. miRs expression screening in TRAIL resistant vs. sensitive glioma cell 
lines- To investigate the involvement of miRs in TRAIL resistance in 
glioblastoma cell lines, we  analyzed the miRs expression profile in TRAIL-
resistant versus TRAIL sensitive cells. The analysis was performed with a 
microarray chip containing 1150 miR probes, including 326 human and 249 
mouse miRs, spotted in duplicates, in collaboration with the lab of Prof. Carlo 
Croce . Data obtained comparing TB10 and LN229 vs. T98G and LN18 cells, 
indicated that seven miR genes were significantly overexpressed in resistant 
glioma cells (TB10 and LN229) with a >1.9-fold change (Table 3). Quantitative 
Real-Time-polymerase chain reaction (qRT-PCR) validated the microarray 
analysis. 
We tested the all indicated miRs for involvement in TRAIL resistance obtaining 
significantly results only for miR-30 family and miR-21 that was extensively 
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investigated. 
 
 
 
Table 3- All differentially expressed miRs have q<0.01 (false positive rate). T test 
p<0.05. These miRs were identified by PAM as predictor of glioma cells with the lowest 
misclassification error.  
 
 
 
5.3. Role of miRs in TRAIL resistance in glioma- In order to test the role of 
these overexpressed miRs in TRAIL sensitivity in glioma, we transfected T98G 
TRAIL-sensitive cells with pre-miR-21, -30b, and -30c. TRAIL sensitivity will be 
evaluated by MTT assay and propidium iodide staining, and colony assay. Data 
obtained with FACS analysis showed that miR-30b, -30c and -21 transfection 
induced TRAIL resistance (Figure 19A-B). In order of further evaluate TRAIL 
sensitivity, we planed to set up colony assays. Cells were transfected with miR-
scrambled, miR-30b and miR-21 for 24 hrs, then were harvested and 2.4 X 10*4 
cells were plated in six well plates. After 24 hr, cells were treated with 50 and 100 
ng/ml of superKiller TRAIL for 24 hr. Cells were let grown for 6 day and then 
coloured with crystal violet-methanol solution.  As shown in Figure 19C cells 
transfected with miR-30b and miR-21 are more sensitive to TRAIL treatment. 
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Figure 17-miRs-21 and -30b/c confer TRAIL resistance. (A) T98G cell lines were 
transfected with miR-21, miR-30b and miR-30c. Cells were then treated with two 
different concentration of superKiller TRAIL for 24 hrs. Cell viability was assessed with 
MTT assay and with propidium iodide staining (B). (C) Colony assay of T98G cell lines 
transfected with a scrambled sequence as negative control and with miR-30c or miR-21 
and then treated with two different doses of superKiller TRAIL as indicated.  
 
 
5.4. Identification of cellular targets of miR-30c and miR-21 in glioma cells- 
A bioinformatics search was used as first attempt using programs available on the 
web including Pictar, TargetScan, miRanda, and Microcosm target. Comparing 
the results obtained from the different searches, we found several potential 
interesting targets of miR-30b, -30c and miR-21 that will be further characterized. 
miR-21 targets different tumor suppressor genes in glioblastoma cells such as 
PTEN (phosphatase and tensin homologue), PDCD4 (programmed cell death 4), 
TPM1 (Tropomyosin 1) and p53. Although those have been already described as 
miR-21 targets, their role in TRAIL resistance has not been already described. As 
shown in Figure 20, miR-21 transfection induced a reduction of PTEN, p53 and 
caspase 3 (already published target) but also p85, the regulatory subunit of PI3K 
(unpublished target).   
We also evaluated the effects of miR-30 on some of the putative targets and found 
that miR-30 transfection induced a reduction of caspase 3  protein levels (Figure 
21). Furthermore we cloned the 3’UTR sequence of caspase 3 into the luciferase 
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expressing vector pGL3-control downstream of the luciferase stop codon; Meg01 
cells were transiently transfected with this construct in the presence of pre-miR-
30c or in the presence of a scrambled oligonucleotide acting as a negative control. 
As shown in Figure  miR-21 significantly reduced luciferase activity compared to 
the scrambled oligonucleotide Figure 22. 
 
 
 
 
 
Figure 20- Target identification of miR-21 (A-B) Western blot analysis of cell lysate 
from T98G transfected with a scrambled sequence as negative control and miR-21. (C) 
Real time PCR of Tap63 mRNA in T98G transfected with a negative control and with 
miR-21. 
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Figure 18-Target identification of miR-30c. (A) Real time PCR of miR-30c expression 
in T98G and U87MG cell lines. (B-C) Western blot analysis of caspase-3 in T98G, 
LN229 and in T98G transfected with a negative control and with pre-miR-30c. (D) Real 
time PCR of caspase-3 mRNA after miR-30c transfection in T98G cell lines. 
 
 
 
 
Figure 19-Validation of miR-30c binding to Caspase 3 mRNA. (A) Alignment 
between miR-30c and 3’UTR Caspase-3 mRNA. (B) Luciferase activity of pgl3-3’UTR 
Caspase -3 vector after MEG01 transfection with pre- miR30-c or negative control. 
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5.5 Validation of miR-21 and miR-30c mechanisms of action- As reported 
before miRs may target different proteins. In order to demonstrate that TRAIL 
resistance observed was carried out by Tap63 and caspase-3 respectively targets 
of miR-21 and miR-30c, we transfected T98G with ectopic Tap63 and caspase-3 
cDNA lacking the miRNA binding site in their 3'UTR and with a control vector or 
miR-21 (Figure 23A) or miR30 c (Figure 23 B), before TRAIL treatment. 
Interestingly, transfection of Tap63 and caspase-3 was able to overcome the 
effects of both miRs (Figure 23A-B). These rescue experiments proved the 
causative connection between miR-21 and TAp63 and caspase-3 and miR-30c and 
TRAIL sensitivity. 
 
 
 
 
Figure 20-Validation of the involvment of caspase-3 and Tap63. (A-B) Cell viability 
assay of T98G cells transfected with miR-30c, miR-30c and caspase-3, miR-21, miR-21 
and Tap63 
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6. Aim III- Identification and characterization of miRs involved in glioma 
response to temolozomide  
 
6.1. Temozolomide sensitivity of human glioma cell lines We analyzed 
temozolomide sensitivity of human glioma cell lines, T98G and U87MG. Cells 
were exposed to 300 Mol of temozolomide for 48 hours and cell death was 
assessed using an MTT assay. As shown in figure 24A, T98G were resistant to 
temozolomide, whereas U87MG cells were sensitive.  To establish a causative 
effect between temozolomide sensitivity and MGMT expression, we analyzed by 
western blot the expression of MGMT protein in U87MG and T98G cell lines. As 
shown in figure 24B, the two cell lines expressed different levels of MGMT 
protein. We compared through a microarray chip (Liu et al 2004) the miRs 
expression profile in U87MG cell lines versus T98G cell lines. We found different 
miRs up regulated in U87MG cell lines and downregulated in T98G and between 
them we focused our attention on miR-221 and -222. As shown in figure 24C, 
Real time PCR confirmed the different expression of those miRs in T98G and 
U87MG. These data indicate that T98G cell lines are more resistant to 
temozolomide treatment, express higher level of MGMT protein and lower level 
of miR-221 and -222 if compared to U87MG. 
 
 
 
Figure 21-Temozolomide sensitivity and MGMT and MiR-221 and -222 expression 
in glioma cell lines. (A) Glioma cell lines treatment with 300Mol of temozolomide for 
24 hr. Cell viability was valuated with a MTT assay. (B) Western blot analysis of MGMT 
expression in U87MG and T98G. (C) Real time expression of miR-221 and -222 
expression in T98G and U87MG.  
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6.2. miR-221 and -222 target MGMT3’UTR. Using bioinformatics analysis 
available on Web sites and through RNA hybrid alignment we identified a 
possible binding site of miR-221 and -222 on 3’UTR sequence of MGMT in 
position 970. To verify if those miRs are capable to bind MGMT 3’UTR we 
cloned the MGMT 3’UTR downstream the luciferase reporter gene in pGL3 
vector. The co-trasfection of miR-221 or -222 and pGL3-MGMT 3’UTR in 
Meg01 cells induced a decrease of luciferase activity while the co-trasfection of 
pGL3 vector expressing a mutant MGMT 3’UTR binding site and miRs-221 and -
222 didn’t induce a significant decrease of luciferase activity. Therefore, the 
mutated sequence was not able to inhibit the expression of MGMT 3’UTR (figure 
25) . 
 
 
 
 
Figure 22- Identification of binding sites of miR-221 and 222 on MGMT 3’UTR. (A) 
Rna Hybrid prediction analyses of miR-222 and MGMT 3’UTR. (B) Luciferase activity 
of Meg01 cells transiently cotransfected with the luciferase reporter containing wild type 
MGMT-3′UTR  or MGMT-3′UTR mutant in the presence of pre-miR-222, miR-221 or 
scrambled oligonucleotide. Representative of at least three independent experiments. 
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6.3. miR-221 and -222 target MGMT protein and mRNA. In order to establish 
a more causative effect between miR-222 and -221and MGMT, we transfected 
T98G cells with pre-miR-221 and -222 for 72hr and analyzed MGMT expression 
levels by western blot and real time PCR. As shown in figure 26A, data confirmed 
the down-regulation of MGMT protein and the decrease of mRNA upon miRs 
transfection. On the contrary, the transfection of U87MG with Anti-miR-221 and 
-222 constructs induced an increase of MGMT protein and mRNA levels (Figure 
26B) . The same downregulation of MGMT protein observed in T98G transfected 
with pre-miRs constructs was observed in T98G stably infected with lentiviral 
construct encoding for an empty vector (tween) and for miR-221 (tween-221) and 
miR-222 (Tween-222) (Figure 26C). 
 
 
Figure 23- miR-221 and -222 regulate MGMT protein and mRNA levels. (A) 
Western blot analysis of MGMT protein and Real time PCR of MGMT mRNA extract 
from T98G transfected with a scrambled sequence or with a pre-miR-221 and -222. (B) 
Western blot analysis of MGMT protein and Real time PCR of MGMT mRNA extract 
from U87MG transfected with a scrambled sequence or with an Anti-miR-221 and -222. 
(C) Western blot analysis of MGMT protein level in stably infected T98G cells with 
lentivirus construct.  
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6.4. miR-221 and -222 modulate temozolomide sensitivity in glioma cell lines. 
To verify if miR-221 and -222 have a role in the modulation of temozolomide 
sensitivity because their effects on MGMT protein and mRNA levels, we studied 
cell vitality with MTT assay. At first, we characterized cell viability of T98G cells 
stably expressing miR-221 and miR-222 (T98G tween). As shown in figure 27 A, 
T98G tween-221 and -222 were more sensitive to treatment with of temozolomide 
(300 Mol for 48 hrs) compared to non infected cells. When we transfected T98G 
cells with miR-221 and -222 the effects of temozolomide were even more evident 
(Figure 27B). This was due to a greater increase of miR expression obtained with 
transient transfection.  
 
 
 
 
 
 
Figure 24- miR-221 and 222 modulate temozolomide sensitivity. (A) T98G, U87MG 
and T98G stably ex pressing miR-221 and -222 were treated with 300Mol of 
temozolomide for 48 hrs and the cell viability was assessed by MTT assay. (B) Cell 
viability assay of T98G transiently transfected with miR-221 and -222 and then treated 
with 300Mol of temozolomide for 48hrs. 
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6.5. miR-221 and -222 and MGMT mRNA levels in glioma samples. To 
evaluate whether MGMT downregulation in glioma was related to increased miR-
222 and -221 levels also in vivo, we analyzed  MGMT and miR-222/ -221 
expression levels in tumour tissue specimens collected from 6  glioblastoma grade 
IV patients. The RNA was extracted by paraffin embed tissue using the Recovery 
ALL Kit  from Ambion. As shown in A and B, we found an inverse correlation 
between miR-222 and -221 levels and MGMT in all glioma samples analyzed 
(Figure 28).  
 
 
Figure 25-Correlation of endogenous miR-221 and 222 and MGMT mRNA 
expression levels in human glioma. Total RNA extracted from tissue specimens 
collected from 6 high grade glioma-affected individuals was used to analyze miR-221 (A) 
and -222 (B) and MGMT mRNA expression by real-time PCR. In each sample, an 
inverse correlation between miR-221 and -222 with MGMTwas observed. 
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7. DISCUSSION AND CONCLUSION 
 
Glioblastoma (GMB) are among the most deadly types of cancer (Tran and 
Rosenthal; 2010). Advances in standard treatments for this tumour, such as 
surgery, radiotherapy, and chemotherapy, have not significantly increased patient 
survival (Huse and Holland; 2010). The lethality of GMB can be attributed to the 
capacity of the cells to migrate and develop foci throughout the brain (Demuth 
and Berens; 2004). It is thought that the invasive behaviour of glioblastoma cells 
is one of the most important causes of poor clinical outcome, enabling tumor cells 
to actively egress from the main mass and invade the surrounding normal brain 
where they are out of reach of surgical resection, radiation, and chemotherapy 
(Giese et al; 2003). 
The mechanisms of the spreading phenotype are not well understood so far. It was 
recently demonstrated that the receptor protein tyrosine phosphatase  (PTP 
negatively regulates GMB cell migration (Burgoyne et al; 2009).  PTP is the 
prototype of the type IIb subfamily of receptor PTPs (RPTP). In a xenograft 
mouse model of intracranially injected U87MG cells, PTP shRNA was able to 
induce cell migration and dispersal (Burgoyne et al; 2009). PTP may be 
considered as a “migration suppressor” with regard to the diffuse infiltrative 
growth pattern observed in human gliomas.  It was previously shown that PTP 
protein is downregulated in glioblastoma and that its levels correlated to tumor 
stage (Burgoyne et al; 2009). In particular, a striking loss of PTP protein was 
observed in highly dispersive GBM compared to less dispersive low-grade 
astrocytomas and normal brain (Burgoyne et al; 2009). It was recently 
demonstrated that one mechanism of PTP down-regulation in GBM is 
proteolytic breakdown (Burgoyne et al; 2009).  
In this study, we identified a new molecular mechanism of PTP downregulation 
in human glioma, by identifying two related microRNAs that target this 
phosphatase. In order to identify new signatures of GMB invasiveness, we 
investigated the microRNA expression profile of tumorigenic U87MG glioma 
cells compared with non tumorigenic T98G cells. We identified five miR genes 
significantly overexpressed in tumorigenic cells with a >2.5-fold change. Among 
the different microRNAs we focused our attention on two highly related miRs, 
miR-221 and -222. MiR-222 and -221 expression levels in human cancer have 
been extensively investigated (Garofalo et al; 2008, Garofalo et al; 2009, Visone 
et al; 2007) and have been frequently found overexpressed in a number of human 
tumors (Pallante et al; 2006, Conti et al; 2009, Pineau et al; 2010). In GMB tissues 
and cell lines miR-222 and -221 were found overexpressed (Ciafrè et al; 2005, 
Conti et al; 2009) and correlated to the stage of the disease. However, the 
molecular targets of those miRs potentially involved in GBM’s invasive 
behaviour had not been clarified. We provide evidence for the first time that miR-
222 and -221 bind to the 3’UTR region of PTP and are able to down-regulate 
PTP at RNA and protein levels. By luciferase assay, we also identified the 
3‘UTR region of the PTP gene that represents the miR binding site. 
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Because PTP has been described to be able to suppress glioma cell migration 
(Burgoyne et al; 2009), we hypothesized that miR-221 and -222 promote cell 
migration by down-regulating PTP expression. In fact, the analysis of cell 
motility in T98G cells transduced with miR-221 or -222 demonstrated that up-
regulation of those miRs in T98G induced an increase of cell motility. The same 
result was obtained in T98G cells transiently transfected with either miR-221 or -
222. Conversely the expression of anti-miR -222 was able to reduce cell migration 
of U87MG. Because miRNAs can affect many different proteins, we validated the 
migration/adhesion effects by co-transfection of miR-222 and ectopic PTP 
22 and -221 
f protein levels in drug resistance. In this work we highlighted the 
 with temozolomide 
ity in non small cell lung cancer and in hepatocarcinoma by modulating 
lacking the miRNA binding site in its 3'UTR. These rescue experiments proved 
the causative connection between miR-222/221  PTP and migration/invasion. 
Moreover, our data show that in specimens of glioma, miR-2
expressions inversely correlates with that of PTP. Therefore, miR-222 and -221 
expression levels could predict the aggressive behaviour of glioma.  
MicroRNAs are also attractive drug targets since they regulate expression of many 
proteins in the cell and are differentially expressed in malignant versus normal 
cells. Recently, multiple studies highlighted the involvement of miR-mediated 
regulation o
possible role of different sets of microRNA in TRAIL and temozolomide 
resistance.  
The present study shows that MGMT protein and mRNA are target of miR-221 
and 222 and that these two miRs are capable to modulate glioblastoma sensitivity 
to temozolomide. So far it has been demonstrated that MGMT activity is 
frequently lost in glioblastoma in the presence of CpG island hypermethylation in 
the promoter region. Therefore, the methylation status of the MGMT promoter 
was considered to be indicative of a good outcome in patients with malignant 
gliomas treated with alkylating agent (Spiegl-Kreinecker et al; 2010). However, in 
some studies the correlation between MGMT promoter methylation and MGMT 
expression levels are contradictory. Therefore other possible mechanisms of 
MGMT modulation should exist. Our study suggests that MGMT may be 
regulated also by microRNA action in particular by miR-221 and 222. 
Surprisingly these data could give us a new consideration of miR-221 and 222 
function in glioma. These two miRs are usually upregulated in high grade tumours 
they could be indicative of a good outcome of patients treated
also in absence a CpG MGMT promoter non methylated. More association study 
on patients need to be done do assess clearly this correlation. 
 Most glioblastomas present resistance to TRAIL, an this resistance may be due to 
a variety of mechanisms, including high decoy receptor expression, low 
expression levels of critical mediators of TRAIL signalling, such as caspase-8 and 
Fas associated death domain, or high expression of inhibitors of apoptosis, such as 
FLICE-inhibitory protein (cFLIP). Therefore, it’s clear that a better 
comprehension of the mechanisms of TRAIL resistance may represent a powerful 
instrument to ameliorate glioblastoma patient treatment.  Recently several works 
explored the role of microRNA in TRAIL resistance. We demonstrated that miR-
221 and miR-222 regulate death receptor signalling and TRAIL apoptosis 
sensitiv
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p27kip1, PTEN and TIMP3 expression (Garofalo et al; 2008, Garofalo et al; 
2009). 
In gliomas, miR-21 was reported to be upregulated , and miR-21 knock-down was 
associated with increased apoptotic activity. Furthermore, Corsten et al (Corsten 
et al; 2007), evaluated the combined effects of miR-21 antagonisms and 
expression in neural precursor cells (NPC) of a secretable variant of the 
cytototoxic agent TRAIL. They found that pre-treatment of glioma cells with 
LNA-anti-miR-21 and TRAIL led to synergistic antitumor effect both in vivo and 
in vitro. Accordingly to this data, we found an upregulation of miR-21 and 30b 
and 30c in our TRAIL resistance glioblastoma cells, U87MG and LN229. 
Interestingly, the up regulation of these miRs in TRAIL sensitive cells  T98G, 
induced an increase of cell viability and a decrease of apoptotic cells, underlying a 
crucial role of miR-21, miR-30b and miR30 c in TRAIL resistance. To clearly 
understand the role of these miRs in TRAIL resistance we looked for their target 
through an internet search. Surprisingly we identified caspase-3 as target of miR-
30c. Another recent work underlines the crucial role of blocking caspase-3 
activity. Infact, a breast cell lines MDA-MB-453 , transfected with 187 individual 
synthetic miRNAs were screened for probing their behaviour in TRAIL pathway. 
Thirty four of these miRs led to a differential caspase-3 activation phenotype. 
l these observation are consistent with 
rous molecular pathways 
involved in gliomagenesis is promising and may provide numerous additional 
andidates for therapeutic targeting in the near future.  
Identifying a miR capable to bind and block caspase-3 directly represent a 
possible strategy to overcame TRAIL resistance.  
Corsten and colleagues (Corsten et al; 2007)  have not demonstrated a clear 
correlation between miR-21 targets and TRAIL resistance. In this work we 
identified as target of miR-21 involved in TRAIL sensitivity the protein TAp-63, 
one of the two major isoforms of TP63 gene. There are evidences that TAp-63 
plays an important role in DNA damage controlling cell cycle and apoptosis in 
human cancer, although its precise role in tumorigenesis remains to be clarified. 
TAp-63 shows clear pro-apoptotic activity, mediated both by death receptors 
(CD95, TNF, TRAIL) and mithocondrial (bax,puma) pathways (Candi et al; 
2007). Recently has been demonstrated that Tap63 is induced by a variety of 
chemotherapeutic agents and that blocking Tap-63 function leads to enhanced 
chemoresistance (Gressner et al; 2005). Al
our hypothesis of a possible role of miR-21 in regulation of TRAIL sensitivity 
through the regulation of Tap-63 protein.   
In conclusion, miR-based regulation of the nume
c
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Selective inhibition of PED protein expression sensitizes B-cell chronic
lymphocytic leukaemia cells to TRAIL-induced apoptosis
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B-cell chronic lymphocytic leukaemia (B-CLL) cells fail to un-
dergo apoptosis. The mechanism underlying this resistance to cell
death is still largely unknown. Tumour necrosis factor-related ap-
optosis-inducing ligand (TRAIL) effectively kills tumour cells but
not normal cells, and thus represents an attractive tool for the
treatment of cancer. Unfortunately, lymphocytes from B-CLL pa-
tients are resistant to TRAIL-mediated apoptosis. Thus, we aimed
to study the involvement of PED, a DED-family member with a
broad antiapoptotic action, in this resistance. We demonstrate
that B lymphocytes obtained from patients with B-CLL express
high levels of PED. Treatment of B-CLL cells with speciﬁc PED
antisense oligonucleotides, a protein synthesis inhibitor or HDAC
inhibitors, induced a signiﬁcant downregulation of PED and sensi-
tized these cells to TRAIL-induced cell death. These ﬁndings sug-
gest a direct involvement of PED in resistance to TRAIL-induced
apoptosis in B-CLL. It also identiﬁes this DED-family member as
a potential therapeutic target for this form of leukaemia.
' 2006 Wiley-Liss, Inc.
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B-cell chronic lymphocytic leukaemia (B-CLL) is the most fre-
quent form of leukaemia in Western countries.1 It is characterized
by clonal proliferation and accumulation of long-lived B lympho-
cytes blocked in the G0/G1 phase of the cell cycle in blood, bone
marrow, lymph nodes and spleen.2,3 The accumulation of B lym-
phocytes in B-CLL is probably consequent to an undeﬁned defect
in the apoptotic machinery rather than to an increase in prolifera-
tion of leukaemic cells.4
Apoptosis is a ﬁnely regulated process that involves several mole-
cules and adaptors. The tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) is a member of the tumour necrosis factor
family that induces apoptosis by binding to 2 membrane-bound
receptors, TRAIL-R1 (DR4) and TRAIL-R2 (DR5).5 The binding
of TRAIL to these receptors results in the recruitment of the adaptor
molecule FADD and caspase 8 to the death-inducing signalling
complex (DISC), followed by the activation of caspase 8.6,7 TRAIL
induces apoptotic cell death in several tumour-derived cell types but
rarely in normal cells.5,8 Therefore, TRAIL is considered a promis-
ing tool for novel therapies. The receptors for TRAIL are constitu-
tively expressed in several tumours, including B-CLL9,10; however,
in B-CLL, its use is limited due to the frequent resistance of the
lymphocytes of these patients to TRAIL-induced cell death.11
One of the causes of cell-death resistance could reside in altered
expression of apoptosis inhibitory molecules belonging to the DED-
containing protein family, such as c-FLIP and PED (also known as
PED/PEA-15),12 which includes procaspase 8, procaspase 10 and
FADD.13 c-FLIP and PED are recruited to the DISC and inhibit the
activation of caspase 8. The expression of both proteins is increased
in several human malignancies.13 However, in B-CLL, the expres-
sion of c-FLIP is not related to TRAIL resistance11,14 suggesting
that other molecules have a role. We have recently demonstrated
that PED is overexpressed in human breast cancer and that its over-
expression contributes to resistance to chemotherapeutic drugs.14
Furthermore, the expression of PED correlates with TRAIL resist-
ance in a human glioma-derived cell line.15
In this study, we aimed to investigate the expression of PED in
B-CLL and its role in the failure of these tumour cells to undergo
TRAIL-induced cell death. We demonstrate that PED protein is
upregulated in the lymphocytes from B-CLL patients with respect
to those from healthy individuals. Furthermore, PED expression is
sensitive to histone deacetylase inhibitors (HDACIs), and speciﬁc
downregulation of PED expression with antisense oligodeoxynu-
cletides increases sensitivity to TRAIL-induced cell death.
Material and methods
Patient information
We obtained peripheral blood from 40 patients diagnosed with
B-CLL as conﬁrmed by clinical, pathological, and ﬂow cytometry
criteria.16 Patient characteristics are reported in Table I. Disease
staging is described using the Binet staging system (evaluating
enlargement of lymph nodes, the presence of anaemia and/or
thrombocytopenia) and the RAI staging system (evaluating the
presence of lymphocytosis alone or in combination with lymphad-
enopathy, spleen or liver enlargement and the presence of anaemia
and thrombocytopenia). All the patients analyzed in this study
were not on any form of medical treatment.
Isolation of peripheral blood lymphocytes
Peripheral blood lymphocytes were isolated by density gradient
centrifugation over Ficoll-Hypaque, as previously reported.17 Pe-
ripheral blood samples were collected in heparin-coated tubes from
healthy human blood donors and patients with B-CLL after obtain-
ing informed consent in accordance with the Declaration of Helsinki.
PBMCs were isolated by gradient centrifugation with lymphocyte-cell
separation medium (Cedarlane Laboratories, Hornby, ON, Canada).
T lymphocytes, NK lymphocytes, granulocytes, and monocytes
were negatively depleted with immunomagnetic microbeads (MACS
microbeads; Miltenyi Biotech, Auburn, CA). The ﬁnal samples had
a purity of more than 90% CD191 B lymphocytes, as assessed by
ﬂow cytometry using speciﬁc FITC- or PE-conjugated monoclonal
antibodies (MoAbs; Becton Dickinson, San Jose, CA).
Materials, culture conditions and reagents
Cells were grown in a 5% CO2 atmosphere in RPMI 1640 con-
taining 10% heat-inactivated foetal bovine serum (FBS), 2 mM
L-glutamine and 100 U/ml penicillin–streptomycin. Media, sera and
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antibiotics for cell culture were from Life Technologies, (Grand
Island, NY). Protein electrophoresis reagents were from Bio-Rad
(Richmond, VA) and Western blotting and ECL reagents from
Amersham (Aringhton Heights, IL). All other chemicals were
from Sigma (St. Louis, MO).
RNA extraction and cDNA ampliﬁcation
RNA was extracted from samples with Trizol (Invitrogen,
Carlsbad, CA) following the manufacturer’s protocol, and converted
to cDNA using Transcriptor Reverse Transcriptase (Roche Diagnos-
tic, Indianapolis, IN) with random primers (Roche Diagnostic). To
detect PED mRNA, 5 ll of the resultant cDNA was added to 50 ll
of PCR mixture containing 13 PCR buffer, 2.5 U of Taq DNA poly-
merase, 1.5 mM MgCl2, 200 lM dNTPs and 20 pmol of each spe-
ciﬁc primer. The following speciﬁc primers were used: PED: (R:50
GATGTTGTTGGTCAGGTCTTGC-30; F:50-GAGCGCTCAGCT-
CCAGAGG-30; GAPDH: 50-TGCCGTCTAGAAAAACCTGC-30
and 50-ACCCTGTTGCTGTAGCCAAA-30 (Primm Srl, Milan, Italy).
The PCR cycling conditions were as follows: 1 cycle at 94C for
2 min and then 25 cycles at 94C for 40 sec, 60C for 30 sec and
72C for 30 sec and a ﬁnal extension for 7 min at 72C.
PED antisense oligodeoxynucleotide synthesis and transfection
PED-antisense phosphorothioate oligodeoxynucleotides (ODNs)
were obtained from Primm. The sequences of the different ODNs
were: A1 (bp 31–50): GCTCAGGGCGCGGGCACTCC; A2 (bp 55–
74): GCCATGACGCCTCTGGAGCT; A3 (bp 51–70): TGACGC-
CTCTGGAGCTGAGC; A4 (bp271–290): TCAGGACGGCGG-
GAGATCTC; A5 (bp1661–16080): CCCCTCCCACCCCCGCTCTG;
A6 (bp 1841–1860): CCAGCAGCCAGCCCTCCCCT. The scrambled
control ODN was GGTCCTCCAGCGAGGATTCG. The ODNs
were transfected in HeLa cells using the lipofectamine method
according to the manufacturer’s instructions. For this study, 80%
conﬂuent cells grown on p60 dishes were washed and cultured with
DMEM without serum or antibiotics, and incubated for 24 hr with
the indicated concentrations of ODN plus 15 ll of lipofectamine.
Five hours later, an equal volume of DMEM supplemented with
20% FBS was added. The medium was then replaced with DMEM
with 10% FBS and cells incubated for an additional 24 hr before
being assayed.
Protein isolation and Western blotting
The A3 PED-antisense, scrambled control phosphorothioate ODN
(5 lM) or 10 lM cycloheximide (CHX) was added to B-CLL cell
cultures for different times (2 days for CHX, 2 and 5 days for
ODNs) and PED expression analyzed by Western blot. Brieﬂy, cell
pellets were washed twice with cold PBS and resuspended in har-
vest buffer (30 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% glyc-
erol, and 0.1% Triton X-100) containing Proteinase Inhibitor Cock-
tail (Roche Diagnostic). Solubilized proteins were incubated for
30 min on ice. After centrifugation at 10,000g for 30 min at 4C,
supernatants were collected. Fifty micrograms of sample extracts
were resolved on 12% SDS-polyacrylamide gels using a mini-gel
apparatus (Bio-Rad) and transferred to Hybond-C extra nitrocellu-
lose (Amersham Pharmacia Biotech, Piscataway, NJ). Membranes
were blocked for 1 hr with 5% nonfat dry milk in TBS containing
0.05% Tween-20 and incubated for 2 hr with the speciﬁed antibodies.
The following antibodies were used: anti-PED serum as previously
described,18 anti-b-actin (Sigma), anti-c-FLIP (Alexis), anti-bcl2
(sc-509) and anti-Bak (sc-832) were from Santa Cruz, anticyto-
chrome c and anti-Bax were from BD Pharmingen, anti-TRAIL
receptors antibodies from ProSci (Poway, CA).
Washed membranes were then incubated for 45 min with HRP-
conjugated anti-rabbit or anti-mouse secondary antibodies (Amer-
sham Pharmacia Biotech) and visualized using chemiluminescence
detection (Amersham Pharmacia Biotech). To measure cytochrome
c released from the mitochondria into the cytosol, cells were lysed
with ice-cold lysis buffer (25 mM Tris-HCl and 5 mM MgCl2
pH 7.4). Supernatant was collected and analyzed by Western blot
with an antibody against cytochrome c. b-Actin was used as a load-
ing control.
Cell death quantiﬁcation and ﬂow cytometry
Apoptosis was analyzed via propidium iodide incorporation in
permeabilized cells by ﬂow cytometry. The cells (5 3 105) were
washed in PBS and resuspended in 500 ll of a solution containing
0.1% sodium citrate, 0.1% Triton X-100 and 50 lg/ml propidium
iodide (Sigma). Following incubation at 4C for 30 min in the
dark, nuclei were analyzed with a Becton Dickinson FACScan
ﬂow cytometer. Cellular debris was excluded from analyses by
raising the forward scatter threshold, and the DNA content of the
nuclei was registered on a logarithmic scale. The percentage of
elements in the hypodiploid region was calculated. Alternatively,
we measured cell viability with the CellTiter 961 AQueous One
Solution Cell Proliferation Assay (Promega, Madison, WI), accord-
ing to the manufacturer’s protocol. Cells were plated in 96-well
plates in triplicates, stimulated and incubated at 37C in a 5% CO2
incubator. Metabolically active cells were detected by adding 20 ll
of MTS to each well. After 2 hr of incubation, the plates were ana-
lyzed on a Multilabel Counter (Bio-Rad).
Flow cytometry for surface receptors
To measure cell surface expression of TRAIL receptors, cells
were collected and washed twice in PBS. One million cells were
incubated with PE-conjugated puriﬁed monoclonal antibodies
against TRAIL receptors (R&D system) or with mouse isotype
control phycoerythrin-conjugated IgG2b, on ice for 1 hr. After
TABLE I – CLINICAL FEATURES OF PATIENTS
Case number Sex WBC (106) Binet RAI
1 M 28.100 C IV
2 F 53.200 A I
3 F 55.500 C IV
4 F 82.730 B II
5 F 53.100 C IV
6 F 33.400 A I
7 M 72.000 A I
8 F 35.000 B I
9 M 42.800 A I
10 M 85.350 C IV
11 M 33.500 C IV
12 M 12.800 A I
13 M 20.700 B II
14 F 5.800 A II
15 F 27.200 A II
16 F 48.300 B II
17 M 14.300 A I
18 M 58.500 C IV
19 M 82.200 A II
20 F 43.500 A I
21 F 22.800 B II
22 M 9.800 A I
23 M 13.400 A I
24 M 12.700 A I
25 M 31.900 B II
26 M 26.200 B II
27 F 19.000 A II
28 M 9.100 C IV
29 F 6.000 A I
30 M 47.700 B II
31 F 58.260 A I
32 F 32.410 A I
33 M 48.430 C IV
34 F 3.889 A I
35 M 50.530 A I
36 F 9.380 C IV
37 F 68.160 B II
38 F 25.200 A I
39 M 68.160 B II
40 F 25.200 A I
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incubation, cells were washed once with 3 ml PBS, centrifuged,
resuspended in 1 ml of PBS and the relative level of surface anti-
gens assessed by FACS analysis (FACSsort; Becton Dickinson).
Effects of HDAC inhibitors
The HDAC inhibitors, valproic acid (VPA, 1 mM) or tricostatin
A (TSA, 100 ng/ml), were added to B-CLL cell cultures for 12 hr
and protein expression analyzed by Western blotting as described.
The effects of these compounds on cell viability were assayed with
the CellTiter 96 AQueous One Solution Cell Proliferation Assay.
Statistical analysis
Unpaired Student’s t-test was performed to determine differen-
ces between mean values for continuous variables. Probability
values <0.05 were considered signiﬁcant. Data were analysed with
SPSS for Windows, release 10.0 (SPSS, Chicago, IL).
Results
PED mRNA and protein expression in B-CLL cells
We assessed PED expression in primary lymphocytes obtained
from B-CLL patients (clinical proﬁles shown in Table I) and
FIGURE 1 – PED expression in human lymphocytes. (a) RNA was
extracted from primary lymphocytes and was subjected to RT-PCR
analysis with PED-speciﬁc primers. GAPDH was used as the control.
A representative experiment is shown. In this experiment we loaded
samples from patients 1, 2, 15, 25 and 32. (b and c) PED expression
was analyzed by Western blotting in total lymphocytes (b) or in puri-
ﬁed CD191 B cells (c) from different patients and controls. Loading
was assessed on the same membrane with an anti-b-actin antibody. A
representative experiment is shown. (d ) Densitometric analysis of
PED expression levels in lymphocytes from 20 patients and 8 unaf-
fected individuals. We represent average PED expression level after
normalization to b-actin.
FIGURE 2 – Effects of antisense oligodeoxynucleotides on PED
expression. (a) HeLa cells were transfected with different PED anti-
sense ODNs (A1–A6), as described in the Material and Methods sec-
tion. The level of PED was analyzed by Western blotting. ODN A3 and
A4 induced 80% and 40% reductions in PED levels, respectively.
(b) HeLa cells were transfected with PED antisense ODN A3 or with
control scrambled ODN at different concentrations. Twenty-four hours
after transfection, cells were harvested and PED expression analyzed by
Western blotting. A representative experiment is shown. (c) HeLa cells
were transfected with PED antisense ODN A3 or with control scrambled
ODN for different lengths of time after which cells were harvested and
PED expression analyzed by Western blotting. Loading was assessed on
the same membrane with an anti-b-actin antibody.
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healthy individuals. PED mRNA was detected in lymphocytes of
patients with B-CLL (Fig. 1a). Furthermore, PED protein expres-
sion was greater in lymphocytes from B-CLL patients than in
those from healthy individuals: this was true when analyzing total
peripheral lymphocytes (Figs. 1b and 1d ) or puriﬁed CD191 B
lymphocytes (Fig. 1c).
Effects of PED downregulation on TRAIL sensitivity
Primary cultures of lymphocytes from B-CLL patients are re-
sistant to TRAIL-induced cell death.10 Since in several tumour
cell lines PED has an inhibitory action towards death-receptor ligands
and chemotherapeutics,12,14 we addressed whether the upregulation
of PED found in B-CLL patients plays a role in the defective
TRAIL sensitivity of leukaemic cells.
To this aim, we used an antisense ODN-based approach to down-
modulate PED expression. Antisense-ODN has been successfully
utilized in B-cell chronic leukaemia.19–21 First, we evaluated the
efﬁcacy of the antisense ODNs designed on 6 different regions of
PED in the coding or in the 30 and 50 nontranslated regions. HeLa
cells are particularly useful for this type of experiment because
they express high endogenous levels of PED and are easily trans-
fected. As shown in Figure 2a, ODNs named A1, A2, A5 and A6
produced no relevant effects on PED expression. Differently, ODN
A3 and A4 induced80% and 40% reductions in the level of PED,
respectively, while a scrambled negative control for ODN A3
(ODN A3Sc) had no effect (Figs. 2b and 2c). Dose–response ex-
periments revealed that in HeLa cells, ODN A3 was effective in re-
ducing PED expression at a concentration as low as 1 lM (Fig. 2b).
On the contrary, ODN A3Sc produced no effect even at a concen-
tration of 5 lM. Time–course experiments revealed that ODN A3
was effective as soon as 24 hr, whereas its control, ODN A3Sc, had
no effect even after 72 hr of incubation (Fig. 2c).
Next, we tested the effect of PED-ODN on primary B cells from
leukaemic patients. Similarly to HeLa cells, in B-CLL derived lym-
phocytes ODN A3 was effective at concentrations ranging from 2
to 5 lM (Fig. 3a), reaching >90% reduction in PED after 48 hr.
FIGURE 3 – Downregulation of PED in
B lymphocytes obtained from B-CLL
patients increases sensitivity to TRAIL-
induced cell death. (a) B-CLL cells were
incubated for 48 hr with 1, 2 or 5 lM anti-
sense ODN (As) or with scrambled ODN
(Sc) or (b) 1, 2 or 5 days with 5 lM anti-
sense ODN (As) or with scrambled ODN
(Sc). The cells were then harvested and
PED expression analyzed by Western blot-
ting. Loading was assessed on the same
blot with an anti-b-actin antibody. West-
ern blot analysis shows that the antisense
ODN induced PED down regulation (left
panels) whereas scrambled ODN produced
no effects (right panels). We performed
similar experiments with lymphocytes from
4 patients and show only representative
data from one. (c) Percentage of hypodi-
ploid nuclei assessed by FACS analysis
in nontransfected B-CLL cells (control)
and in cells treated with PED antisense or
scrambled ODN for 24 hr in the absence
(basal) or presence (TRAIL) of 200 ng
TRAIL/ml for an additional 24 hr. The
data were obtained from 4 independent
experiments using cells from different
patients. *p < 0.05.
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ODN A3Sc had no effect even after 5 days of continuous incuba-
tion at 5 lM (Fig. 3b). The viability of the cells, as assessed with
the CellTiter Proliferation Assay, did not change after incubation
with ODNs (data not shown).
We then determined the involvement of PED in the TRAIL-re-
sistant phenotype of lymphocytes from B-CLL patients. B-CLL
cells were transfected with ODN, and apoptosis evaluated with ﬂow
cytometry by measuring hypodiploidy. As shown in Figure 3c, in
the absence of TRAIL, B-CLL cells displayed a basal level of
16% hypodiploid elements. A similar percentage was measured in
cells transfected with ODN A3Sc. Incubation of nontransfected or
ODN A3Sc-transfected B-CLL cells with TRAIL did not produce
an increment in the percentage of hypodiploid nuclei, reﬂecting
the described low sensitivity of these cells to TRAIL. However,
treatment with PED-speciﬁc antisense ODN A3 increased the per-
centage of hypodiploid nuclei to 22% in the absence of TRAIL,
indicating that PED down-modulation had determined a slight
increase of basal apoptosis. Moreover, ODN A3 sensitized these
cells sufﬁciently to make them responsive to TRAIL-induced cell
death, as demonstrated by the increase in hypodiploidy.
Downregulation of PED expression with CHX
CHX has been reported to enhance and restore sensitivity to death
receptor-induced apoptosis, presumably by reducing the expression
FIGURE 4 – Effects of cycloheximide (CHX) on PED expression and TRAIL sensitivity. (a) BCLL cells were incubated with 10 lM CHX in
the presence or absence of TRAIL (200 ng/ml) for 24 hr. Western blot analysis of B-CLL cells shows that CHX induced PED downregulation,
whereas bcl2, bax, Bak and c-FLIP protein levels were unaffected. Loading was assessed on the same blot with an anti-b-actin antibody. (b) Per-
centage of hypodiploid nuclei assessed by FACS analysis in B-CLL cells with or without treatment with CHX, TRAIL alone or in combination,
for 24 hr. Data were obtained from 4 independent experiments using cells from different patients. *p < 0.05; (c) CHX dose–response of PED
expression. B-CLL cells were incubated with different amounts of CHX, as indicated, for 24 hr, and PED then analyzed by Western blot.
(d) CHX dose–response of TRAIL-induced cell death. B-CLL cells were incubated with different amounts of CHX, as indicated, for 24 hr.
TRAIL (200 ng/ml) was added for 16 hr, and cell viability assessed with the CellTiter Proliferation Assay. There is a direct correlation between
the quantity of CHX and sensitivity to TRAIL.
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of antiapoptotic proteins.22 We thus evaluated the effects of CHX
on the expression of different apoptosis signalling molecules in B-
CLL cells (Fig. 4a). PED levels were found clearly reduced after
treatment with CHX, while the expression of several Bcl-2 family
members (bcl2, Bak, Bax) and c-FLIP were unaffected. PED
expression was not restored by concomitant treatment with TRAIL,
indicating that TRAIL-induced pathways are not involved in the
regulation of PED protein level. These data are in accordance with
results obtained in human glioma cells where we found that PED,
but not c-FLIP, was reduced in the presence of CHX.15 Therefore,
this inhibiting action on PED expression may be critical for CHX-
induced sensitization of tumour cells. We next investigated the
effects of CHX on the sensitivity to TRAIL in primary B-CLL cell
cultures. As shown in Fig. 4b, TRAIL-induced cell death was signif-
icantly enhanced in the presence of CHX, reaching 98% hypodi-
ploid nuclei compared with 36% in the absence of CHX. To
strengthen this observation, we evaluated the dose–response effect
of CHX on PED expression and sensitivity to TRAIL. We found
that the level of PED was correlated to CHX dose (Fig. 4c), and
coherently, that sensitivity to TRAIL increased with increasing
quantities of CHX (Fig. 4d ).
Effects of HDAC inhibitors on PED expression
and TRAIL sensitivity
Recently, several inhibitors of histone deacetylase have entered
clinical trials.23,24 HDACIs exert their antitumour effects through
the ability to induce growth arrest, differentiation and apoptosis.
Recent reports demonstrate that HDACIs sensitize resistant cells of
patients with B-CLL to TRAIL-induced apoptosis by facilitating
increased formation of the TRAIL DISC.25 We therefore tested the
effects of VPA and TSA on PED expression and TRAIL sensitivity
in primary B-CLL lymphocytes. PED expression was clearly re-
duced in lymphocytes from B-CLL patients after incubation with
HDACIs (Fig. 5a). The effects of HDACI on cell death were not
related to c-FLIP, to different components of the mitochondrial
pathway, or to alteration of surface TRAIL DR4 or DR5 receptors,
analyzed either by Western blot or by FACS, since their expression
was not affected by these drugs (Figs. 5a and 6). Pretreatment with
either HDACI determined an increase in TRAIL-induced cell death
(Fig. 5b). Interestingly, TSA induced complete silencing of PED,
and the addition of TRAIL in this setting had a stronger apoptotic
effect than with VPA, thus further supporting the correlation be-
tween PED levels and resistance to TRAIL.
Discussion
B-CLL is presently an incurable malignancy due to accumula-
tion of monoclonal B cells that develop resistance to conventional
anticancer agents. Thus, identiﬁcation and evaluation of novel
agents for the treatment of refractory B-CLL are important and
challenging tasks. TRAIL is an attractive therapeutic tool for B-
CLL and other malignancies because it induces cell death in sev-
eral tumour-derived cell types but rarely in normal cells. However,
many reports have demonstrated the resistance of malignant B
cells to death receptor-induced apoptosis. This study was designed
to investigate the molecular determinants responsible for the pro-
longed survival and accumulation of leukaemic cells in patients
with B-CLL. To this end, we analyzed the role of the DED-con-
taining protein PED, in TRAIL resistance in B-CLL. PED is a
molecule that plays a crucial role in regulating apoptosis signals in
different cell types. We addressed the question of whether PED
expression may contribute to cell death resistance. For this pur-
pose, we used the antisense ODN approach. Antisense ODNs tar-
geted to speciﬁc genes have shown considerable potential as thera-
peutic agents. Antisense therapy uses single-stranded synthetic
ODNs that are either unmodiﬁed or have been chemically modi-
ﬁed to regulate gene expression at the translational step. The spec-
iﬁcity of target gene binding and consequent inhibition of individ-
ual gene products make antisense compounds an attractive new
class of drugs for clinical applications.26 Moreover, chemical
modiﬁcation of the phosphorothioate backbone increases resist-
ance to nuclease digestion and prolongs half-lives within tissues.
Antisense therapy has been proved to be particularly useful in
chronic leukaemia. Previous studies have described that the com-
bination of Bcl-2 antisense ODNs with conventional chemothera-
peutic drugs elicit an enhanced therapeutic effect in B-CLL.27 In
the present study, we have identiﬁed a speciﬁc ODN sequence that
inhibits PED expression in HeLa cells and in B lymphocytes. Fur-
thermore, we describe that in primary cultures of lymphocytes
from leukaemia, speciﬁc inhibition of PED with ODN augments
both spontaneous and TRAIL-induced cell death. The levels of
FIGURE 5 – Effects of HDACIs on PED expression and TRAIL sen-
sitivity. (a) B-CLL cells were preincubated for 24 hr with HDACIs,
either 1 mM valproic acid (VPA) or 100 ng/ml tricostatin A (TSA) as
indicated, and then with 200 ng/ml TRAIL for an additional 16 hr.
Western blot analysis shows that TSA and VPA induced PED downre-
gulation whereas TRAIL did not. c-FLIP, bcl2, Bax, Bak, TRAIL
receptors (DR4) protein levels were unaffected by HDAC inhibitors.
Cytochrome c release, evaluated as described in the Material and Meth-
ods section, did not change after HDACI treatment. Loading was
assessed with b-actin. (b) Viability after treatment with TRAIL.
B-CLL cells were preincubated for 24 hr with 1 mM VPA or 100 ng/
ml TSA, and then with 200 ng/ml TRAIL for an additional 16 hr. Meta-
bolically active cells were detected by the addition of 20 ll MTS to
each well. After 5 hr of incubation, the plates were analyzed with the
CellTiter 961 AQueous One Solution Cell Proliferation Assay. Data
were obtained from 4 independent experiments using cells from differ-
ent patients and expressed as % viable cells. *p < 0.05; **p< 0.001.
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PED correlate with TRAIL resistance also in other malignancies
such as human glioma15 and nonsmall cell lung cancer (NSCLC)
(Condorelli et al., submitted). In NSCLC, the involvement of PED
in the refractoriness to TRAIL-induced cell death was investigated
by silencing PED expression in TRAIL-resistant and high PED-
expressing NSCLC cells, with a PED siRNA. Transfection with
PED-siRNA induced a signiﬁcant downregulation of PED and
sensitized these cells to TRAIL-induced cell death. Thus, PED
may represent a target against TRAIL-induced cell death resist-
ance in several forms of malignancies. Further studies are in pro-
gress in our lab to investigate the potential use of speciﬁc PED
ODNs in enhancing the therapeutic effects of different chemother-
apeutic drugs in B-CLL.
HDACIs have been used in cancer therapy for their potential to
inhibit proliferation and survival of tumour cells. It has been
reported that they cause not only cell cycle arrest and differentia-
tion but also apoptosis. Recent reports demonstrate that HDAC
inhibitors sensitize resistant primary cells from patients with B-
CLL to TRAIL-induced apoptosis by facilitating increased forma-
tion of the TRAIL DISC.25 Here, we describe that the treatment
with 2 different HDACIs, VPA and TSA, induced a reduction in
PED levels and a concomitant increase of cell death. Interestingly,
both HDACIs used in our experimental system did not induce a
reduction of c-FLIP levels. Previous reports have shown that
HDACIs induce downregulation of c-FLIP in some cell types,28
but the effects of HDACIs on c-FLIP downregulation in chronic
leukaemia is controversial. In agreement with our data, other
authors29,30 did not ﬁnd any change in c-FLIP expression upon
treatment with VPA, SAHA, sodium butyrate or depsipeptide.
Thus, data from these authors do not support a role for c-FLIP in
the sensitization of B-CLL lymphocytes to cell death. Aron
et al.31 reported that depsipeptide was able to induce a reduction
of c-FLIP levels in B-CLL, although not in all patients. Further
studies are needed to understand these discrepancies. However, in
our work, we demonstrate that CHX increased sensitivity to
TRAIL through the downregulation of PED and not c-FLIP. These
data further support a prominent role for PED rather than c-FLIP
in the insensitivity of B-CLL to TRAIL. Furthermore, our results
revealed that cytochrome c release was not increased upon
HDACI treatment and that the amount of different bcl2 family
members was not affected.
Taken together these results indicate that PED exerts an antiapop-
totic effect in B-CLL cells, probably by interfering with TRAIL-
DISC signalling. Indeed, PED downregulation restores sensitivity to
TRAIL in B-CLL. Thus, modulation of PED levels could represent
an important tool for improving TRAIL sensitivity in different types
of transformed cells.
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Introduction
Lung cancer is the leading cause of cancer-related mortality in
western countries [1]. The late stage at diagnosis in many patients,
and the high rate of relapse for those initially diagnosed in earlier
stages, contribute to its lethality. Non-small cell lung cancer
(NSCLC) is the most common type of lung cancer, accounting for
approximately 80% of cases [2]. One of the most important issues
that affects survival rate, is resistance to therapeutic drugs. Only
20–30% of treated NSCLC patients have clinical evidence of a
response. Therefore, the development of new therapeutic strategies
is necessary for the treatment of this type of tumour.
Apo2L/TNF-related apoptosis-inducing ligand (TRAIL) is a rel-
atively new member of the tumour necrosis factor (TNF) ligand
family, which induces apoptosis in a variety of cancers. Four 
cognate receptors have been identified: the death receptors,
TRAIL-R1/DR4 and TRAIL-R2/DR5; and the decoy receptors,
TRAIL-R3/DcR1 and TRAIL-R4/DcR2 [3]. The decoy receptors have
been proposed to competitively inhibit TRAIL-induced apoptosis
by acting as non-functional receptors. All four TRAIL receptors are
PED is overexpressed and mediates TRAIL resistance in
human non-small cell lung cancer
Ciro Zanca a, #, Michela Garofalo a, #, Cristina Quintavalle a, Giulia Romano a, c, 
Mario Acunzo a, Pia Ragno b, Nunzia Montuori a, Mariarosaria Incoronato c,
Luigi Tornillo d, Daniel Baumhoer d, Carlo Briguori e, Luigi Terracciano d,
Gerolama Condorelli a, *
a Department of Cellular and Molecular Biology and Pathology, ‘Federico II’ University of Naples, Naples,
Italy & Istituto di Endocrinologia ed Oncologia Sperimentale, C.N.R., IEOS, Naples, Italy 
b Dipartimento di Chimica, Università degli Studi di Salerno, Salerno, Italy
c Fondazione SDN, Naples, Italy
d Institute of Pathology, University of Basel, Basel, Switzerland
e Clinica Mediterranea, Naples, Italy
Received: September 3, 2007; Accepted: February 12, 2008
Abstract
PED (phosphoprotein enriched in diabetes) is a death-effector domain (DED) family member with a broad anti-apoptotic action. PED
inhibits the assembly of the death-inducing signalling complex (DISC) of death receptors following stimulation. Recently, we reported
that the expression of PED is increased in breast cancer cells and determines the refractoriness of these cells to anticancer therapy. In
the present study, we focused on the role of PED in non-small cell lung cancer (NSCLC), a tumour frequently characterized by evasion
of apoptosis and drug resistance. Immunohistochemical analysis of a tissue microarray, containing 160 lung cancer samples, indicated
that PED was strongly expressed in different lung tumour types. Western blotting performed with specimens from NSCLC-affected
patients showed that PED was strongly up-regulated (>6 fold) in the areas of tumour compared to adjacent normal tissue. Furthermore,
PED expression levels in NSCLC cell lines correlated with their resistance to tumour necrosis factor related apoptosis-inducing ligand
(TRAIL)-induced cell death. The involvement of PED in the refractoriness to TRAIL-induced cell death was investigated by silencing PED
expression in TRAIL-resistant NSCLC cells with small interfering (si) RNAs: transfection with PED siRNA, but not with cFLIP siRNA,
sensitized cells to TRAIL-induced cell death. In conclusion, PED is specifically overexpressed in lung tumour tissue and contributes to
TRAIL resistance.
Keywords: lung cancer • apoptosis • AKT
J. Cell. Mol. Med. Vol 12, No 6A, 2008 pp. 2416-2426
#These authors contributed equally to this work.
*Correspondence to: Prof. Gerolama CONDORELLI,
Dipartimento di Biologia e Patologia Cellulare e 
Molecolare & Facoltà di Scienze Biotecnologiche, 
Università degli Studi di Napoli ‘Federico II’, 
Via Pansini, 5, 80131 Naples, Italy. 
Tel.: +39 081 7464416
Fax: +39 081 7701016 
E-mail: gecondor@unina.it
© 2007 The Authors
Journal compilation © 2007 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
doi:10.1111/j.1582-4934.2008.00283.x
J. Cell. Mol. Med. Vol 12, No 6A, 2008
2417© 2007 The Authors
Journal compilation © 2007 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
highly expressed in a wide variety of normal cells, but the expression
of decoy receptors is substantially limited in tumour cells [4, 5]. 
Treatment with TRAIL induces programmed cell death in a
wide range of transformed cells, both in vitro and in vivo,
without producing significant effects in normal cells [6, 7]. This
unique property makes TRAIL an attractive candidate for cancer
therapy. However, a significant proportion of cancer cell lines is
resistant to TRAIL-induced apoptosis [8]. Apoptotic signalling
could be opposed by enhanced expression of intracellular
molecules acting at multiple levels [9, 10]. Among these mole-
cules is PED (phosphoprotein enriched in diabetes) (known also
as PED/PEA-15), a death-effector domain (DED) family member of
15 kD involved in cell growth and metabolism [9, 11, 12]. PED
inhibits the formation of a functional death-inducing signalling
complex (DISC) and the activation of caspase 8, which take place
following treatment with different apoptotic cytokines including
CD95/FasL, TNF- and TRAIL [9, 13–16]. The anti-apoptotic
action of PED is accomplished, at least in part, through its DED
domain, which acts as a competitive inhibitor for pro-apoptotic
molecules during the assembly of the DISC [9, 15]. PED is over-
expressed in a number of different tumours, including human
glioma [13], squamous carcinoma [17], breast cancer [18] and 
B-cell lymphocytic leukaemia [19]. We recently reported that
human breast cancer cells express high levels of PED and that
AKT/PKB activity regulates PED protein levels [18, 19].
Furthermore, high PED expression levels determine resistance of
breast cancer cells to chemotherapy-induced cell death.
In this study, we focused on the involvement of PED in deter-
mining the ‘TRAIL-resistant phenotype’ in NSCLC. We analysed
PED expression in specimens from 27 NSCLC-affected patients
and in a large human tissue microarray containing 160 lung
tumour samples. The effect of silencing PED expression in NSCLC
cell lines was also investigated.
Methods
Materials
Media, sera and antibiotics for cell culture were from Life Technologies,
Inc. (Grand Island, NY, USA). Protein electrophoresis reagents were from
Bio-Rad (Richmond, VA, USA), and Western blotting and ECL reagents
were from Amersham (Aringhton Heights, IL, USA). All other chemicals
were from Sigma (St. Louis, MO, USA) unless otherwise stated. The fol-
lowing primary antibodies were used: anti-PED antibody [11]; anti--actin
antibody (Ab-1, mouse IgM, Oncogene, Darmstadt, Germany); anti-cas-
pase 8 antibody (1C12, Cell Signaling Technology, Inc., Danvers, MA,
USA), anti-caspase 3 antibody (Abcam, Cambridge, USA); anti-caspase 10
antibody (StressGene, Victoria, BC Canada); anti-cFLIP (NF6) antibody
(Alexis, Lausen, Switzerland); anti-FADD antibody (BD Transduction
Laboratories, San Jose, CA, USA); anti-TRAIL receptor antibodies (R&D
Systems, Minneapolis, MN, USA) and anti PARP antibody (SC7150 Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
Cell culture
Human CALU-1 and A459 NSCLC cell lines were grown in DMEM; H460
and A549 cell lines were grown in RPMI. Media were supplemented with
10% heat-inactivated FBS, 2 mM L-glutamine and 100 U/ml penicillin-
streptomycin.
Protein isolation and Western blotting
Lung tissue specimens (neoplastic and adjacent normal tissue) were col-
lected during surgical intervention on 27 patients affected with lung
tumour, in accordance with the ethical standards of the institutional
responsible committee on human experimentation. The clinical and patho-
logical characterization (including tumor, node, metastasis (TNM) staging)
of these patients, which were not receiving medical treatment at the time
of the operation, is shown in Table 1. The collected samples were homog-
enized in 1 ml PBS (0.14M NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.5 mM
KH2PO4) containing 1% Triton X-100 and proteinase inhibitor cocktail, with
a tissue homogenator. Cultured cells were pelleted, washed twice with cold
PBS and lysed in the same harvest buffer. Solubilized proteins were incu-
bated for 30 min. on ice, and after centrifugation at 10,000g for 30 min. at
4°C, supernatants were collected. Fifty micrograms of sample extract were
resolved on 12% SDS-polyacrylamide gels using a mini-gel apparatus and
transferred to Hybond-C extra nitrocellulose. Membranes were blocked for
1 hr with 5% non-fat dry milk in Tris Buffered Saline (TBS) containing
0.05% Tween-20, incubated for 2 hrs with primary antibody, washed and
incubated with secondary antibody, and visualized by chemiluminescence.
Cell death and cell proliferation quantification
Cells were plated in 96-well plates in triplicate and incubated at 37°C in a
5% CO2 incubator. To induce apoptosis, Superkiller TRAIL (Alexis
Biochemicals) was used for 24 hrs at 10 ng/ml. Cell viability was evaluat-
ed with the CellTiter 96® AQueous One Solution Cell Proliferation Assay
(Promega, Madison, WI, USA), according to the manufacturer’s protocol.
Metabolically active cells were detected by adding 20 l of MTS to each
well. After 2 hrs of incubation, the plates were analysed in a Multilabel
Counter (Bio-Rad). Apoptosis was also assessed using annexin V-FITC
Apoptosis Detection Kits followed by flow cytometric analysis. Cells were
seeded at 1.8  106 cells per 100-mm dish, grown overnight in 10% Fetal
Bovine Serum (FBS)/RPMI, washed with PBS, then treated for 24 hrs with
200 ng TRAIL. Following incubation, cells were washed with cold PBS and
removed from the plates by very mild trypsinization conditions (0.01%
trypsin/ethylene diaminetetraacetic acid). The resuspended cells were
washed with cold PBS and stained with FITC-conjugated annexin V antibody
and propidium iodide according to the instructions provided by the manu-
facturer (Roche Applied Science, Indianapolis, IN, USA). Cells (50,000 per
sample) were then subjected to flow cytometric analysis. Propidium iodide
staining and flow cytometry analysis were done as described [19].
Flow cytometry
The relative level of surface TRAIL receptors was assessed by FACS analy-
sis. To this end, 1 million cells were collected and washed twice in PBS,
incubated with PE-conjugated purified monoclonal antibodies against
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TRAIL receptors or with mouse isotype control phycoerythrin IgG2b for 1
hr on ice, and then washed once with 3 ml PBS. After centrifugation, the
cell pellet was resuspended in 1 ml PBS and analysed with a FACSsort
(Becton Dickinson, Franklin Lakes, NJ, USA).
Small interfering (si) RNAs
The Dharmacon siDesign Center software program was used to design a
duplex siRNA targeting PED mRNA (siPED). This duplex consisted of a 21 nt
double-stranded RNA, comprised 19 base pairs with two T, 3’ overhanging
ends, synthesized by Invitrogen (Invitrogen Corporation, Carlsbad, CA, USA)
(UCACUAUGGUGGUUGACUATT). c-FLIP siRNA was purchased from Santa
Cruz Biotechnology, Inc. (sc-35388). siCONTROL Non-Targeting siRNA
Pool #2 (D-001206-14-05) was from Dhamarcon (Lafayette, CO, USA) and
comprised four siCONTROL non-targeting siRNAs. Each individual siRNA
within this pool was characterized by genome-wide microarray analysis
and found to have minimal off-target signatures. 
Transfection experiments
CALU-1 or H460 cells were cultured to 80% confluence in p60 plates.
Control, PED or cFLIP siRNA (100 nM), PED or c-FLIP siRNA were tran-
siently transfected in cells kept in antibiotic-free, serum-containing medium,
using LIPOFECTAMINE 2000, according to the manufacturer’s instructions.
Cells were incubated with siRNAs for the indicated times. PED protein lev-
els were up-regulated where indicated by transfecting cells with 5 g of
pcDNA3-Myc PED [12]. 
Tissue microarray construction 
and immunohistochemistry
Cylinders of 0.6-mm diameter were punched from donor blocks in areas
identified as neoplastic after analysis of haematoxylin and eosin stained
sections. The tissue cylinders were inserted into a recipient paraffin block
using a precision instrument (Beecher Instruments, Sun Prairie, WI, USA)
[20]. Standard indirect staining procedures were used for immunohisto-
chemistry (ABC-Elite-Kit, Vector Laboratories, Burlingame, CA, USA). After
heat-induced pre-treatment (in citrate buffer, pH 6, water bath at 90°C for
30 min.) for antigen retrieval, a rabbit polyclonal anti-PED antibody [11]
was applied for 2 hrs at a dilution of 1:5000 at 37°C. The slides were then
incubated with the secondary, biotinylated antibody. Osmium-enhanced
diaminobenzidine was used as the chromogen. Counterstaining was car-
ried out with Harris’ haematoxylin. Only fresh cut sections were stained to
minimize the influence of slide ageing and maximize repeatability and
reproducibility of the experiment. For negative controls, the primary anti-
body was omitted; as positive control, normal tissue with known PED pos-
itivity was used. For each sample, percentage of positive tumour cells and
staining intensity (0, faint, moderate or intense) were recorded. A case was
graded: (i ) negative, if no cells were stained; (ii ) weakly positive (mild), if
up to 33% of cells were stained; (iii ) moderately positive if 34–66% of cells
were stained or (iv) strongly positive if 67–100% of cells were positive.
Staining intensity was not used for correlation with clinical findings, as it
can vary depending on the manner of tissue fixation. The slides were all
evaluated in 1 day by an experienced pathologist (DB).
Results
PED expression in NSCLC tissue
Specimens were collected from 27 NSCLC-affected patients (clinical
features are summarized in Table 1) and processed for Western
blotting. PED was increased in the tumour tissue of all the patients
P # Sex Age Histology TNM
1 M 49 ADENO T1N0MX
2 M 61 ADENO T2N2MX
3 M 68 ADENO T3N0MX
4 M 64 ADENO T1N0MX
5 M 63 ADENO T2N1MX
6 M 55 ADENO T2N2MX
7 M 56 ADENO T2N0MX
8 M 56 SQUAM T1N1MX
9 M 63 ADENO T3N2MX
10 M 66 ADENO T1N1MX
11 M 77 ADENO T1N0MX
12 M 69 SQUAM T2N0MX
13 M 61 SQUAM T2N0MX
14 F 52 ADENO T2N0MX
15 M 57 ADENO T2N2M1
16 M 80 SQUAM T2N0MX
17 M 63 ADENO T1N2MX
18 M 55 ADENO T1N2MX
19 M 63 SQUAM T2N0MX
20 M 67 SQUAM T1N0MX
21 M 63 SQUAM T1N0MX
22 M 70 SQUAM T3N0MX
23 M 68 SQUAM T1N0MX
24 M 55 ADENO T1N0MX
25 M 64 ADENO T1N0MX
26 M 69 SQUAM T2N0MX
27 M 68 ADENO T1N0MX
Table 1 Clinical features of the patients
Age (years), sex and TNM (tumour, node, metastasis) staging [30] of
patients (P) are reported. All patients were smokers. Histology of the
tumours indicated that most were adenocarcinoma (ADENO) and the
remaining squamous cell carcinomas (SQUAM). 
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analysed and only rarely expressed in the adjacent normal tissue
(Fig. 1A). The mean PED expression level was sixfold higher in the
transformed areas compared to normal tissue (Fig. 1B).
Furthermore, analysis of TNM staging revealed that the expression
of PED was greater during the initial stages of the disease (T1 and
N0) than in T2 and N1 lesions (Fig. 1C). We also analysed PED
expression on a tissue microarray constructed from 160 different
histological lung cancer samples. As shown in Table 2, PED expres-
sion was considered high in the majority of cases and in all the types
of lung tumour present, with only 4% of the tumours analysed
resulting negative for PED staining. Immunohistochemical analysis
of PED expression is depicted in Fig. 2 where it is possible to
evaluate the different PED staining intensity. Part (A) represents an
example of PED negative staining; part (B), of mild; part (C) of mod-
erate and part (D) of strong PED staining. The majority of samples
showed strong staining for PED.
PED expression correlates with
resistance to TRAIL in NSCLC cell lines
PED is a DED-containing protein that inhibits the formation of a
functional DISC following treatment with different apoptotic stim-
uli, including TRAIL, in several cell types [9, 15, 21]. We therefore,
investigated whether PED expression correlated with resistance to
TRAIL in different NSCLC cell lines. As shown in Fig. 3A, PED is
Fig. 1 PED expression is
increased in human lung
cancer. (A) Western blots
showing expression of
PED in tumour (T) and
adjacent normal (N) lung
tissue from some of the 27
NSCLC-affected patients
(Pt). -Actin was used for
the loading control. (B)
Graph of densitometric
analysis. Mean  SD PED
expression of all the
tumour samples (T) nor-
malized to -actin and
expressed as percentage
respect to the adjacent
normal tissue (N). PED
was >6-fold higher in can-
cer tissue compared to
normal areas. (C) PED
expression during T1, T2,
T3 and N0, N1 and N2
stages of the disease. PED
expression is greater dur-
ing the initial stages (T1
and N0) of the disease
compared with the T2 and
N1 lesions.
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expressed at higher levels in CALU-1 cells compared to H460 cells.
Intermediate levels of expression were observed in A459 and
A549 cells. When exposed to TRAIL, H460 cells underwent TRAIL-
induced cell death, whereas CALU-1 cells were completely resist-
ant (Fig. 3B and C). A459 and A549 cells exhibited intermediate
sensitivities to TRAIL (Fig. 3B and C). Therefore, PED expression
levels correlated with TRAIL resistance in the NSCLC cell lines
analysed. We also studied several components of the extrinsic cell
death signalling pathway. As shown in Fig. 3A, the expression of
these TRAIL signalling molecules was comparable in the four cell
lines, although c-FLIP expression was slightly lower in H460 cells. 
TRAIL resistance in NSCLC cells
does not depend on the expression 
of TRAIL receptors
TRAIL resistance could be correlated with different expression
levels of TRAIL receptors. To exclude this possibility, we investi-
gated the cell surface expression of all four TRAIL receptor sub-
types in CALU-1 and H460 cells. As shown in Fig. 4, expression
of functional and decoy TRAIL receptors was comparable in the
two cell lines.
Histological type
PED expression
Total
Negative sssMild Moderate Strong
Adenocarcinoma 1 (2.3%) 8 (18.6%) 10 (23.2%) 24 (55.8%) 43
Large cell carcinoma 1 (2.4%) 2 (4.8%) 15 (36.5%) 23 (56.1%) 41
Small cell carcinoma 2 (6.6%) 5 (16.6%) 7 (23.3%) 16 (53.3%) 30
Squamous cell carcinoma 2 (4.3%) 11 (23.9%) 13 (28.2%) 20 (43.4%) 46
Top number indicates number of cases present in the tissue microarray; the bottom number indicates its relative percentage. PED expression was
graded: negative: no staining; mild: 0–33% positively staining cells; moderate: 34–66% positively staining cells and strong: 67–100% positively
staining cells.
Fig. 2 PED expression levels in NSCLC
cancer samples. Immunohistochemical
analysis of paraffin-embedded NSCLC sec-
tions labelled with anti-PED antibody
(1:5000) and revealed by secondary,
biotinylated antibody. (A) Negative; (B) mild;
(C) moderate and (D) strong staining.
Table 2 PED expression analysed in the lung cancer tissue microarray
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Effect of the down-regulation of PED and c-FLIP
on insensitivity to TRAIL in CALU-1 cells
To better clarify the role of PED in TRAIL resistance in lung cancer
cells, we transfected CALU-1 cells with PED siRNA. PED siRNA
specificity was tested in CALU-1 cells by the co-transfection of
PED siRNA with Myc-tagged PED cDNA [12]. The PED siRNA
duplex suppressed both endogenous (15 kD) and exogenous (23
kD) PED expression, whereas a control siRNA was not effective in
reducing PED protein levels (Fig. 5A). This silencing effect was
evident at 48 hrs and more marked at 72 hrs. We found that also
other in cell lines (HeLa, Human embryonic kidney 293) PED
siRNA was able to knock-down PED expression (data not shown).
Transfected cells were then exposed to TRAIL. As expected,
siRNA-mediated knock-down of PED was responsible for sensiti-
zation of CALU-1 cells to TRAIL-induced cell death (Fig. 5B).
Interestingly, comparable results were obtained when we
knocked-down PED expression in A459 and A549 cells (Fig. 5B).
The treatment of CALU-1 cells with a specific c-FLIPL siRNA
down-regulated c-FLIPL expression but did not increase sensitivi-
ty to TRAIL-induced cell death (Fig. 5C). These data further con-
firm that PED protects lung cancer cells from TRAIL-induced
apoptosis, and that inhibiting PED expression results in increased
TRAIL sensitivity.
Effects of silencing PED on caspase activation 
in CALU-1 cells
We then examined the activation of caspase 8 and PARP upon
exposure to TRAIL in CALU-1 cells treated with PED siRNA. As
shown in Fig. 6A, TRAIL-induced caspase 8 and PARP activation
was greater in CALU-1 cells following PED siRNA transfection.
Effect of increasing PED expression on TRAIL 
sensitivity in H460 cells
To further evaluate the role of PED in apoptosis resistance, TRAIL-
sensitive H460 cells were transfected with PED cDNA to up-regulate
Fig. 3 PED expression correlates with TRAIL resistance in NSCLC cell
lines. (A) Fifty micrograms of total cell extract from CALU-1, H460,
A459 and A549 cells were analysed by Western blotting for the expres-
sion of PED and other TRAIL signalling molecules. -Actin was used
as the loading control. Representative blots are shown. (B) Viability
after treatment with TRAIL. Cells were incubated with superkiller TRAIL
(10 ng/ml) for 24 hrs and viability evaluated as described in the meth-
ods section. Mean  SD of three independent experiments in triplicate.
(C) Annexin V and propidium iodide staining of NSCLC cells after
TRAIL treatment. Mean  SD of four independent experiments in
duplicate.
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PED protein levels and then analysed for their susceptibility to
TRAIL-induced cell death. Increasing the expression of PED in
these cells (Fig. 6C) rendered them resistant to TRAIL, as
assessed by Western blotting for caspase 8 and PARP (Fig. 6B) or
by a cell viability assay (Fig. 6D).
Discussion
Increased expression of DED family members with anti-apoptotic
functions, such as PED, represents a possible mechanism by
which tumour cells escape apoptosis. PED acts primarily by pre-
venting the interaction between the adaptor molecule, FADD, and
procaspase-8 [9, 15]. We have reported that PED inhibits the
anti-apoptotic signal of death receptors in many different cell
types, including breast carcinoma and glioma [9, 13–16], in
which it is overexpressed. Lung tumours are among the most
aggressive types of cancer and are frequently resistant to drug-
induced cell death [1]. Eighty percentage of lung cancers are of
the NSCLC type. Advances in standard treatment for this tumour,
such as surgery, radiotherapy and chemotherapy, have not signif-
icantly increased patient survival. Thus, novel treatment strate-
gies are urgently needed to improve the clinical management of
this serious disease. Recent studies have demonstrated that tar-
geting TNF superfamily death receptors is a promising strategy
for the treatment of cancer [22]. Apoptosis-based anti-cancer
therapies are designed to achieve tumour eradication through the
Fig. 4 Surface expression of TRAIL receptors does not differ in TRAIL-resistant and TRAIL-sensitive cells. Surface expression of the
four TRAIL receptor isotopes (R1, R2, R3 and R4) was analysed by flow cytometry with specific PE-conjugated antibodies. Isotype-
matched antibodies were used as control for unspecific binding. Receptor expression levels were comparable in CALU-1 and H460 cells. 
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Fig. 5 Down-regulation of PED restores TRAIL sensitivity in CALU-1 cells. (A) PED siRNA or a control oligo were transiently transfected in CALU-1
cells in the presence or absence of PED-Myc cDNA. Cells were incubated for 48 or 72 hrs and analysed by Western blotting. The PED siRNA duplex
suppressed both exogenous and endogenous PED expression, whereas control siRNA had no effects. (B) PED siRNA effects in A459 and A549 cells.
PEDsi RNA, transfected in NSCLC cells was able to reduce PED expression levels (right panel) and induce an increase in TRAIL sensitivity (left panel),
as assessed by flow cytometry. Mean  SD of two independent experiments in duplicate. (C) c-FLIPL siRNA or PED siRNA were transfected as
described in Methods. Cells were analysed for c-FLIP expression after 72 hrs incubation. c-FLIPL siRNA but not PED siRNA was able to reduce 
c-FLIPL expression Effects of silencing PED and c-FLIPL on TRAIL-induced cell death: CALU-1 cells were transfected with siRNA for PED, c-FLIPL or
control for 48 hrs, after which cells were trypsinized, plated in 96-well plates in triplicate and further incubated with superkiller TRAIL for 24 hrs.
Metabolically active cells were then detected as indicated in the Methods. Mean  SD of four independent experiments in duplicate. Down-regulation
of PED, but not cFLIPL, was responsible for increased sensitivity of CALU-1 cells to TRAIL-mediated cell death.
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Fig. 6 Effects of PED on caspase activation. (A) CALU-1 cells were transfected with PED or control siRNA for 72 hrs and then treated with superkiller
TRAIL for the indicated times. Lysates were examined by Western blotting with anti-caspase 8 or anti-PARP antibodies. Cleavage of caspase 8 and
PARP was detected at a greater amount in CALU-1 cells transfected with PED siRNA. -Actin was used as the loading control. (B) PED cDNA 
(PED-Myc) was transiently transfected in H460 cells and cells were analysed for caspase 8 and PARP activation as previously described or for or for
cell viability (D) as indicated. (C) Western blot analysis of PED expression revealed that transfection increased PED expression levels in H460 cells.
-Actin was used as the loading control. Representative blots are shown.
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use of death-inducing molecules capable of activating the apop-
totic program selectively in neoplastic cells. Due to its specific
toxicity for transformed cells, recombinant forms of TRAIL are
among the most promising apoptosis-based anti-tumour agents
[7, 23–25]. In fact, a number of biotech and pharmaceutical com-
panies developed recombinant TRAIL/Apo2L as well as human-
ized agonistic mAb targeting TRAIL-R1 or TRAIL-R2 that are cur-
rently being evaluated in phase I and phase II clinical trails [7].
However, in a number of patients, tumour cells evade death sig-
nals generated by drugs through the activation of effective anti-
apoptotic mechanisms [26–28]. In the present report, we demon-
strate that PED is overexpressed in lung cancer tissue obtained
from 27 NSCLC-affected patients. Interestingly, TNM staging
revealed that PED expression is greater during the first phase of
the disease (T1) than in T2 lesions. The analysis of PED expres-
sion in pre-malignant lesions, such as metaplastic bronchial
lesions, could shed light on the role of PED in tumour initiation,
progression and invasiveness. This study shows that PED regu-
lates the susceptibility to TRAIL-induced death in lung cancer
cells. In fact, although the levels of PED differ significantly in
CALU-1 (TRAIL-insensitive) and H460 (TRAIL-sensitive) cells,
the levels of the other signalling components (such as TRAIL
receptors caspases, and FADD) were comparable. Modulation of
the sensitivity to TRAIL by PED was confirmed by down regulat-
ing PED expression with PED siRNA: when transfected, the oth-
erwise TRAIL-insensitive CALU-1 cells became susceptible to this
cytotoxic cytokine. Moreover, PED overexpression in H460 cells
was able to change their phenotype from TRAIL-sensitive to
TRAIL insensitive. 
Because resistance of different tumours may be mediated by
diverse survival mechanisms, we investigated the role of c-FLIP in
TRAIL resistance by down-regulation of c-FLIP expression with a
specific siRNA. As already observed in other tumour types such as
glioma [13] and B-cell chronic leukaemia [19], the effects of PED
are prevalent over those mediated by c-FLIP for sensitivity to
TRAIL. Thus, it is possible that c-FLIP and PED contribute differ-
ently, depending to the cell type or tumour type to induce resist-
ance to TRAIL. Our data thus demonstrate that PED plays a major
role in TRAIL resistance in NSCLC. Although PED expression was
completely and specifically inhibited by the transfection with PED
siRNA duplex, TRAIL sensitivity was not fully recovered. These
results suggest that it is likely that there might be alternative
mechanisms for TRAIL resistance. We have recently addressed
this point by a microRNAs screening of TRAIL resistance in
NSCLC and found several new microRNAs and targets involved in
TRAIL resistance (Garofalo et al., in press).
Mice that are genetically deficient in the TRAIL gene, exhibit
increased susceptibility to experimental and spontaneous tumours
[29], suggesting an important role of endogenous TRAIL in
tumour surveillance. Thus, the overexpression of a gene involved
in resistance to TRAIL could be important for responsiveness to
chemotherapy. Because expression levels of PED are a focal point
for the regulation of apoptosis, PED represents a key target for
treatment of cancer.
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To deﬁne novel pathways that regulate susceptibility to
tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL) in non-small cell lung cancer (NSCLC),
we have performed genome-wide expression proﬁling of
microRNAs (miRs). We show that in TRAIL-resistant
NSCLC cells, levels of different miRs are increased,
and in particular, miR-221 and -222. We demonstrate
that these miRs impair TRAIL-dependent apoptosis by
inhibiting the expression of key functional proteins.
Indeed, transfection with anti-miR-221 and -222 rendered
CALU-1-resistant cells sensitive to TRAIL. Conversely,
H460-sensitive cells treated with -221 and -222 pre-miRs
become resistant to TRAIL. miR-221 and -222 target the
30-UTR of Kit and p27kip1 mRNAs, but interfere with
TRAIL signaling mainly through p27kip1. In conclusion, we
show that high expression levels of miR-221 and -222 are
needed to maintain the TRAIL-resistant phenotype, thus
making these miRs as promising therapeutic targets or
diagnostic tool for TRAIL resistance in NSCLC.
Oncogene advance online publication, 4 February 2008;
doi:10.1038/onc.2008.6
Keywords: microRNA; non-small cell lung cancer;
apoptosis
Introduction
MicroRNAs (miRs) are a small noncoding family of
19–25nt RNAs that play an important role in the negative
regulation of gene expression by base-pairing to
complementary sites on the target mRNAs (Calin and
Croce, 2006). CurrentlyX460 miRs have been identiﬁed
in humans and other eukaryotic species (miR registry,
www.sanger.ac.uk/Software/Rfam/mirna/index.shtml).
The expression pattern of miRs is often developmentally
regulated and/or tissue speciﬁc, although some miRs are
steadily expressed in the whole organism (Liu et al.,
2004; Sempere et al., 2004). In lower species, miRs are
involved in a variety of basic processes, for example, cell
proliferation and apoptosis (Xu et al., 2004; Cheng
et al., 2005), neuronal development (Smirnova et al.,
2005), fat metabolism (Xu et al., 2003) and stress
response (Dresios et al., 2005). In some studies, key
target mRNAs have been identiﬁed but relatively little is
known about the functional role of miRNAs in
mammalian species. We do know, however, that miR-
181 is involved in the control of lymphopoiesis (Chen
et al., 2004), miR-375 regulates insulin secretion by
targeting myotrophin mRNA (Poy et al., 2004), and the
miR-let7 family may play a role in oncogenesis via RAS
oncogene mRNAs (Johnson et al., 2005). miR-15a and
miR-16-1 are deleted or downregulated in the majority
of chronic lymphocytic leukemia (Calin et al., 2005).
Functional studies indicated that miR-221 and -222
inhibit normal erythropoiesis and erythroleukemic cell
growth at least in part via Kit receptor downmodulation
(Felli et al., 2005), and their ectopic overexpression
directly results in p27kip1 downregulation in aggressive
prostate carcinoma (Galardi et al., 2007). Lung tumors
are among the most deadly types of cancer. Advances in
standard treatments for this tumor, such as surgery,
radiotherapy and chemotherapy, have not signiﬁcantly
increased patient survival. One of the most important
issues that affects survival rate is resistance to ther-
apeutic drugs. Only 20–30% of treated non-small cell
lung cancer (NSCLC) patients have clinical evidence of
a response. Therefore, the development of new ther-
apeutic strategies is necessary for the treatment of this
type of cancer. The Apo2L/tumor necrosis factor
(TNF)-a-related apoptosis-inducing ligand (TRAIL) is
a relatively new member of the TNF family known to
induce apoptosis in a variety of cancers (Schaefer et al.,
2007). TRAIL can bind to ﬁve receptors, of which four
are located at the cell surface: TRAIL-R1 (DR4),
TRAIL-R2 (DR5), TRAIL-R3 (DcR1) and TRAIL-
R4 (DcR2). Only two of these receptors, R1 and R2,
contain a functional cytoplasmic death domain motif
and are capable of delivering the apoptotic signal of
Received 13 November 2007; revised 21 December 2007; accepted 4
January 2008
Correspondence: Professor G Condorelli, Dipartimento di Biologia e
Patologia Cellulare e Molecolare and Facolta` di Scienze Biotecnolo-
giche, Universita` degli Studi di Napoli Federico II, Via Pansini 5,
Naples 80131, Italy.
E-mail: gecondor@unina.it
Oncogene (2008), 1–11
& 2008 Nature Publishing Group All rights reserved 0950-9232/08 $30.00
www.nature.com/onc
TRAIL by association of the death domain with the
Fas-associated death domain protein (FADD), contain-
ing the death effector domain, which is involved in the
activation of caspase 8 (Falschlehner et al., 2007). The
other two receptors, DcR1 and DcR2, are ‘decoy
receptors’ and lack the ability to initiate the apoptotic
cascade. Treatment with TRAIL induces programmed
cell death in a wide range of transformed cells, both
in vitro and in vivo, without producing signiﬁcant effects
in normal cells (Falschlehner et al., 2007; Schaefer et al.,
2007). However, a signiﬁcant proportion of human
cancer cells are resistant to TRAIL-induced apoptosis,
and the mechanism of sensitization seems to differ
among cell types. Different studies relate resistance to
TRAIL-induced cell death to downstream factors. It has
been shown that downregulation of PED or cellular
FLICE-like inhibitory protein (c-Flip) can sensitize cells
to TRAIL-induced apoptosis (Fulda et al., 2000;
Garofalo et al., 2007). However, the mechanism of
TRAIL resistance is still largely unknown.
In this study, to identify novel mechanisms implicated
in TRAIL resistance, we performed a genome-wide
expression proﬁling of miRs in four different cell lines.
We found that miR-221 and -222 are markedly
upregulated in TRAIL-resistant, and downregulated in
TRAIL-sensitive, NSCLC cells. Our experiments indicate
that miR-221 and -222 modulate TRAIL sensitivity in
lung cancer cells mainly by modulating p27kip1 expression
and TRAIL-induced caspase machinery.
Results
The cytotoxic effects of TRAIL in human non-small cell
lung cancer
We analysed TRAIL sensitivity of different human
NSCLC cell lines: A459, A549, CALU-1 and H460.
Cells were exposed to TRAIL for 24 and 48 h
(Figure 1a) after which cell death was assessed using
a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay or by ﬂuorescence-activated cell
sorting (FACS) with annexin V and propidium iodide
staining (data not shown). As shown in Figure 1a, H460
cells underwent TRAIL-induced cell death whereas
CALU-1 cells did not display sensitivity when exposed
to soluble TRAIL; A459 and A549 cells showed an
intermediate sensitivity. A possible mechanism of the
differential sensitivity of the tested cells to TRAIL-
induced apoptosis could be due to the variability of the
cell surface levels of the death receptors resulting in
increased apoptotic signaling in the sensitive cells.
However, functional TRAIL receptor isoforms
(TRAIL-R1 and -R2) analysed by western blot
(Figure 1b) or FACS analysis (data not shown) revealed
comparable levels of expression in TRAIL-sensitive
compared to TRAIL-resistant cells. Furthermore,
although H460 cells express low levels of DcR1, the
expression of DcR2 receptor is greater compared to
CALU-1. Therefore, the expression of the decoy
receptors within the two cell lines is balanced.
miRs expression screening in TRAIL-resistant
versus -sensitive NSCLC cell lines
To investigate the involvement of miRs in TRAIL
resistance, we analysed the miRs expression proﬁle in
TRAIL-resistant (CALU-1) and semi-resistant NSCLC
cell lines (A459 and A549) versus TRAIL-sensitive cell
line (H460). The analysis was performed with a
microarray chip containing 1150 miR probes, including
326 human and 249 mouse miRs, spotted in duplicates
(Liu et al., 2004). Pair-wise signiﬁcance analysis (PAM)
of the microarray indicated that ﬁve miR genes were
signiﬁcantly overexpressed in resistant NSCLC cells
with a >1.5-fold change (Figure 2). These miRs were
miR-222, -100, -221, -125b and -15b (Table 1). Three of
these miRs, miR-222, -221 and -100, showed dramatic
overexpression with 5- to 8-fold higher levels in resistant
Figure 1 Sensitivity of non-small cell lung cancer (NSCLC) to
tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL)-inducing apoptosis. (a) NSCLC cells were incubated with
Super-Killer-TRAIL (400 ngml1) for 24 and 48 h and viability was
evaluated as described in ‘Experimental procedures’ section.
Mean±s.d. of four independent experiments repeated in triplicate.
H460 cells were more sensitive to TRAIL-induced apoptosis
compared to CALU-1. A459 and A549 exhibited an intermediate
sensitivity. (b) TRAIL receptors expression in CALU-1 and
H460 cells. Total extract (50mg) was loaded onto 10%
SDS–polyacrylamide gels (PAGE). The membrane was blotted
with anti-TRAIL-R1/DR4, TRAIL/DR5 (1mgml1) and DcR1
and DcR2 antibodies (0.5 mgml1). Loading control was obtained
with anti-b-actin antibody (1:5000).
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NSCLC cells compared to the sensitive NSCLC cells.
Downregulation occurred for only two miRs, miR-9 and
-96 (Table 1). To validate the microarray analysis, we
performed quantitative real-time-polymerase chain
reaction (qRT-PCR) of the most overexpressed miRs
(miR-222, -100, -221, -125b) and of the downregulated
miR-9 in NSCLC cells. The analysis conﬁrmed the
results obtained by the microarray (Figure 3a). The
expression of miR-222 in NSCLC cells was also
conﬁrmed with Northern blot (Figure 3b).
Role of miR-221 and -222 in TRAIL resistance
in NSCLC
To test the role of these overexpressed miRs in
TRAIL sensitivity in lung cancer, we transfected H460
TRAIL-sensitive cells with pre-miR-221 and -222.
Increased expression of these miRs upon transfection
was conﬁrmed by real-time PCR (data not shown).
Overexpression of miR-221 and -222 in H460 cells made
these cells more resistant to TRAIL-induced cell death
by about 40%, as assessed by MTT assay (Figure 4a).
Figure 2 MicroRNA (miR) expression signature in resistant versus sensitive non-small cell lung cancer (NSCLC) cells. Fold changes (resistant
versus sensitive) of the miRs present in NSCLC cells. The tree displays the log2 transformation of the average fold changes. Arrays were mean
centered and normalized by using Gene Cluster 2.0. Average linkage clustering was performed by using uncensored correlation metric.
Table 1 Up- and downregulated miRs in TRAIL-resistant NSCLC cells
miRNAs Chromosomal location Fold change
has-miR-222 Xp11.3 8.6
has-miR-100 3q 26.1 8.3
has-miR-221 Xp11.3 5.9
has-miR-125b 11q23-24 5.4
has-miR-15b 3q26.1 3.6
hasmiR96 7q32.2 0.5
has-miR-9 1q23.1 0.072
All differentially expressed miRs have Qo0.01 (false-positive rate).
t-Test, Po0.05. These miRs were identiﬁed by PAM as predictor of
NSCLC with the lowest misclassiﬁcation error. All the miRs, except
miR-9 and -96, are upregulated in the TRAIL-resistant cells compared
to the TRAIL-sensitive one.
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The same results were obtained by annexin V–ﬂuore-
scein isothiocyanate (FITC) staining (Figure 4b).
Interestingly, pre-miR-100 also increased TRAIL
sensitivity, while pre-miR-125b and control miR
overexpression did not produce any effect (data not
shown). We also tested the effects of miRs 221 and
222 on the activation of caspase 8, 3 and poly-
(ADP-ribose)polymerase (PARP). Interestingly, while
in H460 cells, TRAIL induced the activation of caspase
cascade, as assessed by the appearance of the cleaved
fragment, the co-incubation of TRAIL with pre-miRs
221 or 222 induced a reduction of TRAIL-mediated cell
death machinery activation (Figure 4c). We also tested
the effect of miR-221 and -222 on the expression of some
of TRAIL signaling molecules. Interestingly, Mcl-1 and
FADD were upregulated, suggesting an indirect effect of
those miRs. TRAIL receptors expression was not
affected by miR-221 and -222 upmodulation (Figure 4e).
Anti-miR inhibitors are sequence-speciﬁc nucleotides
that speciﬁcally target and knock down individual miR
molecules. We transfected CALU-1 TRAIL-resistant
cells with anti-miR inhibitors -221 and -222 and then
assessed TRAIL sensitivity. The levels of miR-221
and -222, assessed by real time (RT)–PCR, were reduced
(data not shown). Interestingly, the inhibition of miR-
221 and -222 expression with the speciﬁc anti-miR
inhibitor was able to change the insensitive TRAIL
phenotype to a sensitive one (Figure 5a). A scrambled
nonspeciﬁc anti-miR did not produce any effect.
TRAIL receptors expression was not affected by
miR-221 and -222 downmodulation (Figure 5b).
p27kip1 and Kit expression in NSCLC
We analysed the predicted targets of the three most
signiﬁcantly overexpressed miRNAs (miR-222, -100 and
-221) in TRAIL-resistant cells. In this study, we focused
on miR-221 and -222, which are located close to each
other on the short arm of the X chromosome. The
concordant expression pattern in NSCLC suggested
shared regulatory mechanisms for the expression of
these two clustered miRs. They are upregulated in
miR-222
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Figure 3 MicroRNAs (miRs) down- and upregulated in tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL)-resistant or -sensitive non-small cell lung cancer (NSCLC) cells. (a) Real-time PCR of the most promising miR targets
obtained with microarray screening was performed by extracting RNA from the different NSCLC cells, as described in ‘Experimental
procedures’ section. Total 5 mg of RNA in 10 ml PCR reaction was used. TaqMan DCT values were converted into absolute copy
numbers using a standard curve from synthetic lin-4 miRNA. Data are expressed as the relative expression of the different miRs,
compared to 18S rRNA. miRs 222, 100, 221, 125b were markedly upmodulated in resistant but not in sensitive cell cultures, while
miR-9 was markedly downmodulated. (b) Northern blot analysis of miR-222 expression. RNA (10mg) was loaded onto a precast 15%
denaturing polyacrylamide gel (Bio-Rad). RNA was then electrophoretically transferred to BrightStar blotting membranes and
membrane incubated with labeled miR-222 probe. miR-222 was strongly upregulated in TRAIL-resistant CALU-1 cells.
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TRAIL-resistant NSCLC cells and may promote
TRAIL resistance by blocking expression of key
functional proteins. Different studies have demonstrated
that both the proto-oncogene Kit and the tumor
suppressor p27kip1 are miR-221 and -222 targets (Felli
et al., 2005; He et al., 2005; Poliseno et al., 2006; le Sage
et al., 2007). We thus investigated Kit and p27kip1
expression in NSCLC cells. Western blotting of NSCLC
cells with a monoclonal anti-Kit antibody revealed two
bands of B140 and 120 kDa, corresponding to the
mature fully and the partially glycosylated Kit isoforms
(Tamborini et al., 2004; Figure 6a). Interestingly, Kit
protein was markedly upregulated in sensitive, and
downregulated in resistant, NSCLC cells. FACS analy-
sis, used for quantitative determination of cell surface
Kit-receptor expression (Figure 6b), conﬁrmed the
western blot results. Next, we analysed p27kip1 expres-
sion in NSCLC cells. Interestingly, as for Kit, western
blot analysis showed that p27kip1 is clearly detectable in
H460 cells, is reduced in A459 and A549 cells, and
completely absent in CALU-1 cells (Figure 6a). Kit and
p27kip1 were both targets of miR-221 and -222 in human
NSCLC cells since their expression was modulated in
CALU-1 cells upon anti-miR-222 transfection or
in H460 cells treated with pre-miR-221 and -222
(Figure 6c). Furthermore, p27kip1 was downregulated in
Figure 4 MicroRNA (miR)-222 transfection induced tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
resistance in H460 cells. Cell death effects of miRs: cells were transfected either with control-scrambled miR or with 100 nmol of
pre-miR-221, -222 or -100. Twenty-four hours after transfection, cells were spitted into 96-well plates and treated with 400 ngml1 of
Super-Killer TRAIL for 24 h. Apoptosis was evaluated either with CellTiter Assay (a), or with annexin V staining (b). The same cells
were also assessed for caspase activation and expression of TRAIL signaling molecules by western blot (c–e). Total extract (80mg) was
loaded onto 10% SDS–polyacrylamide gels (PAGE). The membrane was blotted with the different antibodies as indicated. Loading
control was obtained using anti-b-actin antibody. MiR-221 and -222 overexpression induced TRAIL resistance in H460 cells.
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H460 cells transfected with premiR-221 and -222
(Figure 6d). A gene expression proﬁling in
TRAIL-resistant and -sensitive NSCLC cells, using
oligonucleotide microarrays, conﬁrmed the down-
regulation of Kit and p27kip1 in CALU-1-resistant
NSCLC cells (data not shown).
Role of the miR-221 and -222 targets, p27kip1 and Kit, on
TRAIL-mediated apoptosis in NSCLC
To investigate whether p27kip1 or Kit were involved in
TRAIL resistance, we silenced these genes with speciﬁc
siRNAs and then evaluated TRAIL sensitivity. Speciﬁc
anti-Kit or anti-p27kip1 siRNAs induced a reduction of
Figure 5 Effects of anti-microRNAs (miRs) on cell death. (a) CALU-1 cells were transfected with 100 nM of anti-miRs 222, 221 or a
scrambled control. Twenty-four hours after transfection, cells were split into 96–well plates and treated with 400 ngml1 of Super-Killer
tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) for 24 h, and cell viability was assessed as previously
described. Downregulation of miRs 221 and 222 in CALU-1 cells increased TRAIL sensitivity. (b) The same cells extract were also
assessed for expression of TRAIL receptors R1 and R2 by western blot. Loading control was obtained using anti-b-actin antibody.
Figure 6 Kit and p27kip1 expression in non-small cell lung cancer (NSCLC) cells. (a) Proteins from CALU-1, A459, A549 and H460
cells were extracted with radioimmuno precipitation assay (RIPA) buffer. Sample extract (50mg) was resolved on 7.5%
SDS–polyacrylamide gels (PAGE) and transferred to Hybond-C nitrocellulose. Membranes were incubated with anti-Kit primary
antibody (0.2mgml1) or anti-p27 antibody. (b) Fluorescence-activated cell sorting (FACS) analysis of cell surface Kit expression. Cells
were stained with primary antihuman h-SCFR afﬁnity-puriﬁed goat immunoglobulin G (IgG; 1 mgml1) or mouse mAb 002 (isotype
control) followed by 10ml of secondary antibody, Fluorescein-conjugated goat F(ab’)2, as described in ‘Experimental procedures’
section. Surface and total Kit expression was higher in the H460 cells. (c) CALU-1 cells were transfected with 100 nmol of
anti-microRNAs (miR)-221 and -222 for 48 h. Total extract (50mg) was loaded onto 7.5–12% SDS–PAGE. The membrane was blotted
with anti-Kit (0.2mgml1) or anti-p27kip1 (1mgml1) antibody. Loading control was obtained with anti-b-actin antibody (1:5000).
Anti-miR-221 and -222 were able to increase Kit and p27kip1 expression. (d) p27kip1 expression upon miR-222 and -221. Cells were
transfected with either scrambled or miR-221 and -222 and p27kip1 expression was assessed by western blot. miR-222 and -221 were able
to downregulate p27kip1 expression.
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endogenous expression of Kit or p27kip1 proteins by
about 70% (Figures 7a and d). To evaluate the role of
p27kip1 and Kit in these cells, we measured survival after
treatment with TRAIL. Surprisingly, anti-p27kip1 siRNA
transfection increased H460 cell resistance to TRAIL as
assessed by annexin V staining (Figure 7b) or PARP
and caspase 8 activation (Figure 7c); on the contrary
anti-Kit siRNA transfection (Figure 7e).
Discussion
Apoptosis-based anticancer therapies are designed to
achieve tumor eradication through the use of death-
inducing molecules capable of activating the apoptotic
program selectively in neoplastic cells. Owing to its
speciﬁc toxicity for malignant cells, recombinant forms
of TRAIL are among the most promising apoptosis-
based antitumor agents (Walczak et al., 1999; Walczak
and Krammer, 2000). Therapy based on the use of
agonistic TRAIL receptor antibodies is now in phase 2
clinical trial in different kinds of cancer, included
NSCLC (Koschny et al., 2007). However, in a number
of patients, tumor cells evade death signals generated by
drugs through the activation of effective antiapoptotic
mechanisms (Brown and Attardi, 2005; Ghobrial et al.,
2005). The aim of the present study was to identify
speciﬁc signatures as potential therapeutic targets for the
TRAIL-resistant phenotype in non-small cell lung
cancer (NSCLC).
For this purpose, we analysed miRs expression proﬁle
in TRAIL-resistant (CALU-1) and semi-resistant
NSCLC cell lines (A459 and A549) versus a TRAIL-
sensitive cell line (H460). We identiﬁed ﬁve miRs
Figure 7 Effect of p27kip1 and Kit inhibition on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) resistance in
human non-small cell lung cancer (NSCLC) cells. (a) H460 cells were cultured to 80% conﬂuence and transiently transfected with anti-
p27kip1 siRNA, a pool of four target-speciﬁc 20–25 nt siRNAs designed to knock down p27 gene expression. Total cell extract (50 mg)
was loaded onto 12% SDS–polyacrylamide gels (PAGE). Anti-p27 siRNA induced a marked downregulation of p27 expression in
H460 cells. (b, c) Interfering with p27 expression increased TRAIL resistance in H460 cells, as assessed by annexin V (b) or poly-(ADP-ribose)
polymerase (PARP) and caspase 8 activation (c). Mean±s.d. of four independent experiments in duplicate. *Po0.005 (±TRAIL);
wPo0.001 (Scrambled þTRAIL) versus (si-p27þTRAIL). (d) H460 cells were transiently transfected with siKit RNA and analysed by
western blot. Anti-Kit siRNA induced a marked downregulation of Kit expression in H460 cells. (e) Annexin V staining of apoptotic
cells upon 24 h of TRAIL incubation. Inhibition of Kit did not induce a signiﬁcant increment in TRAIL sensitivity. Mean±s.d.
of three independent experiments in duplicate. *Po 0.005. The Student’s t-test was used as statistical method. *Po0.005
(Scrambled±TRAIL) versus (siKit±TRAIL). yP>0.05 (ScrambledþTRAIL versus siKitþTRAIL).
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upregulated in the resistant cell lines (miR-222, -100,
-221, -125b and -15b) and between these we further
analysed four of them with the highest fold change
(miR-222, -100, -221 and -125b). This pattern was
speciﬁc for NSCLC cells since we did not ﬁnd the same
pattern in breast cancer cells analysed with the same
array (data not shown).
Forced overexpression of the miR-222, -100 and -221,
but not of miR-125b, in the sensitive H460 cells
increased resistance to TRAIL in these cells, thus
indicating that repression of their target proteins is
implicated in causing TRAIL resistance. Kept together,
our results show that the sensitivity of a cancer cell to a
deﬁned external signal is dictated by the expression of a
small number of miRs.
Further, to support the involvement of miR-mediated
regulation of protein levels in TRAIL resistance, we
investigated the potential protein targets of miRs
identiﬁed in our screening. We focused on the two
highly related miRs, miR-221 and -222, that recognize
several predicted target genes involved in intracellular
signaling (and cell death), and thus good candidate
regulators of cell response to TRAIL.
Recent reports revealed that the receptor tyrosine
kinase Kit and the cyclin-dependent kinase (cdk)
inhibitor, p27kip1, are both miR-221 and -222 functional
targets (Felli et al., 2005; He et al., 2005; Poliseno et al.,
2006; le Sage et al., 2007). Here we demonstrate that
silencing of p27kip1, but not of Kit, increases TRAIL
resistance. This result well supports the implication of
miR-221 and -222 in determining the resistant/sensitive
phenotype in NSCLC cells, and indicates p27kip1 among
target proteins that contribute to maintain cell sensitiv-
ity to TRAIL-induced cell death. Taken together these
results indicate that even though miR-221 and -222
regulate the levels of both p27kip1 and Kit proteins, their
effects on TRAIL sensitivity are mainly mediated by
p27kip1. However, it seems plausible that silencing of
other additional targets of miR-221 and -222 contributes
to TRAIL resistance in NSCLC cells. miR-221-
and -222-mediated downregulation of p27kip1 has been
implicated in maintaining a more aggressive cancer
phenotype, thus indicating p27kip1 as bona ﬁde tumor
suppressor (Galardi et al., 2007). p27kip1 is a member of
cdk inhibitory proteins with putative tumor suppressor
functions (Sherr and Roberts, 1999). More recently,
p27kip1 has been described to play different roles
depending on the cell type context and on its cytosolic
or nuclear cellular localization (Blain et al., 2003;
Coqueret, 2003). The functions of p27kip1 in the apoptotic
process remain unclear. Adenovirus-mediated transient
overexpression of p27kip1 was demonstrated to induce
apoptosis in transfected cell (Craig et al., 1997; Katayose
et al., 1997). Other reports describe p27 as antiapoptotic
gene (St Croix et al., 1996; Eymin et al., 1999). Therefore,
this suggests that the survival effects of p27kip1 are cell-type
speciﬁc and may be mediated by p27 effects on anti-
apoptotic protein expression (Eymin et al., 1999; Woltman
et al., 2003). Whether similar molecular mechanisms
underlie the increase in TRAIL resistance upon silencing
of p27kip1 remains to be further investigated.
The role of miRs in the regulation of TRAIL
signaling has been described, although not in lung
cancer. Mott et al. (2007) described that miR-29b is able
to regulate Mcl1-1 protein and thus TRAIL-mediated
cytotoxicity in cholangiocarcinoma cell lines. Corsten
et al. (2007) demonstrated that the combined effect of
miR-21 antagonism and soluble TRAIL delivery in
glioma cells leads to increase in caspase activity and cell
death in glioma cells. More recently, Ovcharenko et al.
(2007) described a genome-scale miRs and RNAi screen
in breast cancer cells. They found a number of different
miRs that target TRAIL signaling molecules. Interest-
ingly, they have also found an interrelationship between
cell cycle regulation and apoptosis signal transduction
pathways.
In conclusion, our results demonstrate that the
intracellular levels of few miRs may modulate sensitivity
of NSCLC cells to a death receptor ligand with
important implications in the design of new therapeutic
agents.
Experimental procedures
Materials
Media, sera and antibiotics for cell culture were from
Life Technologies, Inc. (Grand Island, NY, USA).
Protein electrophoresis reagents were from Bio-Rad
Laboratories (Richmond, VA, USA) and western
blotting and ECL reagents from GE Healthcare
(Piscataway, NJ, USA). All other chemicals were from
Sigma (St Louis, MO, USA).
Cell culture
Human CALU-1 and A549 NSCLC cell lines were
grown in Dulbecco’s modiﬁed Eagle’s medium contain-
ing 10% heat-inactivated fetal bovine serum (FBS) and
with 2mM L-glutamine and 100Uml1 penicillin–
streptomycin. H460 and A459 cell lines were grown in
RPMI containing 10% heat-inactivated FBS and with
2mM L-glutamine and 100Uml1 penicillin–streptomycin.
Western blotting
Total proteins from CALU-1, A459, A549 and H460
cells were extracted with radioimmunoprecipitation
assay (RIPA) buffer (0.15mM NaCl, 0.05mM Tris-
HCl, pH 7.5, 1% Triton, 0.1% SDS, 0.1% sodium
deoxycholate and 1% Nonidet P40). Sample extract
(50 mg) was resolved on 7.5–12% SDS–polyacrylamide
gels (PAGE) using a mini-gel apparatus (Bio-Rad
Laboratories) and transferred to Hybond-C extra
nitrocellulose. Membranes were blocked for 1 h with
5% nonfat dry milk in Tris-buffered saline containing
0.05% Tween 20, incubated for 2 h with primary
antibody, washed and incubated with secondary anti-
body, and visualized by chemiluminescence. The follow-
ing primary antibodies were used: Kit (R&D System,
Minneapolis, MN, USA), and a secondary anti-goat
immunoglobulin G (IgG) antibody peroxidase conju-
gate (Chemicon, Pittsburg, PA, USA); anti-TRAIL-R1,
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-R2, -R3 and -R4 (Santa Cruz Inc., Santa Cruz, CA,
USA), anti-p27kip1 (Santa Cruz Inc), anti-caspase 8 (Cell
Signaling, Danvers, MA, USA), anti-caspase 3 and anti-
PARP (Santa Cruz Inc), anti-b-actin antibody (Sigma),
anti-Mcl-1, anti-Bcl2,FADD (Santa Cruz), anti-FLIP
(Alexis Biochemicals, Lausen, Switzerland). Expression
levels were analysed with Scion Image.
FACS analysis
For ﬂow cytometry analysis of cell surface Kit, cells
were stained with primary antihuman h-SCFR afﬁnity-
puriﬁed goat IgG or mouse mAb 002 (isotype control,
both from R&D Systems), followed by secondary
antibody, Fluorescein-conjugated goat F(ab’)2 (R&D
Systems).
Cell death and cell proliferation quantiﬁcation
Cells were plated in 96-well plates in triplicate and
incubated at 37 1C in a 5% CO2 incubator. Super-Killer
TRAIL (Alexis Biochemicals) was used for 24–48 h at
400 ngml1. Cell viability was evaluated with the
CellTiter 96 AQueous One Solution Cell Proliferation
Assay (Promega, Madison, WI, USA), according to the
manufacturer’s protocol. Metabolically active cells were
detected by adding 20 ml of MTT to each well. After 2 h
of incubation, the plates were analysed in a Multilabel
Counter (Bio-Rad Laboratories). Apoptosis was
assessed using annexin V–FITC apoptosis detection kits
followed by ﬂow cytometric analysis. Cells were seeded
at 1.8 106 cells per 100mm dish, grown overnight in
10% FBS/RPMI, washed with phosphate-buffered
saline (PBS) and then treated for 24 h with 200 ng
TRAIL. Following incubation, cells were washed with
cold PBS and removed from the plates by trypsinization.
The resuspended cells were washed with cold PBS and
stained with FITC-conjugated annexin V antibody
according to the manufacturer’s instructions (Roche
Applied Science, Indianapolis, IN, USA). Cells (50 000
per sample) were then subjected to ﬂow cytometric
analysis. Flow cytometry analyses were done as
described (Garofalo et al., 2007). The fraction of H460
cells treated with TRAIL was taken as the apoptotic cell
population. The percentage of apoptosis indicated
was corrected for background levels found in the
corresponding untreated controls.
RNA extraction and Northern blotting
Total RNA was extracted with TRIzol solution
(Invitrogen, Carlsbad, CA, USA) and the integrity of
RNA was assessed with an Agilent BioAnalizer 2100
(Agilent, Palo Alto, CA, USA). Northern blotting was
performed as described (Calin et al., 2002). Total RNA
(10 mg) from cell lines was loaded onto a precast 15%
denaturing polyacrylamide gel (Bio-Rad). The RNA
was then electrophoretically transferred to BrightStar
blotting membranes (Ambion, Austin, TX, USA). The
oligonucleotides used as probes were the complementary
sequences of the mature miRNA (miRNA registry):
miR-221, 50-GAAACCCAGCAGACAATGTAGCT-30;
miR-222, 50-GAGACCCAGTAGCCAGATGTAGCT-30.
miR probes were end-labeled with [g-32P]-ATP by
T4 polynucleotide kinase (USB, Cleveland, OH,
USA). Prehybridization and hybridization were
carried out in Ultrahyb Oligo solution (Ambion)
containing 106 c.p.m. per ml probes overnight at 37 1C.
The most stringent wash was with 2 SSC and 1%
SDS at 37 1C. For reuse, blots were stripped by boiling
and reprobed. As a loading control U6 rRNA was
used. The image of Northern hybridization signals
was produced by using Stormscanner and Image-
Quant TL softwares (Molecular Dynamics, Sunnyvale,
CA, USA).
miRNA microarray experiments
Total RNA (5 mg) from each sample was reverse
transcribed using biotin end-labeled random octamer
oligonucleotide primer. Hybridization of biotin-labeled
complementary DNA was performed on a new Ohio
State University custom miRNA microarray chip
(OSU_CCC version 3.0), which contains 1150 miRNA
probes, including 326 human and 249 mouse miRNA
genes, spotted in duplicates. The hybridized chips were
washed and processed to detect biotin-containing
transcripts by streptavidin–Alexa647 conjugate and
scanned on an Axon 4000B microarray scanner (Axon
Instruments, Sunnyvale, CA, USA).
Raw data were normalized and analysed in Gene-
spring 7.2 software (zcomSilicon Genetics, Redwood
City, CA, USA). Expression data were median centered
by using both the Genespring normalization option and
the global median normalization of the Bioconductor
package (www.bioconductor.org) with similar results.
Statistical comparisons were done by using the Gene-
spring ANOVA tool, Predictive Analysis of Microarray
and the Signiﬁcance Analysis of Microarray softwares
(http://www-stat.stanford.edu/Btibs/SAM/index.html).
Real-time PCR
Real-time PCR was performed using a standard Taq-
Man PCR Kit protocol on a 7900HT Sequence
Detection System (P/N 4329002, Applied Biosystems,
Austin, TX, USA). The 10 ml PCR reaction included
0.67 ml RT product, 1 ml TaqMan Universal PCR
Master Mix (P/N 4324018, Applied Biosystems),
0.2mM TaqMan probe, 1.5mM forward primer and
0.7mM reverse primer. The reactions were incubated in
a 96-well plate at 95 1C for 10min, followed by 40 cycles
of 95 1C for 15 s and 60 1C for 1min. All reactions
were run in triplicate. The threshold cycle (CT) is
deﬁned as the fractional cycle number at which the
ﬂuorescence passes the ﬁxed threshold. The comparative
CT method for relative quantization of gene expression
(User Bulletin no. 2, Applied Biosystems) was used
to determine miRNA expression levels. The y axis
represents the 2ðDCT Þ, or the relative expression of
the different miRs. miRs expression was calculated
relative to 18S rRNA and multiplied by 104.
Experiments were carried out in triplicate for each data
point, and data analysis was performed by using
software (Bio-Rad).
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Transfection of Pre-miRs and anti-miR miRNA inhibitors
in NSCLC cells
TRAIL-sensitive cell lines (H460) were cultured to 80%
conﬂuence in p60 plates with a serum-free medium
without antibiotics and then transfected with 100 nmol
of pre-miR-221 and -222 oligonucleotides or negative
control for 48 h (Ambion). CALU-1 cells were cultured
to 80% conﬂuence in p60 plates with a serum-free
medium without antibiotics. Total 100 nmol of 221 and
222 anti-miR inhibitors (Ambion) were transiently
transfected in cells using Lipofectamine 2000 according
to manufacturer’s instructions. Cells were incubated in
the presence of the speciﬁc anti-miR inhibitors and
negative control (a random sequence anti-miR mole-
cule) for 48 h. Subsequently, TRAIL-induced cell death
was analysed as previously described.
Anti-p27kip1 siRNA transfection in NSCLC
H460 cells were cultured to 80% conﬂuence and
transiently transfected using Lipofectamine 2000 with
anti-p27kip1 siRNA (Santa Cruz), a pool of four target-
speciﬁc 20–25 nt siRNAs designed to knock down gene
expression. p27kip1 siRNA (20 nmol) was transfected
with 6 ml transfection reagent, as described in the
manufacturer’s protocol.
Statistical analysis
Continuous variables are expressed as mean values±
standard deviation (s.d.). The Student’s t-test was used
to determine the role of miRs, anti-miRs, Kit or p27
expression on NSCLC cells apoptosis. Po0.05 was
considered signiﬁcant.
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Abstract
Akt is a serine threonine kinase with a major role in transducing survival signals and regulating proteins involved in apoptosis.
To find new interactors of Akt involved in cell survival, we performed a two-hybrid screening in yeast using human full-length
Akt c-DNA as bait and a murine c-DNA library as prey. Among the 80 clones obtained, two were identified as Bcl-w. Bcl-w is a
member of the Bcl-2 family that is essential for the regulation of cellular survival, and that is up-regulated in different human
tumors, such as gastric and colorectal carcinomas. Direct interaction of Bcl-w with Akt was confirmed by immunoprecipitation
assays. Subsequently, we addressed the function of this interaction: by interfering with the activity or amount of Akt, we have
demonstrated that Akt modulates the amount of Bcl-w protein. We have found that inhibition of Akt activity may promote
apoptosis through the downregulation of Bcl-w protein and the consequential reduction in interaction of Bcl-w with pro-
apoptotic members of the Bcl-2 family. Our data provide evidence that Bcl-w is a newmember of the Akt pathway and that Akt
may induce anti-apoptotic signals at least in part through the regulation of the amount and activity of Bcl-w.
Citation: Garofalo M, Quintavalle C, Zanca C, De Rienzo A, Romano G, et al. (2008) Akt Regulates Drug-Induced Cell Death through Bcl-w Downregulation. PLoS
ONE 3(12): e4070. doi:10.1371/journal.pone.0004070
Editor: Neil Hotchin, University of Birmingham, United Kingdom
Received June 10, 2008; Accepted November 22, 2008; Published December 30, 2008
Copyright:  2008 Garofalo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was partially supported by funds from: Associazione Italiana Ricerca sul Cancro, AIRC (G.C.), MIUR-FIRB (RBIN04J4J7), EU grant EMIL (European
Molecular Imaging Laboratories Network) contract No 503569. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript. C.Q. is a recipient of Clinica Mediterranea- Federico II FiXO Training program. G.R. is recipient of Fondazione SDN fellowship. We
wish to thank Dr. Vittorio de Franciscis and Michael Latronico for paper revision, and Maria Fiammetta Romano and Simona Romano for their help with FACS
analysis.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: gecondor@unina.it
. These authors contributed equally to this work.
Introduction
Akt is a serine–threonine kinase downstream of PTEN/PI3K,
involved in cellular survival pathways [1,2]. In mammalian cells, the
three Akt family members, Akt1/PKBa, Akt2/PKBb, and Akt3/
PKBc are encoded by three different genes [3,4]. They are
ubiquitously expressed, although their levels are variable, depending
upon the tissue type and pathological/physiological state. Increased
expression or activation of Akt has been described as a frequent
phenomena in human cancer [1,5,6]. Akt has been demonstrated to
phosphorylate a number of proteins involved in apoptotic signaling
cascades, including the Bcl-2 family member BAD [7], pro-caspase 9
[4], the forkhead transcription factors, FKHR and FKHRL1 [8,9],
and p21 cipWAF1. Phosphorylation of these proteins prevents
apoptosis through several mechanisms [10]. Apoptosis, or pro-
grammed cell death, is an evolutionarily conserved mechanism of
elimination of unwanted cells [11]. Apoptosis is triggered via two
principal signaling pathways [12]. The extrinsic pathway is activated
by the engagement of death receptors on the cell surface [13]. The
other pathway is triggered by various intracellular and extracellular
stresses, such as growth–factor withdrawal, hypoxia, DNA damage,
and anticancer therapy [13,14]. Intrinsic-pathway induced-apoptosis
is generally regulated by the fine balance of Bcl-2 family proteins in a
cell- and tissue-specific manner [11]. Apoptosis is believed to be the
major mechanism responsible for chemotherapy-induced cell death
in cancer. However, tumor cells often retain the ability to evade drug-
induced death signals because of the activation of anti-apoptotic
mechanisms [15–17]. Understanding these evading mechanisms is a
first step needed for the design of rational anticancer therapy.
Therefore, we decided to address the role of Akt in apoptosis
resistance in human cancer by finding new partners involved in
resistance to cell death. To this end, we performed a two hybrid
screening in yeast using human full-length Akt c-DNA as bait and a
murine c-DNA library as prey. Among the possible interactors of Akt,
we decided to focus on Bcl-w, a member of the Bcl-2 family.
Biochemical experiments confirmed the interaction of Akt with Bcl-
w. Further, we demonstrate that Akt modulates the half-life of Bcl-w.
We also found that Bcl-w is a substrate of Akt and, more importantly,
that Akt regulates its anti-apoptotic activity and interaction with some
of the pro-apoptotic members of the Bcl-2 family.
Methods
Materials
Media, sera, and antibiotics for cell culture were from Life
Technologies, Inc. (Grand Island, NY, USA). Protein electropho-
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resis reagents were from Bio-Rad (Richmond, VA, USA), and
Western blotting and ECL reagents were from GE Healthcare. All
other chemicals were from Sigma (St. Louis, MO, USA).
Plasmids
Plasmids pEF FLAG(hs) Bcl-w , pEF EE Bax, pEF EE Bik, pEF
EE Bad cDNAs were kindly provided by Elisabeth Cory and
David Huang laboratories (Victoria, Australia). Akt wild type (HA-
Akt, cDNA), Akt E40 K (constitutively active Akt cDNA, HA-Akt-
D+) and Akt K179M (dominant negative Akt cDNA, HA-Akt-D-)
were a kind gift of Prof. G.L. Condorelli (University of Rome ‘‘La
Sapienza’’).
Cell culture
Human HeLa and HEK-293 cell lines were grown in DMEM
containing 10% heat-inactivated FBS and with 2 mM L-glutamine
and 100 U/ml penicillin-streptomycin.
Yeast Two-hybrid System
All experiments were performed in the yeast reporter MaV203.
The cDNA library was synthesized from rat FRTL-5 cell poly(A)+
RNA plasmid by Life Technologies and cloned into the
pPC86GAL4AD vector, and was kindly provided by Prof.
Roberto Di Lauro (Naples, Italy). Screening of the library was
performed essentially following instructions for the ProQuest two-
hybrid system (Life Technologies) and has been previously
described [18]. The GAL4 DNA-binding domain/hAkt fusion
was obtained from Dr. Alfonso Bellacosa (Fox Chase Cancer
Centre, Philadelphia, Pennsylvania, USA). Subsequently, yeast
pLEx4-Akt plasmid was transformed with the pPC86AD-cDNA
library and plated onto plates lacking histidine in the presence of
3AT (aminotriazole; 10 mM). Approximately 1.26106 individual
clones were plated, and about 200 grew on the selective medium.
Resistant colonies were grown on a master plate and then replica-
plated onto selection plates to determine their ability to induce
three independent reporters (HIS3, URA3, and lacZ). Eighty
independent clones were isolated after this first screening. DNA
was isolated from each positive clone and sequenced to identify the
inserts. Independent pPC86AD clones were retransformed into
yeast and tested for interaction with a fresh Akt clone.
Generation of Bcl-w deletion mutants
We generated by PCR two deletion mutants of Bcl-w cDNA,
using as template the plasmid pEF FLAG Bcl-w: the following
primers were used for the bclw-BH4 mutant, which included only
the N-terminal BH4 domain (45 aa): BH4-For-HINDIII:cccaagct-
tatggactacaaagacgatgacgataaag and BH4-Rev-Xba1: gctcta-
gaggcttggtgcagcgggtc; the following primers were used for CT-
Bcl-w, which included the remaining coding sequence of 97aa:
CT-For-HINDIII: cccaagcttcccagcagctgacccgct and CT-Rev-
Xba1: gctctagatcacttgctagcaaaaaaggccc.
Temperature cycles were the following: 95uC 1 minute; 95uC
50 seconds, 60uC 50 seconds, 68uC 7 minutes for 35 cycles; 68uC
2 minutes. The amplified sequences were cloned in p3X-Flag-
CMV previously linearized with the restriction enzymes HINDIII
and XbaI.
Generation of stable transfectants
HeLa cells were transfected with 4 mg of Flag-Bcl-w cDNA
using lipofectamine 2000 according to the manufacturer’s protocol
(InVitrogen, Carlsbad, CA). After 48 hr of transfection, cells were
selected using a medium containing 10% FBS, 2 mMol L-
glutammine, 100 U/ml pen/strep, and 3.75 mg/ml of puromicine.
After 15 days the clones were isolated and maintained in culture
with 2.5 mg/ml of puromicine. Twenty colonies were isolated and
tested through western blot to verify the expression of the
construct.
Western blotting
Total protein from HeLa and HEK 293 cells was extracted with
RIPA buffer (0.15 mM NaCl, 0.05 mM Tris-HCl, pH 7.5, 1%
Triton, 0.1% SDS, 0.1% sodium deoxycolate and 1% Nonidet
P40). Fifty mg of sample extract were resolved on 7.5–12% SDS-
polyacrylamide gels using a mini-gel apparatus (Bio-Rad Labora-
tories, Richmond, CA) and transferred to Hybond-C extra
nitrocellulose. Membranes were blocked for 1 hr with 5% non-fat
dry milk in TBS containing 0.05% Tween-20, incubated over night
with primary antibody, washed and incubated with secondary
antibody, and visualized by chemiluminescence. The following
primary antibodies were used: Anti Flag M2 and anti-b-actin
antibody from Sigma (St. Louis, MO, USA), anti HA and anti EE
from Covance (Berkeley,CA USA); anti Bcl-w from Abcam
(Cambridge, MA); anti-Akt, -Phospho Akt substrate, -phospho
ser473 Akt from Cell signalling (Danvers, MA USA); anti-Bcl2, -
BAD, -BIK and -BAX from Santa Cruz, Inc (Santa Cruz, CA
USA), caspase -9 and -3 from Cell Signaling (Danvers, MA USA),
and PARP antibodies from Santa Cruz (Santa Cruz, CA USA).
Phosphorylation experiments
In order to study Bcl-w phosphorylation in intact cells, 293 cells
were transiently transfected with different Akt cDNAs constructs
as indicated. After 24 h, the cells were rinsed with 150 mM NaCl
and incubated in serum-free culture medium for 16 h at 37uC.
Insulin (final concentration, 100 nM) or 20% serum was then
added, and the cells were rapidly rinsed with ice-cold saline
followed by solubilization with 0.5 ml of RIPA buffer per dish for
1 hr at 4uC. Lysates were centrifuged at 5,0006g for 20 min, and
solubilized proteins were precipitated with the indicated antibod-
ies, separated by SDS-PAGE, and revealed by western blot with
the anti-Akt substrate antibody that recognizes all the phosphor-
ylated Akt substrates (Cell Signaling, Danvers, MA USA).
Phospho-(Ser/Thr) Akt Substrate Antibody preferentially recog-
nizes peptides and proteins containing phospho-Ser/Thr preceded
by Lys/Arg at positions 25 and 23. Some cross-reactivity has
been described for peptides that contain phospho-Ser/Thr
preceded by Arg/Lys at positions 23 and 22, thus recognizing
also a low-stringency Akt kinase motif.
Immunoprecipitation
Cells were cultured at a final concentration of 90% in p100
plates. The cells were harvested with RIPA Buffer on a shaker for
30 minutes. 1 mg of total extract was immunoprecipitated using
the indicated antibodies (5 mg/ml Anti-FLAG, 2 mg/ml Anti-HA,
3 mg/ml anti-Akt, 5 mg/ml anti-Bcl-w, 3 mg/ml anti-EE), for
16 hrs on shaker. Then, A/G beads (Santa Cruz, Santa Cruz, CA
USA) were added for two hrs. The beads were washed for three
times with washing buffer (50 mM Tris Hcl pH 7.5, 150 mM
NaCl, 0.1% Triton, 10% glycerol), and then 20 ml of sample
buffer was added; the samples were boiled at 100uC for 5 minutes
and then the supernatants resolved by SDS-PAGE.
Cytosol/mitochondria separation
Cells were grown in p100 plates and the mitochondrial and
cytoplasmic fractions isolated using the Mitochondria/Cytosol
Fractionation Kit (Biovision San Francisco, CA USA) according to
the manufacturer’s protocol.
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Akt Kinase Assay
Akt activity was assayed in vitro as previously reported [19].
Briefly, HEK-293 cells were transfected with 4 mg of Flag-Bcl-w
cDNA. 1 mg of total cell extract was immunoprecipitated using an
anti-FLAG antibody (Sigma) and A/G beads (SantaCruz, Santa
Cruz, CA USA) for 18 hr. The beads were incubated in a kinase
reaction mixture containing 20 mM HEPES [pH 7.2], 1 mM
MgCl2, 10 mMMnCl2,1 mM dithiothreitol, 5 mM ATP, 0.2 mM
EGTA, 1 mM protein kinase inhibitor, 10 mCi of [c–32P]ATP,
and 2 mg of rAkt (Cell signaling, Danvers, MA USA) for
30 minutes at room temperature. The samples were boiled at
100uC for 5 minutes, centrifuged and the supernatant loaded on a
12.5% maxi protean gel (BioRad, Richmond VA, USA). The gel
was run overnight and then visualized by autoradiography.
Cell death and cell proliferation quantification
Cells were plated in 96-well plates in triplicate and incubated at
37uC in a 5%CO2 incubator. Different chemotherapics (30 mg/
ml cisplatin, 10 mg/ml epirubicin) were added for 24 hrs to the
medium. Cell viability was evaluated with the CellTiter 96H
Aqueous One Solution Cell Proliferation Assay (Promega,
Madison, WI), according to the manufacturer’s protocol. Meta-
bolically active cells were detected by adding 20 ml of MTT to
each well. After 2 h of incubation, the plates were analyzed in a
Multilabel Counter (Bio-Rad, Richmond, VA, USA). Apoptosis
was assessed using PI (propidium iodide)-FITC staining followed
by flow cytometric analysis. Cells were seeded at 1.86106 cells per
100 mm dish, grown overnight in 10% FBS/DMEM, washed with
PBS, then treated for 24 hours with chemotherapics. Following
incubation, cells were washed with cold PBS and removed from
the plates by mild trypsinization. The resuspended cells were
washed with cold PBS and stained with PI-FITC staining
according to the instructions provided by the manufacturer
(Roche Applied Science, Indianapolis, IN). Cells (50,000 per
sample) were then subjected to flow cytometric analysis. Flow
cytometry analysis were done as described [20]. The percentage of
apoptosis indicated was corrected for background levels found in
the corresponding untreated controls.
siRNA transfection
HeLa cells were cultured to 80% confluence and transiently
transfected using LIPOFECTAMINE 2000 with 100 nM anti-Akt
Figure 1. Akt interacts with Bcl-w. (A) Co-immunoprecipitation of endogenous Akt with Bcl-w. Wt HeLa cells were lysed and 1 mg of protein
extract immunoprecipitated using an anti-Bcl-w antibody. Immunoprecipitates and total lysates (50 mg) were separated on 12%SDS polyacrilamide
gel and blotted with an anti-Akt antibody. As negative control, proteins were incubated with beads without antibody (B) Co-immunoprecipitation of
transfected Akt with FLAG-Bcl-w or EE-BAD. HEK-293 cells were tansfected with 2 mg of HA-Akt and 2 mg of FLAG-Bcl-w or EE-BAD cDNAs, as
indicated. After 48 hr, cells were lysed, and 1 mg of protein extract was immunoprecipitated using an anti-HA antibody. Immunoprecipitates were
subsequently blotted with anti-HA, anti-Flag or anti-EE antibodies, as indicated. (C) HEK-293 cells were transfected with 2 mg of either wt-Bcl-w cDNA
or the deletion mutants, Bcl-w/BH4 or Bcl-w/CT, as indicated. Protein extracts were immunoprecipitated using an anti-Akt antibody.
Immunoprecipitates and total lysates were resolved on 12%SDS-PAGE and transferred to Hybond-C nitrocellulose. Membranes were incubated
with an anti-FLAG antibody. Both deletion mutants, Bclw/BH4 and Bclw/CT, immunoprecipitated with Akt.
doi:10.1371/journal.pone.0004070.g001
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siRNA (Dharmacon, Lafayette, CO USA), a pool of 4 target-
specific 20–25 nt siRNAs, or 150 nM anti-Bcl-w si-RNA (InVi-
trogen, Carlsbad, CA) with 6 ml transfection reagent, as described
in the manufacturer’s protocol.
Results
Akt interacts with Bcl-w
To find new interactors of Akt, we performed a yeast two-
hybrid screening with human full-length Akt c-DNA sequence as
bait and a murine c-DNA thyroid library as prey. Among the 100
clones obtained, two were identified as Bcl-w, covering its full
coding sequence. To confirm the interaction between Akt and Bcl-
w, we immunoprecipitated proteins from untreated, Akt-trans-
fected, and Bcl-w-transfected cells with an anti-Bcl-w antibody.
We found that Akt co-immunoprecipitates with Bcl-w in extracts
from untransfected and transfected cells (Figure 1A and 1B). The
extent of Akt binding with Bcl-w was comparable to that with its
substrate, Bad (Figure 1B).
Bcl-w contains four Bcl-2 homology (BH) domains and a
transmembrane (TM) fragment at the C-terminal region, impor-
tant for its insertion into the mitochondrial outer membrane. We
verified whether these regions are important for the interaction
with Akt. For this, HA-Akt cDNA was transfected together with
one of two Bcl-w domain-region cDNAs obtained by PCR and
fused to the FLAG epitope: these were the BH4 domain (45 aa) of
Bcl-w, located at the N-terminus, and the remaining portion of the
protein (97aa). Extracts were immunoprecipitated with an anti-
Flag antibody and blotted with an anti-HA antibody. We found
that Akt interacts with both Bcl-w deletion mutants, indicating that
Akt may interact with Bcl-w at multiple sites (Figure 1C).
Role of Akt activation on Akt/Bcl-w interaction
To find whether the activity of Akt influences its interaction
with Bcl-w, HeLa cells were transfected either with wild type Akt
(Akt wt) cDNA or with one of two mutants: an HA-tagged kinase
dead-Akt construct (Akt D2) with dominant negative functions,
and a constitutively active Akt construct (Akt D+). Protein extracts
were immunoprecipitated with a monoclonal anti-HA antibody
and then blotted with an anti-FLAG antibody. We found that Bcl-
w interacts with wild type Akt and more efficiently with the
activated kinase, but not with the kinase-dead Akt (Figure 2A).
Figure 2. Akt activity regulates Bcl-w expression. (A) HeLa cells were transfected with 2 mg of HA-Akt wt, Akt D+, or HA-Akt D2 cDNA and
2 mg Flag-Bcl-w for 48 hrs. Protein extracts were immunoprecipitated with an anti-HA monoclonal antibody. Immunoprecipitates were resolved on
12% SDS-PAGE and transferred to Hybond-C nitrocellulose. Membranes were incubated with anti-Flag antibody (0.2 mg/ml). 50 mg of total sample
extracts were also analyzed by western blot using the indicated antibodies. Loading control was obtained using anti-b actin antibody. (B) HeLa cells
were transfected with 4 mg of HA-Akt wt, HA-Akt D+, or HA-Akt D2 cDNA for 48 hrs. Protein extracts were blotted with anti-Bcl-w antibody in order
to detect endogenous levels of Bcl-w. Loading control was obtained with anti-b actin antibody. (C) Cells were transfected with 100 nM of siAkt-RNA
for 48 hrs. Cellular proteins were solubilized and analyzed by western blot using the indicated antibodies. (D) HeLa cells were treated with 10, 20 or
40 mM of LY294002 for 24 hrs. Protein extracts were analyzed by western blot using the indicated antibodies. Loading control was obtained using
anti-b actin antibody. (E) Bcl-w HeLa cells were treated with 10 mM of MG-132 for 8 hrs. 40 mg of protein extracts were analyzed by western blot with
anti-Bcl-w antibodies. Loading control was obtained using anti-b actin antibody.
doi:10.1371/journal.pone.0004070.g002
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Akt regulates Bcl-w expression
When we transfected cells with Akt D2, we noticed a fall in the
expression of Bcl-w (Figure 2A). Therefore, lack of interaction
between Bcl-w and the kinase-dead Akt could have been due to
reduced expression of Bcl-w rather than to poor interaction with
Akt D2. To address this issue, we inhibited Akt in three different
ways: by interfering with its endogenous function; by treating cells
with Akt-siRNA; and by inhibiting the PI3K/Akt pathway with a
specific drug. In order to interfere with endogenous Akt activity,
we transfected cells with the previously described Akt mutant
cDNAs (Akt wt, Akt D+, and Akt D2). We found that Bcl-w was
reduced after transfection with inactive Akt, whereas Bcl-w
expression increased upon transfection with Akt D+ (Figure 2B).
In order to knock down endogenous Akt, HeLa cells were
transfected with a pool of Akt siRNAs. We found that endogenous
Akt expression, analyzed by Western blot, was reduced by .80%
after 48 hrs. This reduction in Akt expression was followed by a
drastic reduction in the level of Bcl-w. Moreover, the expression of
the anti-apoptotic protein, Bcl-2, but not of the pro-apoptotic
protein, Bax, was also reduced (Figure 2C). Finally, incubation of
HeLa cells with 10, 20 or 40 mM of LY294002, a specific inhibitor
of the PI3K pathway, resulted in reduced amount of Bcl-w protein
(Figure 2D). All these results provide evidence that the kinase
activity of Akt regulates the expression of Bcl-w.
To gain insight on the mechanism of Akt-mediated Bcl-w
regulation, we treated Bcl-w/HeLa cells with the proteasome
inhibitor, MG-132, for 8 hrs and then analyzed Bcl-w levels by
western blot (Figure 2E). The inhibition of the proteasome did not
result in an increase in Bcl-w expression, suggesting that the
ubiquitin pathway is not directly involved in the regulation of Bcl-
w by Akt.
Role of Akt in Bcl-w subcellular localization
Bcl-w is an anti-apoptotic protein weakly linked to the outer
mitochondrial membrane [21]. To verify its intracellular localiza-
tion, extracts of HeLa cells were fractionated to isolate
mitochondria from the cytosol. We found that Bcl-w is present
mainly in mitochondrial protein extracts (Figure 3A). To clarify
the role of Akt in determining Bcl-w cellular localization, HeLa
cells were transfected with Akt wt, Akt D+, or Akt D2 cDNAs
before fractional separation. We found that the presence of the
kinase-dead Akt mutant reduced the amount of Bcl-w linked to the
mitochondrial fraction and induced only a slight increase in the
cytosolic one (Figure 3B). Similar results were obtained in cells
transfected with Akt siRNA (Figure 3C). Thus, Akt acts mainly on
Bcl-w expression.
Akt phosphorylates Bcl-w
Akt is a serine threonine kinase that phosphorylates different
pro- and anti-apoptotic proteins. Thus, in vitro and in vivo
phosphorylation assays were performed to uncover whether Bcl-w
is a substrate of Akt. For in vitro assays, cells were transfected with
Flag-Bcl-w and the extracts obtained immunoprecipitated using a
monoclonal anti-Flag antibody. Immunoprecipitates were incu-
bated with a constitutively active Akt recombinant protein in the
presence of cP32ATP. We found that Akt phosphorylates Bcl-w in
vitro, although not with the same efficiency as histone H2B
(Figure 4A).
To study the effects of Akt kinase activity on Bcl-w
phosphorylation in intact cells, we generated HeLa cells that
stably expressed Flag-Bcl-w (HeLa/Bcl-w). HeLa/Bcl-w cells were
stimulated with insulin or 10% serum for 15 min, and protein
extracts then immunoprecipitated using an anti-Flag antibody and
Figure 3. Akt controls Bcl-w localization. (A) HeLa cells were subjected to fractionated separation of mitochondrial/cytosolic proteins using a
mitochondria/cytosol fractionation kit (Biovision). Protein extracts were loaded onto 15% SDS polyacrilamide gel, and analyzed by western blot by
anti-Bcl-w antibody. As a control of the mitochondrial fraction, an anti-cox4 antibody was used. (B) HeLa cells were transfected with 2 mg of HA-Akt
WT, D+, or D2 for 48 hrs. Cells were subjected to mitochondria/cytosol separation as above. Protein extracts were analyzed by western blot using
anti-Bcl-w, anti-Akt, or anti-cox4 antibodies. (C) Cells were transfected with 100 nM of siAkt-RNA for 48 hrs. Cytosol and mitochondria were isolated
as described in the methods and analyzed by western blot using the indicated antibodies.
doi:10.1371/journal.pone.0004070.g003
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blotted with an anti-phospho (Ser/Thr) Akt substrate antibody
that recognizes the Akt substrate motif. We found that the
phosphorylated band corresponding to Bcl-w immunoprecipitates
upon stimulation with serum or insulin. These results taken
together provide evidence that Bcl-w may be a substrate of Akt
both in vitro and in intact cells (Figure 4B).
In turn, to investigate whether Bcl-w overexpression regulates
Akt kinase activity, HEK293 cells were co-transfected with Flag-
Bcl-w and HA-tagged Gsk3b, one of the main Akt substrates.
48 hours after transfection, the cells were stimulated with insulin
for 10 min, cellular extracts immunoprecipitated with an anti-HA
antibody, and then immunoblotted with an antibody that
recognizes the phosphorylated form of Gsk3b. We did not find a
change in the extent of Gsk3b phosphorylation by overexpressing
Bcl-w (Figure 4C). Therefore, Bcl-w binds to Akt and is a direct
substrate of Akt; however, this binding does not alter the activity of
Akt on other substrates.
Role of Bcl-w/Akt interaction on cell death
Given that Bcl-w is an anti-apoptotic member of the Bcl-2-
family, we investigated the role of Akt activity on this function. We
first analyzed the effect of Bcl-w overexpression in preventing
apoptosis induced by two different chemotherapics, i.e. cisplatin
and epirubicin, in HeLa/Bcl-w compared to parental untrans-
fected HeLa cells. Cells were treated with 30 mg/ml cisplatin or
with 10 mg/ml epirubicin for 24 hr. Cell death was assessed with a
cell viability assay, with propidium iodide staining followed by
FACS analysis, or by caspase 9, 23, and PARP activation. We
found that HeLa/Bcl-w cells were 80–90% resistant to cell death
induced by the chemotherapics. This was confirmed by analysis of
the activation state of the intrinsic apoptotic pathway (caspase 9,
23, and PARP) (Figure 5A).
To test the role of Akt activity on the antiapoptotic function of
Bcl-w, we repeated the above experiments in Bcl-w/HeLa cells
transfected for 48 hr either with Akt D2 cDNA or with Akt
siRNAs. We found that the inhibition of Akt kinase activity or
protein quantity resulted in a strong activation of the downstream
effector PARP (Figure 5 b, left panel), that is partially reflected as
reduction of pro-survival effect of Bcl-w (,20%) (Figure 5B). Thus,
Akt activity mediates the anti-apoptotic function at least in part by
regulating the intracellular levels of Bcl-w. Given that inhibiting
Akt results in a reduction of Bcl-w levels, these results suggest that
Akt may contribute to Bcl-w protective effects mainly by
regulating its intracellular levels.
To further confirm this, we down-regulated Bcl-w expression
with two specific Bcl-w-siRNAs, and analyzed the effects of Bcl-w
down-regulation on chemotherapy-induced cell death. We found
that 72 hrs of incubation with Bcl-w siRNAs drastically reduced
Bcl-w protein (Figure 6 A) although to different extents (siRNA61
was more effective than siRNA62). The assessment of cell viability
Figure 4. Akt phosphorylates Bcl-w in vitro and in vivo. (A) HeLa cells were transfected with 2 mg of DNA of Flag Bcl-w, solubilized, and 1 mg
of protein extract was immunoprecipitated with an anti-M2 Flag antibody. Immunoprecipitates were incubated with recombinant constitutive active
Akt (rAkt), and in vitro kinase assay was conducted as described in the methods. Samples were loaded onto 2.5% SDS-PAGE and analyzed by
autoradiography. As positive control we used Histone2B (H2B). (B) HeLa Bcl-w stable expressing clones were serum starved for 18 hrs and then
stimulated with 100 nM insulin or with 20% serum for 15 min as indicated. Cells were solubilized and immunoprecipitated with an anti-M2 Flag
antibody. Immunoprecipitates were loaded onto SDS-PAGE and blotted with an anti-phospho Akt substrate antibody that recognizes all the
phosphorylated Akt substrates. Total extracts were analyzed by western blot using the indicated antibodies. (C) HeLa cells were transfected with
2 mg of pcDNA3 empty vector or 2 mg of HA-GSK3b, and 2 mg of Flag-Bcl-w for 48 hrs. Cells were stimulated with 100 nM insulin for 15 min,
solubilized, immunoprecipitated using an anti-HA antibody, and analyzed by western blot using an anti-phospho-Gsk3 antibody. Total extracts were
analyzed by western blot using the indicated antibodies. Bcl-w overexpression does not affect Akt activity.
doi:10.1371/journal.pone.0004070.g004
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(Figure 6B) and of apoptotic cells (Figure 6C) provided evidence
that the effect of cell death induced by chemotherapics was
proportional to the expression of Bcl-w. Furthermore, by reducing
Bcl-w level, we obtained the same ,20% increase in cell death
that we observed in HeLa cells treated with Akt siRNA. Thus, the
reduction in Bcl-w expression secondary to Akt inactivation
contributes to the resistance of cancer cells to chemotherapy-
induced cell death.
Akt regulates Bcl-w interaction with Bcl-2 family
members
The intrinsic apoptotic pathway is regulated by the net
interactions of pro- and anti-apoptotic Bcl-2 members [22]. To
evaluate the effect of Akt activity on the interaction of Bcl-w with
the pro-apoptotic Bcl-2 members, we set up co-immunoprecipi-
tation experiments with Bcl-w and Bad, Bik, or Bax in cells
overexpressing the dominant negative Akt cDNA. We found that
Akt inactivation resulted in a drastic reduction of Bcl-w interaction
with the pro-apoptotic proteins (Figure 7). This further confirms
the stimulatory role of Akt activity on Bcl-w anti-apoptotic
function.
Discussion
Apoptosis is believed to be the major mechanism of chemo-
therapy-induced cell death in cancer [23,24]. Unfortunately, many
tumour cells evade drug-induced death signals [25]. Akt is an
important survival-signaling molecule, whose function is frequent-
ly found altered in human cancer [5,26]. Therefore, we decided to
address the role of Akt in apoptosis resistance in human cancer by
finding new partners of Akt by two hybrid screening in yeast.
Among the interactors of Akt that we found, we focused on Bcl-w,
a pro-survival member of the Bcl-2 protein family [27,28] that has
received less attention compared to its other family members. By
genetic and biochemical methods, we have demonstrated here that
Akt interacts with the N- and C-terminal sequences of the Bcl-w
protein, and phosphorylates Bcl-w both in vitro and in the intact
cell. The analysis of the Bcl-w sequence did not reveal a canonical
Akt phosphorylation motif [29]. However, there is evidence that
Akt may phosphorylate cellular substrates at the level of a partially
conserved sequence motif [29]. Bcl-w posses at least 6 serine/
threonines that are included in ‘‘degenerated’’ Akt phosphoryla-
tion sites. By site-directed mutagenesis, we mutated two of these
sites (ser 62 and ser 83) substituting the serine with an alanine (data
Figure 5. Akt regulates the anti-apoptotic function of Bcl-w. (A) HeLa control cells and HeLa cells stably expressing Flag-Bcl-w were plated in
96 well plates in triplicate and treated with 30 mg/ml of cisplatin or 10 mg/ml of epirubicin for 24 hr. Apoptosis was analyzed by Cell Vitality assay, by
propidium iodide staining and FACS analysis, or by western blot for caspase cascade activation with anti-caspase-3, -9, and PARP antibodies. Loading
control was obtained with anti b-actin. (B) HeLa-Flag Bcl-w cells were transfected with 4 mg of HA-Akt D2 cDNA or with 100 nM of siAkt-RNA for
48 hrs and then treated with 30 mg/ml of cisplatin for 24 hr. Cell death was then analyzed as described above. Total lysates were analyzed by western
blot using an anti-PARP antibody. Loading control was obtained with an anti-b-actin antibody. Inactivation of Akt activity resulted in a reduction in
the protective effect of Bcl-w on cell death.
doi:10.1371/journal.pone.0004070.g005
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not shown). These mutations did not result in a change of Bcl-w
phosphorylation state, so the hypothetical Akt phosphorylation site
must be located elsewhere. We are now addressing this issue.
We have also demonstrated here that interfering with the
activity or amount of Akt reduces the quantity of Bcl-w protein;
oppositely, transfection of a dominant active Akt mutant increased
the content of Bcl-w in cells.
Akt-mediated Bcl-w down-regulation was observed to occur also
in glioma (data not shown). Thus, Akt affects Bcl-w function in
various cell types at least in part by regulating its expression. The
mechanisms underlying this are not clear, but the regulation of Bcl-
w protein levels is unlikely mediated by the ubiquitin-proteasome
pathway, as evidenced by the negative result obtained with a
proteasome inhibitor. Furthermore, Akt inhibition did not produce
an effect on Bcl-w mRNA, as evaluated by Real Time PCR (data
not shown). Other possible Akt-mediated regulatory effects on RNA
or protein stability are under investigation in our laboratory.
Several studies have suggested that Akt may regulate the
balance between pro- and anti-apoptotic signals, at least in part by
regulating the cellular localization of Bcl-2 family members
[30,31]. Thus, in this study we have analyzed the effect of Akt
activation on the subcellular localization of Bcl-w. We found Bcl-w
predominantly associated with the mitochondrial fraction, as
previously described also by O’Reilly et al. [32]. The presence of
the kinase-dead Akt mutant reduced the amount of Bcl-w linked to
this fraction, but it did not increase Bcl-w in the cytosol; we
obtained similar results with cells transfected with Akt siRNA.
Thus, via binding and phosphorylating Bcl-w, Akt may control
Bcl-w activity mainly through the regulation of Bcl-w protein
expression. We are conducting experiments with Bcl-w phosphor-
ylation mutants to formally prove this conclusion.
Moreover, with the intent to clarify the role of Akt-mediated
regulation of Bcl-w on its anti-apoptotic functions, we established a
Bcl-w overexpressing cell line. These cells exhibit a significant
decrease of chemotherapy-mediated cell death. When we
evaluated the effects of decreasing Akt activity on survival in
Bcl-w/HeLa cells, we found a ,20% increase in cell death.
However, when we analyzed cell death by western blot of PARP
activation, the active PARP fragment was present exclusively in
Bcl-w/HeLa cells incubated with Akt D2 cDNA. Thus, even
though the differences that we observe with FACS analysis and cell
vitality are of small entity, the end point, that is cell death
evaluated as PARP activation, is reached only in Bcl-w cells where
Akt has been inactivated.
Figure 6. Effects of Bcl-w si RNA on cell death. (A) Cells were transfected with 150 nM of siBcl-w-RNAs for 72 hrs. Total lysates were analyzed by
western blot using anti-Bcl-w antibodies. Loading control was obtained with an anti-b-actin antibody. (B, C) Cells were transfected with 150 nM of
siBcl-w-RNAs for 48 hrs. Then, the cells were splitted into 96 wells and then treated with 30 mg/ml of cisplatin for 24 hr. Cell death was then analyzed
with MTT (B) or propidium iodide staining and FACS analysis (C). Bcl-w down-regulation induces an increase of cell death.
doi:10.1371/journal.pone.0004070.g006
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On the other hand, our data provide evidence that Bcl-w is not
the only defense mechanism of the cell toward chemotherapy-
induced apoptosis, and many other Bcl-2 family members may
mediate anti-apoptotic signals. Therefore, downregulation of Akt
may result in a pronounced efficacy in cancer cells were Bcl-w
predominates over the other Bcl-2 family members [33–35].
When appropriate stimuli are present, homodimerization of
pro-apoptotic members of the Bcl-2 family activates the intrinsic
apoptotic cascade. Bcl-w interacts with pro-apoptotic members of
the Bcl-2 family, such as Bad, Bax, and Bik, blocking the formation
of the homodimers and, thus, the activation of the apoptotic
cascade. Events that inhibit the formation of these Bcl-w/pro-
apoptotic Bcl-2 member complexes may lead to the activation of
apoptosis [36]. We show here that Bcl-w/Bax, Bcl-w/Bad, and
Bcl-w/Bik interactions were drastically reduced in cells overex-
pressing dominant-inactive Akt cDNA, indicating that Akt activity
is necessary for these interactions. Therefore, Akt may regulate the
anti-apoptotic function of Bcl-w, reducing its amount in the cell
and, thus, impairing the balance of homo- and heterodimer
formation upon apoptotic stimuli.
Bcl-w can be up-regulated in tumors such as gastric and
colorectal cancer [33–35]. Interestingly, the PI3k-Akt pathway is
involved in the progression and chemoresistance of these types of
cancer [37–39]. Therefore, increased Akt activity can be
speculated to promote survival and anti-apoptotic signaling in
cancer cells at least in part through increasing Bcl-w levels.
Recently, Bcl-w was reported to promote gastric cancer cell
invasion, by inducing matrix metalloproteinase-2 expression [34].
Bcl-w is up-regulated also through pathways besides the Akt one:
Tran et al. demonstrated that Bcl-w can be up-regulated via the
NFkB pathway activated by TWEAK (tumor necrosis factor-like
weak inducer of apoptosis) through stimulation of its receptor,
Fn14; moreover, the TWEAK-Fn14 pathway can induce survival
of glioma cells, at least in part by up-regulating the quantity of Bcl-
w protein [40]. In addition, Yao et al. reported that up-regulation
of Bcl-w protein mediates the neuroprotective effect of estrogens
[41]. Therefore, Bcl-w participates in a number of different
systems that regulate survival and anti-apoptotic pathways.
The results that we have presented here provide the first
evidence that Akt interacts with, and regulates the levels of, Bcl-w,
moving the balance of the Bcl-2 family toward anti-apoptotic
members. Enhancement of this Akt/Bcl-w anti-apoptotic pathway
can be speculated as one mechanism responsible for the reduced
sensitivity to apoptosis of cancer cells that are resistant to
chemotherapy-induced cell death. This finding may be of
importance in optimizing a strategy for the treatment of cancers,
such as gastric and colon adenocarcinoma, in which Bcl-w has
been found to be increased.
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www.aacrPED/PEA-15 (PED) is a death effector domain family member of 15 kDa with a broad antiapoptotic function
found overexpressed in a number of different human tumors, including lung cancer. To date, the mechanisms
that regulate PED expression are unknown. Therefore, we address this point by the identification of micro-
RNAs that in non–small cell lung cancer (NSCLC) modulate PED levels. In this work, we identify miR-212 as a
negative regulator of PED expression. We also show that ectopic expression of this miR increases tumor
necrosis factor–related apoptosis-inducing ligand (TRAIL)–induced cell death in NSCLC cells. In contrast,
inhibition of endogenous miR-212 by use of antago-miR results in increase of PED protein expression and
resistance to TRAIL treatment. Besides, in NSCLC, we show both in vitro and in vivo that PED and miR-212
expressions are inversely correlated, that is, PED is upregulated and miR-212 is rarely expressed. In conclusion,
these findings suggest that miR-212 should be considered as a tumor suppressor because it negatively regu-
lates the antiapoptotic protein PED and regulates TRAIL sensitivity. Cancer Res; 70(9); OF1–9. ©2010 AACR.Introduction
Lung cancer is one of the most common causes of cancer-
related deaths worldwide. About 80% of all lung cancers
are of the non–small cell lung carcinoma (NSCLC) type,
which is divided in to three subtypes: squamous cell carcino-
ma (25–30%), adenocarcinoma (40%), and large-cell carcino-
ma (10–15%; ref. 1). Because of their resistance to therapeutic
drugs, standard treatment of these tumors has only a 20% to
30% positive clinical response. Therefore, to develop new
therapeutic strategies to improve therapy for NSCLC is
important in understanding the molecular mechanisms
involved in cell death resistance.
Apoptosis is the predominant mechanism by which cancer
cells die in response to cytotoxic drugs. Resistance to drug
treatment is due to deregulation of apoptosis-related proteins.
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journals.org(DED) family member of 15 kDa having a variety of effects on
cell growth and metabolism (2–4). PED/PEA-15 was found
overexpressed in a number of different human tumors, includ-
ing gliomas, squamous carcinoma, thyroid, breast, lung can-
cer, and B-cell chronic lymphocytic leukemia (5–9). PED/
PEA-15 has a broad antiapoptotic action, being able to inhibit
both the intrinsic and the extrinsic apoptotic pathways. Inhi-
bition of the extrinsic pathway is accomplished through its
DED, which likely acts as a competitive inhibitor for proapop-
totic molecules during the assembly of the death-inducing sig-
naling complex (3, 6). Recently, regulation of PED/PEA-15
phosphorylation by PTEN was shown to play a key role in de-
termining whether a cell dies by type I or type II Fas-induced
apoptosis (10). We recently showed that in NSCLC, PED/
PEA-15 overexpression is responsible for a tumor necrosis
factor–related apoptosis-inducing ligand (TRAIL)–resistant
phenotype (9). Furthermore, PED is upregulated in breast
cancer where it induces resistance to chemotherapeutic treat-
ment (8, 9). To date, although PED/PEA-15 is overexpressed
in a number of different cancer types, the mechanisms that
regulate its expression are unknown.
An important mechanism of protein expression regulation
involves microRNAs (miRNA). These molecules are evolution-
arily conserved, endogenous noncoding RNAs of about 22 nu-
cleotides (nt) in length that function at the posttranscriptional
level (11). In animals, single-stranded miRNAs bind with spe-
cific mRNAs through sequences that are partially complemen-
tary to the 3′ untranslated region (UTR) of the target mRNA
(12). miRNAs are involved in numerous cellular processes in-
cluding development, differentiation, proliferation, apoptosis,
and response to stress (13, 14). To date, more than 600 human
miRNAs have been experimentally identified and estimated toOF1
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OF2regulate more than one third of cellular mRNAs. Interestingly,
numerous oncogenes and tumor suppressor genes are regulat-
ed bymiRNAs. With the advent of miRNA expression profiling,
significant effort is being made to correlate miRNA expression
with tumor prognosis (15, 16). To date, a number of downre-
gulated miRNAs found in lung cancer correlate with patient
survival (17, 18) and with therapeutic response (19).
In this article, we identify amiRNA that regulates PED/PEA-
15 expression. Our data indicate that miR-212 negatively mod-
ulates PED/PEA-15 expression and sensitizes non–small cell
lung cancer (NSCLC) cells to TRAIL-induced apoptosis. More-
over, we report that NSCLC-affected lung tissue overexpres-
sing PED/PEA-15 protein has a concordant downregulation
of miR-212.
Materials and Methods
Cell culture and transfection. Calu-1 (NSCLC) cells were
grown in DMEM; H460 cells were grown in RPMI. Media
were supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 2 mmol/L L-glutamine, and 100 units/mL pen-
icillin/streptomycin. For transient transfection, cells at 50%
confluency were transfected using Lipofectamine 2000 (Invi-
trogen) with 100 nmol/L (final) of pre-miR-212, pre-miR-34a,
pre-miR-124a, scrambled, or antisense miR-212 (Applied Bio-
systems). Transfections were done with Lipofectamine 2000
according to the manufacturer's instructions (Invitrogen).
Meg01 cells (human, chronic myelogenous leukemia cells)
were grown in RPMI 1640 + 2 mmol/L glutamine + 10% FBS.
Lung cancer samples. A total of 18 snap-frozen normal
and malignant lung tissues (12 men and 6 women; median
age, 70.0 y; range, 55–82 y) were collected at the Ohio State
University Medical Center (Columbus, OH).
Protein isolation and Western blotting. Cells were
washed twice in ice-cold PBS and lysed in JS buffer [50
mmol/L HEPES (pH 7.5) containing 150 mmol/L NaCl, 1%
glycerol, 1% Triton X100, 1.5 mmol/L MgCl2, 5 mmol/L
EGTA, 1 mmol/L Na3VO4, and 1× protease inhibitor cocktail].
Protein concentration was determined by the Bradford assay
(Bio-Rad) using bovine serum albumin as the standard, and
equal amounts of proteins were analyzed by SDS-PAGE
(12.5% acrylamide). Gels were electroblotted onto polyvinyli-
dene difluoride membranes (Millipore). For immunoblot ex-
periments, membranes were blocked for 1 h with 5% nonfat
dry milk in TBS containing 0.1% Tween 20 and incubated at
4°C overnight with primary antibody. Detection was done with
peroxidase-conjugated secondary antibodies using the
enhanced chemiluminescence system (Amersham-Pharmacia
Biosciences). Primary antibodies used were anti-PED (3),
anti–caspase-8 (Cell Signaling), and anti–β-actin (Sigma).
Cell death quantification. Calu-1 cells were transfected
with pre-miR-212 or control for 48 h. Cells were then trypsi-
nized, plated in 96-well plates in triplicate, and further incu-
bated with 10 or 25 ng/mL superkiller TRAIL (Alexisis
Biochemicals) for 24 h. Cell viability was evaluated with the
CellTiter 96 AQueous One Solution Cell Proliferation Assay
(Promega) according to the manufacturer's protocol. Meta-
bolically active cells were detected by adding 20 μL of MTSCancer Res; 70(9) May 1, 2010to each well. After 2 h of incubation, the plates were analyzed
in a Multilabel Counter (BioTek).
Cell death assessment by Annexin V staining. Calu1 cells
were transfected with 100 nmol/L miR scrambled and with
100 nmol/L miR-212. After 48 h, cells were treated with 10 or
25 ng/mL of TRAIL for 24 h, harvested, washed twice with
cold PBS, and stained with Annexin V-FITC Apoptosis Detec-
tion Kit 1 (BD Pharmingen). Briefly, cells were resuspended
in 100 μL of 1× binding buffer and 5 μL of Annexin V and
then incubated for 15 min at room temperature. Apoptotic
cells were analyzed by flow cytometry.
RNA extraction and real-time PCR. Total RNAs (miRNA
and mRNA) were extracted using miRNeasy Mini Kit
(Qiagen) according to the manufacturer's protocol. Reverse
transcription of total miRNA and mRNA was done starting
from equal amounts of total RNA/sample (1 μg) using miS-
cript Reverse Transcription Kit (Qiagen). For cultured cells,
quantitative analyses of PED, glyceraldehyde-3-phosphate
dehydrogenase (as an internal reference), miR-212, and
RNU5A (as an internal reference) were done by real-time
PCR using specific primers (Qiagen), miScript SYBR Green
PCR Kit (Qiagen), and QuantiTect SYBR Green PCR Kit
(Qiagen), respectively. The reaction for detection of mRNAs
was done as follows: 95°C for 15 min, 40 cycles of 94°C for
15 s, 55°C for 30 s, and 72°C for 30 s. The reaction for de-
tection of miRNAs was done as follows: 95°C for 15 min, 40
cycles of 94°C for 15 s, 55°C for 30 s, and 70°C for 30 s. To
analyze PED and miR-212 expression in lung tissue speci-
mens (neoplastic and normal tissue), real-time PCR was
done using a standard TaqMan PCR Kit protocol on an
Applied Biosystems7900HT Sequence Detection System
(Applied Biosystems). The reactions were incubated at
95°C for 10 min, followed by 40 cycles of 95°C for 15 s
and 60°C for 1 min.
All reactions were run in triplicate. The threshold cycle (CT)
is defined as the fractional cycle number at which the fluores-
cence passes the fixed threshold. For relative quantitation,
the 2(−ΔCT) method was used as previously described (20). Ex-
periments were carried out in triplicate for each data point,
and data analysis was done by using Bio-Rad IQ software.
Luciferase assay. The 3′UTR of the human PED gene was
PCR amplified using the PED primers 5′-tctagaaaggcaaaga-
gaccactcaaccccca-3′ (forward) and 5′-tctagaatgttcttcaccaag-
gagagagggaaggtt-3′ (reverse) and cloned downstream of the
Renilla luciferase stop codon in pGL3 control vector (Prome-
ga), giving rise to pcDNA/PED-clone1 (3). This construct was
used to generate, by inverse PCR, the p3′-UTRmut-PED plas-
mid (primers: PED-mut1, FW 5′-tgtttgtactcctgtgctgtcctgag-
taccagc-3′, RW 5′-gctggtactcaggacagcacaggagtacaaaca-3′;
PED-mut2, FW 5′-agttgttcctactcagcactctaaacctagggagg-3′,
RW 5′-cctccctaggtttagagtgctgagtaggaacaact-3′). MeG01 cells
were cotransfected with 1 μg of p3′UTR-PED and with p3′
UTRmut-PED plasmid and 1 μg of the Renilla luciferase ex-
pression construct pRL-TK (Promega) with Lipofectamine
2000 (Invitrogen). Cells were harvested 24 h posttransfection
and assayed with Dual Luciferase Assay (Promega) according
to the manufacturer's instructions. Three independent
experiments were done in triplicate.Cancer Research
MicroRNA and TRAIL ResistancemiRNA locked nucleic acid in situ hybridization of
formalin-fixed, paraffin-embedded tissue section. In situ
hybridization was carried out on deparaffinized human lung
and liver tissues using previously published protocol (21),
which includes a digestion in pepsin (1.3 mg/mL) for 30
min. The sequence of the probes containing the six dispersed
locked nucleic acid (LNA) modified bases with digoxigenin
conjugated to the 5′ end was miR-212-(5′) UAACAGUCUCCA-
GUCACGGCC. The probe cocktail and tissue miRNA were co-
denatured at 60°C for 5 min, followed by hybridization at 37°C
overnight and a low stringency wash in 0.2× SSC and 2%
bovine serum albumin at 4°C for 10 min. The probe-target
complex was seen due to the action of alkaline phosphatasewww.aacrjournals.orgon the chromogen nitroblue tetrazolium and bromochloroin-
dolyl phosphate. Negative controls included the use of a probe,
which should yield a negative result in such tissues. No coun-
terstain was used to facilitate colabeling for PED protein. After
in situ hybridization for the miRNAs, as previously described
(21), the slides were analyzed for immunohistochemistry using
the optimal conditions for PED (1:800, cell conditioning for 30
min). For the immunohistochemistry, we used the Ultrasensi-
tive Universal Fast Red system fromVentanaMedical Systems.
We used normal lung tissues as controls for these proteins.
The percentage of tumor cells expressing PED and miR-212
was then analyzed with emphasis on colocalization of the
respective targets (miR-212 and either PED).Figure 1. PED expression is regulated by miR-212. A, top, complementary sites on PED 3′UTR for miR-34a, miR-124a, and miR-212. The capital
letters identify perfect base matches according to the Pictar, TargetScan, miRanda, and miRBase softwares (bottom). Western blot analysis of cellular
extracts of Calu-1 cells transfected for 72 h with pre-miR-34a, pre-miR-124a, pre-miR-212, or a scrambled oligonucleotide (scrb). Cell lysates were
immunobloted with anti-PED antibody. To confirm equal loading, the membrane was probed with anti–β-actin antibody as indicated. B, Meg01 cells were
transiently cotransfected with the luciferase reporter containing PED 3′UTR and pre-miR-212 or scrambled oligonucleotide. C, left, complementary sites
for miR-212 on PED 3′UTR. The bold letters identify the deletion regions of mutants (mut) 1 and 2, respectively. Right, Meg01 cells were transiently
transfected with the luciferase reporter containing full-length PED 3′UTR, mut1, or mut2 in the presence of pre-miR-212 or scrb. C and D, luciferase activity
was evaluated 24 h after transfection as described in Materials and Methods. Representative of at least three independent experiments.Cancer Res; 70(9) May 1, 2010 OF3
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OF4Statistical analysis. Continuous variables are expressed
as mean values ± SD. One-tailed Student's t test was used
to compare values of test and control samples. P < 0.05
was considered significant.
Results
Identification of miRNA involved in PED regulation. To
identify miRNAs that specifically target PED (PED/PEA-15),
we used bioinformatic analyses available on the web, includ-
ing Pictar, TargetScan, miRanda, and miRBase. Comparing
the results obtained from the different searches, we found
that miR-34a, miR-124a, and miR-212 consistently showed
the highest score of probability for targeting PED 3′UTR.
PED 3′UTR contains two potential binding sites for miR-
212 at nt 507 and nt 741, one for miR-34a at nt 1142, and
two for miR-124a at nt 1491 and nt 1527 (Fig. 1A, top).
To asses whether exogenous expression of the selected
miRNAs induced PED downregulation, we used Calu-1 cells,
which express high PED levels (9). To this end, Calu-1 cellsCancer Res; 70(9) May 1, 2010were transiently transfected with 100 nmol/L of the indicated
pre-miRNAs for 72 hours, and PED expression levels then
identified by Western blot analysis (Fig. 1A, bottom).
As shown, miR-212 induced the greatest decrease in PED
protein.
The most widely used approach for experimentally validat-
ing miRNA targets is to clone the predicted miRNA-binding
sequence downstream of a luciferase reporter construct and
to cotransfect it with the miRNA of interest. To this end, we
cloned the 3′UTR sequence of human PED into the luciferase
expressing vector pGL3-control downstream of the luciferase
stop codon; Meg01 cell lines were transiently transfected
with this construct in the presence of pre-miR-212 or a
scrambled oligonucleotide acting as a negative control. As
reported in Fig. 1B, miR-212 significantly reduced luciferase
activity compared with the scrambled oligonucleotide. This
indicates that miR-212 binds to the 3′UTR of Ped and impairs
PED mRNA translation.
As reported above, miR-212 targets two regions of the 3′
UTR of PED mRNA (Fig. 1A). To determine which of the
two regions is implicated in the binding with miR-212, we
generated two deletion mutants (Fig. 1C, left): mut1, lacking
the first binding site, GACTGTT (top); and mut2, lacking the
second binding site, AGACTGTT (bottom). The two mutants
were cloned into the 3′UTR of the luciferase gene and co-
transfected with pre-miR-212 into the Meg01 cell line. As
shown in Fig. 1C (right), miR-212 did not significantly reduce
luciferase activity in the presence of the mut2 sequence. This
result indicates that miR-212 targets PED mRNA at the
AGACUGUU sequence.
miR-212 modulates PED mRNA levels. To asses whether
PED upregulation in lung cancer cells was due to decreasing
expression of miR-212, we analyzed in Calu-1 and H460 cells,
expressing different amounts of PED protein (Fig. 2A), the
levels of miR-212 and PED mRNA by real-time PCR. As
shown in Fig. 2B and C, an inverse correlation between
PED mRNA and miR-212 levels was found.
It is known that miRNAs regulate gene expression either
by direct cleavage of the targeted mRNAs or by inhibiting
translation (22). To determine whether the binding of miR-
212 to PED 3′UTR results in mRNA degradation, Calu-1 cells
were transfected for 48 or 72 hours with pre-miR-212, and
PED expression was then evaluated by real-time PCR and
Western blot. As shown in Fig. 3A, exogenous expression of
miR-212 induced a marked reduction of PED mRNA (top) as
well as PED protein (middle) levels. The efficiency of miR-212
transfection was evaluated by reverse transcription-PCR (RT-
PCR; bottom). Next, to assess whether miR-212 plays a phys-
iologic role in controlling PED expression, we treated H460
cells, which express high levels of miR-212, with a specific
antago-miR-212. As shown in Fig. 3B, increased expression
of PED mRNA (top) and PED protein (middle) was evident
already at 48 hours of antago-miRNA transfection. The effi-
ciency of antago-miR-212 transfection was evaluated by RT-
PCR of the endogenous miRNA (bottom). Taken together, the
results show that in lung cancer cells, PED and miR-212 ex-
pressions are inversely correlated and that miR-212 regulates
PED expression.Figure 2. PED and miR-212 expression levels are inversely correlated in
NSCLC. A, cell lysates from Calu-1 and H460 cells were immunoblotted
with anti-PED antibody. To confirm equal loading, the membrane was
immunoblotted with anti–β-actin antibody. Blots are representative of at
least four independent experiments. B and C, total RNA (mRNAs and
miRNAs) was extracted from Calu-1 and H460 cells and 1 μg was
reverse transcribed and amplified as described in Materials and Methods.
Relative expressions of PED mRNA (B) and miR-212 (C) were calculated
using the comparative CT methods. Columns, mean of four different
experiments; bars, SD. *, P < 0.05, Student's t test. There is an inverse
correlation between PED and miR-212 expressions in NSCLC.Cancer Research
MicroRNA and TRAIL ResistancemiR-212 and PED mRNA levels in NSCLC tissue. To eval-
uate whether PED upregulation in lung cancer is related to
decreased miR-212 levels also in vivo, we analyzed PED and
miR-212 expression levels in tissue specimens collected from
18 patients (14 NSCLC-affected individuals and 4 with nor-
mal lung tissue). As shown in Fig. 4, in normal lung samples,
the levels of miR-212 were high whereas PED was expressed
at low levels. On the contrary, in the majority of lung cancer
samples, miR-212 was expressed at low levels and PED was
overexpressed.
To corroborate these findings, in situ hybridization analy-
sis was done, using 5′-dig-labeled LNA probes, on NSCLC and
normal lung tissues, followed by immunohistochemistry for
PED (Fig. 5). MiR-212 and PED expressions were inversely re-
lated in NSCLC and the adjacent normal lung tissues. Lung
cancer cells showed high expression of PED and rarely ex-
pressed miR-212 (Fig. 5A–C), whereas the adjacent nonmalig-
nant lung expressed miR-212 abundantly and rarely showed
detectable PED signal (Fig. 5A–C). Costaining of PED and
miR-212 showed that the two labelings did not overlapwww.aacrjournals.org(Fig. 5C-c), showing that PED andmiR-212 were not expressed
in the same cell. In situ hybridization was done for 110 sam-
ples. The majority of cancer cells were positive for PED (84%).
Seventy-three percent of the samples were negative for miR-
212. When we analyzed for double staining, we found that
60% (65 of 110 patients) of the cells were PED positive/miR-
212 negative (PED+/miR−), 24% (26 of 110 patients) were
PED+/miR+, 3.6% (4 of 110 patients) were PED−/miR+, and
13% (15 of 110 patients) were PED−/miR−. These results further
support our above finding that the upregulation of PED in
lung cancer is dependent on decreased miR-212 levels.
MiR-212 increases TRAIL-induced cell death in NSCLC
cells. We have previously shown that a TRAIL-resistant pheno-
type in NSCLC is related to overexpression of PED (9). The ob-
servation that miR-212 targets PED suggests that ectopic
expression of this miRNA should increase sensitivity to TRAIL.
To this aim, we transfected Calu-1 cells with pre-miR-212, and
caspase-8 activation was then evaluated following treatment
with TRAIL (Fig. 6A). As shown, PED expression decreased in
the presence of exogenous miR-212, and caspase-8 activationFigure 3.miR-212 regulates PED expression levels. A, top, Calu-1 cells were transfected for 48 and 72 hwith pre-miR-212 or scrb. After transfection, total RNA
was extracted and 1 μg was reverse transcribed and amplified as described in Materials and Methods. As shown, PED mRNA was downregulated by
miR-212 transfection. Middle, cell lysates from Calu-1 cells were collected after 48 and 72 h from pre-miR-212 or scrb transfections and immunoblotted with
anti-PED antibody. To confirm equal loading, the membrane was immunoblotted with anti–β-actin antibody. As shown, decreasing amount of PED protein
was evident in the presence of exogenous pre-miR-212 (bottom). Relative expression of ectopic miR-212 after the transfection was evaluated. B, top,
H460 cells were transfected for 48 and 72 h with antago-miR-212 (anti-212) or scrb. After transfection, total RNA was extracted and 1 μg was reverse
transcribed and amplified as described in Materials and Methods. As shown, an increasing amount of PED mRNA was evident in the presence of exogenous
anti-212 (middle). Cell lysates from H460 cells were collected after 48 and 72 h from anti-212 or scrb transfections and immunoblotted with anti-PED
antibody. To confirm equal loading, themembranewas immunoblottedwith anti–β-actin antibody. As shown, an increasing amount of PEDproteinwas evident
in the presence of exogenous anti-212 (bottom). Relative expression of endogenous miR-212 after the antago-miR-212 transfection was evaluated.
Blots are representative of at least four independent experiments. Columns, mean of four different experiments; bars, SD. *, P < 0.05, Student's t test.Cancer Res; 70(9) May 1, 2010 OF5
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OF6was evident 2 hours after TRAIL treatment (compare lane 5
with lane 6 and lane 7 with lane 8). To further confirm this re-
sult, we analyzed TRAIL-induced cell death in the presence of
exogenous pre-miR-212 with a cell viability assay (Supplemen-
tary Fig. S1A) and Annexin V apoptosis assay (Fig. 6B and
Supplementary Fig. S1B for representative dot blot). By time
course and dose/response analysis (data not shown), we found
that to better appreciate a difference in cell viability, low con-
centrations of TRAIL were needed. To this end, Calu-1 cells
were transfected for 48 hours with pre-miR-212, then stimulat-
ed with 10 and 25 ng/mL of TRAIL for 24 hours, and cell death
was evaluated. As shown in Fig. 6B, transfection of miR-212 in-
creased TRAIL-induced cell death up to 3-fold that of Calu-1
cells. Thus, PED downregulation induced by miR-212 increases
sensitivity to TRAIL in lung cancer cells.
To further evaluate the role of miR-212 in apoptosis sensi-
tivity, TRAIL-sensitive H460 cells were transfected with an-
tagomiR-212 to decrease endogenous miR-212 and then
analyzed for their susceptibility to TRAIL-induced cell death.
As shown in Fig. 6C, antago-miR treatment increased PED
protein and rendered H460 cells more resistant to TRAIL.
To confirm that PED is an important target of miR-212 for
regulation of apoptosis, Calu-1 cells were transfected with
pre-miR-212 in the presence or in the absence of PED-mycCancer Res; 70(9) May 1, 2010cDNA that lacks 3′UTR. As shown in Fig. 6D, ectopic expres-
sion of miR-212 and PED-myc cDNA restores the apoptotic
resistance, assessed as caspase-8 activation. To confirm this
result, we analyzed TRAIL-induced cell death in the presence
of exogenous pre-miR-212 and PED-myc with a cell viability
assay, obtaining the same results (Supplementary Fig. S1C).
Taken together, these results indicate that miR-212 increases
TRAIL sensitivity by targeting the antiapoptotic protein PED.
Discussion
The resistance of tumors to current chemotherapeutic
protocols remains a major problem in cancer therapy. De-
fects in the apoptotic program may contribute to treatment
resistance and tumor progression and may be caused by de-
regulated expression of antiapoptotic molecules. Better
knowledge of tumor biology is providing the opportunity to
treat lung cancer with a new class of anticancer drugs. PED is
overexpressed in lung cancer, as well as in other human tu-
mors including gliomas, squamous carcinoma, breast cancer,
and thyroid cancer, and its overexpression is related to resis-
tance to chemotherapy and TRAIL-induced cell death (4–9).
Furthermore, we recently showed that PED is upregulated
and induces resistance to TRAIL in NSCLC (9). Even so, theFigure 4. Correlation of endogenous miR-212 and PED mRNA expression levels in human lung cancer. Left, total RNA extracted from tissue specimens
collected from 14 NSCLC-affected individuals and 4 control individuals was used to analyze miR-212 and PED mRNA expression by real-time PCR
(right). Average of control versus tumor samples. Columns, mean PED or miR-212 expression of all the tumor samples (T) and normal tissue (N); bars, SD.
*, P < 0.05, t test. As shown, there is an inverse correlation between miR-212 and PED mRNA expression levels. The normal lung RNA expressed high
miR-212 and low PED mRNA levels; all the tumors analyzed expressed high PED mRNA and very low miR-212 levels.Cancer Research
MicroRNA and TRAIL Resistancemolecular mechanisms of deregulation of PED expression in
cancer cells are still unknown. We therefore have set out to
identify possible miRNAs able to regulate PED expression in
human lung cancer.
Here, we found that in lung cancer cells, miR-212 was able
to target PED 3′UTR and decrease its levels, thus suggesting
that by maintaining PED levels low, miR-212 action may con-
tribute to tumor suppression.
Over the past few years, several miRs have been implicated
in various human cancers. Both losses and gains of miR func-
tion have been shown to contribute to cancer development
through a range of mechanisms (23, 24).
More often in various human tumors has been observed
an overexpression of miRs, and several of these miRs func-
tion as oncogenes. When downregulated, miRNAs are consid-
ered tumor suppressor because they usually prevent tumor
development by negatively inhibiting molecules involved in
apoptosis resistance.
Different studies show that lung adenocarcinoma has a
miR expression signature that greatly adapts to the use of
clinical data in predicting an individual's survival. Low ex-
pression of let-7a and high expression of miR-155 are linked
to unfavorable clinical outcome in lung cancer (17). The miR-
34 cluster (miR-34a, miR-34b, miR-34c) is repressed in can-
cers and miR-34c is involved in p53 tumor suppression in
many cancers, including lung cancer (25, 26). Bandi et al.
(27) identified miR-15a and miR-16 as frequently deleted inwww.aacrjournals.orgNSCLC, implying an increase of cell cycle. Furthermore, Nas-
ser et al. (28) showed that miR-1 was downregulated in lung
cancer and was related to increased migration and motility
of lung cancer cells.
Using real-time RT-PCR, Yu et al. (29) analyzed miR ex-
pression in 112 different NSCLC patients. They found that
two miRs acted as antitumoral genes (miR-221 and let-7a)
and three miRs were risky for NSCLC (miR-137, miR-372,
and miR-182). Liu et al. (30) found that miR-34c, miR-145,
and miR-142-5p were suppressed in transgenic lung cancers
as well as human normal versus malignant lung tissues.
MiR-212 expression levels in human cancer have not been
extensively investigated thus far. Recently, miR-212 downre-
gulation has been found to be involved in lung cancer re-
sponse to chemotherapy, in particular to docetaxel (31).
The molecular targets responsible to this resistance have
not been identified thus far, but it would be interesting to
speculate that PED may participate in this process.
Our data show that in sample specimens from lung cancer,
miR-212 expression is low compared with normal samples.
Interestingly, miR-212 expression inversely correlates with
PED expression and with response to TRAIL treatment.
Therefore, miR-212 expression could predict therapeutic re-
sponse to TRAIL in lung cancer.
The mechanisms of miR-212 downregulation in human
cancer are not clear at the moment. miR-212 is located on
human chromosome 17, in a region that is frequently lostFigure 5. Immunohistochemistry and in situ hybridization of lung carcinoma and normal tissue samples. MiR-212 (blue; A-a) and PED (red; B-b) expressions
were inversely related in lung cancer and the adjacent normal lung tissues (C-c shows colocalization expression of PED and miR-212). Top, PED (B) and
miR-212 (A) expressions were confined mostly to cancer cells. However, note that cancer cells express PED and do not express miR-212 and vice versa (C).
Bottom, a nest of cancer cells expressing only miR-212 (a). Note that PED expression (b) is confined to the benign stromal cells that are found in the
desmoplastic tissue surrounding the cancer cells nest. Bar, 25 μm. Themagnification is the same for all images. D-d, H&E.One hundred ten lung carcinoma and
normal samples were analyzed. As described in the text, the majority of cancer cells were positive for PED and negative for miR-212. In the cases of lung
carcinoma where both miR-212 and PED expressions were noted, cancer cells expressing PED were distinct from those expressing miR-212.Cancer Res; 70(9) May 1, 2010 OF7
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OF8in different human cancers (32), and this may represent a
mechanism to explain its low expression.
The silencing of miR in cancer can be caused not only by
deletions and mutations but also by epigenetic changes.
Altered patterns of epigenetic modifications, in particular
the methylation of CpG islands in the promoter regions
of some miRs, have been described (33). The miR-212 pro-
moter region is possibly rich in CpG islands. Experiments
are under way in our lab to clarify whether methylation
may be a mechanism involved in the regulation of miR-
212 expression levels.
In summary, miRs are potential antineoplasitc agents. Per-
haps combination therapy with different miRs will be needed
to confer desired antitumorigenic effects. It will be critical toCancer Res; 70(9) May 1, 2010discern which miRs are overexpressed in lung cancer and
which need to be inactivated to inhibit lung carcinogenesis.
Conceivably, these miRs or their derivates would become
agents to treat or chemoprevent lung cancer.Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.Acknowledgments
We thank Dr. Vittorio de Franciscis and Michael Latronico for paper
revision, and Maria Fiammetta Romano and Simona Romano for their help
with FACS experiments.Figure 6.miR-212 transfection induces TRAIL sensitivity. A, Calu-1 cells were transfected either with pre-miR-212 or with scrb. After 72 h, cells were treated
with 200 ng/mL Super-Killer TRAIL for the indicated times. Lysates were analyzed by Western blotting with anti–caspase-8 and anti-PED antibodies.
Cleavage of caspase-8 was more evident in Calu-1 cells transfected with miR-212 compared with scrb. β-Actin antibody was used as loading control.
B, Calu-1 cells were transfected either with pre-miR-212 or with scrb for 48 h. Then, the cells were incubated with 10 or 25 ng/mL of Super-Killer
TRAIL for 24 h. Apoptosis was evaluated with Annexin V staining. Columns, mean of four independent experiments in triplicate; bars, SD. Downregulation of
PED by miR-212 was responsible for increased sensitivity of Calu-1 cells to TRAIL-mediated cell death. C, H460 cells were transfected either with
anti-212 or with scrb for 48 h, then the cells were incubated with 25 ng/mL Super-Killer TRAIL for 24 h. Top, upregulation of PED expression after
antago-miR transfection was evaluated by Western blotting using anti-PED antibody. β-Actin antibody was used as loading control. Bottom, cell viability
was evaluated by CellTiter Assay. Columns, mean of four independent experiments in triplicate; bars, SD. D, Calu-1 cells were transfected with
miR-212 in the presence or absence of PED-myc recombinant protein. After 72 h, cells were treated with 200 ng/mL Super-Killer TRAIL for 3 h and
caspase-8 activation was analyzed by Western blotting with anti–caspase-8 antibodies. Cleavage of caspase-8 was more evident in Calu-1 cells
transfected with miR-212 in the absence of PED-myc recombinant protein. Expressions of PED-myc (18 kDa) and endogenous PED (15 kDa) were evaluated
with anti-PED antibody. β-Actin antibody was used as loading control.Cancer Research
MicroRNA and TRAIL ResistanceGrant Support
Associazione Italiana Ricerca sul Cancro (G. Condorelli), Ministero dell'Is-
truzione, dell'Università e della Ricerca-Fondo per gli Investimenti della Ricer-
ca di Base grant RBIN04J4J7, EU grant EMIL (European Molecular Imaging
Laboratories Network) contract no. 503569, and Fondazione SDN.www.aacrjournals.orgThe costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
Received 09/10/2009; revised 01/12/2010; accepted 02/02/2010; published
OnlineFirst 04/13/2010.References
1. Travis WD. Pathology of lung cancer. Clin Chest Med 2002;23:
65–81.
2. Condorelli G, Vigliotta G, Cafieri A, et al. PED/PEA-15: an anti-
apoptotic molecule that regulates FAS/TNFR1-induced apoptosis.
Oncogene 1999;18:4409–15.
3. Condorelli G, Vigliotta G, Iavarone C, et al. PED/PEA-15 gene
controls glucose transport and is overexpressed in type 2 diabetes
mellitus. EMBO J 1998;17:3858–66.
4. Renault F, Formstecher E, Callebaut I, Junier MP, Chneiweiss H. The
multifunctional protein PEA-15 is involved in the control of apoptosis
and cell cycle in astrocytes. Biochem Pharmacol 2003;66:1581–8.
5. Xiao C, Yang BF, Asadi N, Beguinot F, Hao C. Tumor necrosis factor-
related apoptosis-inducing ligand-induced death-inducing signaling
complex and its modulation by c-FLIP and PED/PEA-15 in glioma
cells. J Biol Chem 2002;277:25020–5.
6. Kitsberg D, Formstecher E, Fauquet M, et al. Knock-out of the neural
death effector domain protein PEA-15 demonstrates that its expres-
sion protects astrocytes from TNFα-induced apoptosis. J Neurosci
1999;19:8244–51.
7. GarofaloM, RomanoG,Quintavalle C, et al. Selective inhibition of PED
protein expression sensitizes B-cell chronic lymphocytic leukaemia
cells to TRAIL-induced apoptosis. Int J Cancer 2007;120:1215–22.
8. Stassi G, Garofalo M, Zerilli M, et al. PED mediates AKT-dependent
chemoresistance in human breast cancer cells. Cancer Res 2005;65:
6668–75.
9. Zanca C, Garofalo M, Quintavalle C, et al. PED mediates TRAIL
resistance in human non small cell lung cancer. J Cell Mol Med
2008;12:2416–26.
10. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene
regulation. Nat Rev Genet 2004;5:522–31.
11. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification
of novel genes coding for small expressed RNAs. Science 2001;294:
853–8.
12. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows
that some microRNAs down-regulate large numbers of target
mRNAs. Nature 2005;433:769–73.
13. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hemato-
poietic lineage differentiation. Science 2004;303:83–6.
14. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of
human miRNAs and indications for an involvement of miRNA in cell
growth and apoptosis. Nucleic Acids Res 2005;33:1290–7.
15. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of
a new tale. Cancer Res 2006;66:7390–4.
16. Calin GA, Croce CM. MicroRNA signatures in human cancers.
Nat Rev Cancer 2006;6:857–66.
17. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molec-
ular profiles in lung cancer diagnosis and prognosis. Cancer Cell
2006;9:189–98.18. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression
of the let-7 microRNAs in human lung cancers in association with
shortened postoperative survival. Cancer Res 2004;64:3753–6.
19. Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures of
TRAIL resistance in human non-small cell lung cancer. Oncogene
2008;27:3845–55.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data
using real-time quantitative PCR and the 2(−ΔΔC(T)) method.
Methods 2001;25:402–8.
21. Nuovo G, Lee EJ, Lawler S, Godlewski J, Schmittgen T. In situ
detection of mature microRNAs by labeled extension on ultramer
templates. Biotechniques 2009;46:115–26.
22. Robins H, Press WH. Human microRNAs target a functionally distinct
population of genes with AT-rich 3′ UTRs. Proc Natl Acad Sci U S A
2005;102:15557–62.
23. Croce CM. Causes and consequences of microRNA dysregulation in
cancer. Nat Rev Cancer 2009;10:704–14.
24. Garofalo M, Condorelli GL, Croce CM, Condorelli G. MicroRNAs as
regulators of death receptors signaling. Cell Death Differ 2009, Epub
ahead of print.
25. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in
papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005;102:
19075–80.
26. Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of
miRNA34 candidate tumor-suppressor genes. Curr Biol 2007;17:
1298–307.
27. Bandi N, Zbinden S, Gugger M, et al. miR-15a and miR-16 are
implicated in cell cycle regulation in a Rb-dependent manner and
are frequently deleted or downregulated in non-small cell lung
cancer. Cancer Res 2009;69:5553–9.
28. Nasser MW, Datta J, Nuovo G, et al. Down-regulation of micro-RNA-1
(miR-1) in lung cancer. Suppression of tumorigenic property of lung
cancer cells and their sensitization to doxorubicin-induced apoptosis
by miR-1. J Biol Chem 2008;283:33394–405.
29. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts sur-
vival and relapse in lung cancer. Cancer Cell 2008;13:48–57.
30. Liu X, Sempere LF, Galimberti F, et al. Uncovering growth-suppres-
sive MicroRNAs in lung cancer. Clin Cancer Res 2009;15:1177–83.
31. Rui W, Bing F, Hai-Zhu S, Wei D, Long-Bang C. Identification of mi-
croRNA profiles in docetaxel-resistant human non-small cell lung
carcinoma cells (SPC-A1). J Cell Mol Med 2009, Epub ahead of print.
32. Konishi H, Sugiyama M, Mizuno K, et al. Detailed characterization of
a homozygously deleted region corresponding to a candidate tumor
suppressor locus at distal 17p13.3 in human lung cancer. Oncogene
2003;221892–905.
33. Peacock JW, Palmer J, Fink D, et al. PTEN loss promotes mito-
chondrially dependent type II Fas-induced apoptosis via PEA-15.
Mol Cell Biol 2009;29:1222–34.Cancer Res; 70(9) May 1, 2010 OF9
c-FLIPL enhances anti-apoptotic Akt functions
by modulation of Gsk3b activity
C Quintavalle1, M Incoronato2, L Puca1, M Acunzo1, C Zanca1, G Romano2, M Garofalo1,3, M Iaboni1, CM Croce3 and G Condorelli*,1,4,5
Akt is a serine–threonine kinase that has an important role in transducing survival signals. Akt also regulates a number of
proteins involved in the apoptotic process. To find new Akt interactors, we performed a two-hybrid screening in yeast using
full-length Akt cDNA as bait and a human cDNA heart library as prey. Among 200 clones obtained, two of them were identified as
coding for the c-FLIPL protein. c-FLIPL is an endogenous inhibitor of death receptor-induced apoptosis through the caspase-8
pathway. Using co-immunoprecipitation experiments of either transfected or endogenous proteins, we confirmed the interaction
between Akt and c-FLIPL. Furthermore, we observed that c-FLIPL overexpression interferes with Gsk3-b phosphorylation levels.
Moreover, through its effects on Gsk3b, c-FLIPL overexpression in cancer cells induced resistance to tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL). This effect was mediated by the regulation of p27Kip1 and caspase-3 expression.
These results indicate the existence of a new mechanism of resistance to TRAIL in cancer cells, and unexpected functions of
c-FLIPL.
Cell Death and Differentiation (2010) 17, 1908–1916; doi:10.1038/cdd.2010.65; published online 28 May 2010
Apoptosis, or programmed cell death, is an evolutionarily
conserved mechanism of elimination of unwanted cells. This
endogenous death machinery is triggered via two principal
signaling pathways.1 The extrinsic pathway is activated by the
engagement of death receptors on the cell surface. The
binding of ligands, such as Fas, tumor necrosis factor (TNF),
or TNF-related apoptosis-inducing ligand (TRAIL) to cognate
death receptors (DRs) induces the formation of the death-
induced signaling complex (DISC). This DISC complex in turn
recruits caspase-8 and promotes the cascade of procaspase
activation.2 The intrinsic pathway is triggered by various
intracellular and extracellular stresses, signals of which
converge mainly to the mitochondria.2,3 The balance between
pro- and anti-apoptotic members of apoptosis is crucial for the
regulation of survival and cell death. Aberrant resistance to
apoptosis may lead to the development of cancer.
Cellular FLICE-inhibitory protein (c-FLIP) is a death effector
domain (DED)-containing family member that inhibits one of
the most proximal steps of DR-mediated apoptosis. Two
isoforms of c-FLIP are commonly detected in human cells: a
long form (c-FLIPL) and a short form (c-FLIPS). c-FLIPL, a
55-kDa protein, contains two DEDs and a caspase-like
domain, whereas c-FLIPS, a 26-kDa protein consists only of
two DEDs.4 Both isoforms are recruited to the DISC, prevent
procaspase-8 activation and block DR-mediated apoptosis,
although through different mechanisms.5,6 c-FLIPL is over-
expressed in a number of different tumors and its over-
expression is related to TRAIL resistance.7,8 Beside cell
death, c-FLIPL might also regulate other DR-mediated signals
that may be important for tumor-promoting functions, such as
proliferation, migration, inflammation or metastasis.9–11 The
activation of the transcription factor NF-kB, the PKB/Akt
pathway and mitogen-activated protein kinases (MAPKs),
such as c-Jun N-terminal kinase (JNK), extracellular signal-
regulated kinase (ERK) and p38, has been demonstrated to
be a consequence of DR triggering.9 Akt is a serine–threonine
kinase that regulates the expression and the function of a
number of proteins involved in the apoptotic process.12 Akt
interaction or phosphorylation of different signaling molecules
may regulate their function by different mechanisms, including
increased protein stability, cellular localization or binding to a
different cellular partner. Akt interacts with a number of
proteins involved in apoptotic signaling cascades, including
BAD,13 caspase-9,14 the Forkhead transcription factor
FOXO315 and Bcl-w.16 The interaction of Akt with one of
these proteins prevents apoptosis through several different
mechanisms.13 One major Akt substrate is the serine–
theronine kinase Gsk3.17 Originally studied for its role in
glycogen metabolism and insulin action, Gsk3, present in the
cells in two isoforms, Gsk3a and Gsk3b, has subsequently
been shown to have central functions in many cellular
processes, including transcription, cell cycle division, cell fate
determination and stem cell maintenance, as well as in
apoptosis.17,18 Gsk3 is constitutively active in resting cells,
and is functionally inactivated after phosphorylation in
response to different stimuli.
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In this study, we set out to find and investigate new possible
partners of Akt that may participate in the regulation of the
apoptosis pathway. In this study, we provide evidence that Akt
directly interacts with c-FLIPL. Furthermore, we demonstrate
that c-FLIPL modulates the activation of Gsk3b. We also
provide evidence that this interaction is important for the
regulation of TRAIL sensitivity, through the regulation of p27
and caspase-3 levels.
Results
Akt interacts with c-FLIPL. To find new Akt interactors, we
performed a yeast two-hybrid screening. We used the
full-length human Akt cDNA sequence as bait and a human
cDNA heart library as prey. Among the 200 clones obtained,
two were identified to code for the anti-apoptotic protein,
c-FLIPL. To prove the interaction between Akt and c-FLIPL,
we performed immunoprecipitation experiments on
endogenous proteins and on protein extracts from cells
transfected with Akt and c-FLIPL cDNAs. We were able to
confirm the Akt–c-FLIPL interaction in extracts from
transfected cells (Figure 1a), and in endogenous proteins
from different cell lines (Figure 1b). To verify whether Akt
activity has a role in Akt–c-FLIPL interaction, HeLa cells were
transfected with either wild-type Akt cDNA or with two
different Akt mutants: kinase-dead Akt (Akt D) and
constitutively active Akt (Akt Dþ ). Protein extracts were
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immunoprecipitated using a monoclonal anti-Flag antibody
and subsequently blotted using an anti-HA antibody. As
shown in Figure 1a, c-FLIPL interacted at comparable levels
with both the activated kinase and the kinase-dead Akt.
c-FLIPL is characterized by two death effector domains
(DEDs), which are important for interaction with members of
the apoptosis cascade. We examined whether these DED
domains were important for the interaction with Akt. For this
purpose, we generated three different mutants: cFLIPL I-DED,
missing the first DED; cFLIPL II-DED, missing the second
DED; and cFLIP DDED, missing both DEDs. The three
mutants were transfected together with HA–Akt cDNA into
HeLa cells. Extracts were immunoprecipitated using anti-Flag
antibody and blotted with an anti-HA antibody. As shown in
Figure 1c, all the c-FLIPL deletion mutants interacted with Akt,
indicating that neither DED domain is necessary for the
interaction with Akt.
We next investigated whether the carboxy terminal of
c-FLIPL was the region of interaction with Akt. For this
purpose, we generated different carboxy-terminal c-FLIPL
mutants named: c-FLIPL F1 (a.a. 1–253), c-FLIPL F3 (a.a.
1–339), c-FLIPL F5 (a.a. 1–434), c-FLIPL R0 (a.a. 1–149) and
c-FLIPL R1 (a.a. 1–182). Each mutant was transfected
together with HA–Akt cDNA in HEK-293 cells. Extracts were
immunoprecipitated after 48 h with anti-Flag antibody and
blotted with anti-HA antibody. Akt interacted with F3 and F5
mutants but not with F1, R0 or R1 mutants (Figure 1d). The
interaction of Akt with the short c-FLIP isoform (FLIPs) was
barely detectable (Figure 1e). This suggests that the Akt–c-
FLIP-interacting region is located between a.a. 253 and a.a.
339, within the caspase-like domain.
Role of c-FLIPL on growth factor-mediated Akt
signaling. Beside cell death, c-FLIPL also regulates other
DR-mediated signals. Thus, we set out to verify whether Akt–
c-FLIPL interaction might modulate Akt activation. For this
purpose, we first transfected increasing amounts of c-FLIPL
cDNA and assessed the levels of the activated Akt using
specific phospho-Akt antibodies. The overexpression of
c-FLIPL did not induce significant differences in insulin-
induced Akt phosphorylation (Figure 2a), even though
it modified the phosphorylation of Gsk3b. As shown in
Figure 2b, c-FLIP expression induced a reduction in
endogenous Gsk3b basal phosphorylation level, in a dose-
dependent manner. A similar inhibition of Gsk3b phos-
phorylation, both basal and upon insulin stimulation, was
observed on co-transfecting the HA–Gsk3b together with c-
FLIP (Figure 2c). Such inhibition was not observed in the
presence of c-FLIPs (Figure 2f).
This inhibition was not observed in HeLa cells transfected
with c-FLIPL mutants that do not interact with Akt, suggesting
that Akt–c-FLIP interaction is necessary for this effect (Figure
2d and e).
Role of c-FLIP modulation of Gsk3b pathway on TRAIL-
induced cell death. Although it has been clearly shown that
c-FLIPL overexpression may cause resistance to TRAIL, the
effects of Gsk3b on cell death are more controversial.19
However, recently it was described that Gsk3b is involved in
the resistance to TRAIL-induced apoptosis. Therefore, we
investigated whether c-FLIPL-induced apoptosis resistance
upon extrinsic pathway activation was at least in part
mediated by its effects on Gsk3b activation.
For this purpose, HeLa cells were transfected with Flag
c-FLIPL cDNAs alone or in the presence of lithium chloride, an
inhibitor of Gsk3 activity.20 The cells were subsequently
incubated with TRAIL, and cell death was assessed using a
cell viability assay or with propidium iodide staining followed
by FACS analysis. As shown in Figure 3a and b, c-FLIPL
overexpression decreased the sensitivity of HeLa to TRAIL-
induced apoptosis. However, treatment with LiCl completely
counteracted the protective effect of c-FLIP on cell death
(Figure 3a and b). To exclude unspecific effects of LiCl on cell
death, the role of the Gsk3b pathway in the anti-apoptotic
effect of c-FLIP was further evaluated using a specific Gsk3b
kinase-inactive cDNA (Gsk3b-KI) and measuring caspase-8
activation. As shown in Figure 3c and d, c-FLIPL over-
expression reduced TRAIL-induced caspase-8 activation,
and this effect was counteracted by both LiCl and Gsk3b-KI
cDNA. LiCl andGsk3b-KI or GSk3bWTcDNA did not produce
any effects on endogenous c-FLIPL levels (Supplementary
Figure 1a).
Effects of c-FLIPL on p27
Kip1 expression. Recently,
Gsk3b inhibition has been suggested to regulate the cell
cycle through regulation of p27Kip1 levels.21 In addition,
we have recently shown that miRNAs regulate p27Kip1
expression and TRAIL sensitivity.22 Therefore, we
addressed the question of whether the effect of c-FLIPL on
TRAIL resistance was mediated through Gsk3b activity and
thus on p27 expression levels.
As shown in Figure 4a, we observed that the levels of
p27Kip1 were drastically reduced in HEK-293 cells stably
overexpressing c-FLIPL. A similar result was observed also in
HeLa cells stably (HeLa Tween FLIP) or transiently over-
expressing c-FLIPL (Flag FLIP; Figure 4b). However, over-
expression of c-FLIPL deletion mutants of the Akt interaction
site did not induce reduction in p27Kip1 levels (Figure 4c).
Moreover, this effect was not observed in the presence of
c-FLIPs (Figure 4f).
The downregulation of Gsk3b, by a specific siRNA or
inactivation with LiCl, induced an increase in p27Kip1 levels in
HeLa Tween FLIPL compared to cells transfected with a
scrambled siRNA (Figure 4d). Taken together these results
indicate that the effect of c-FLIP on p27Kip1 is mediated by
Gsk3b activity. We next investigated whether c-FLIPL–Gsk3
regulate p27Kip1 at mRNA levels. To assess this point, HeLa
cells were transfected with 5mg of Flag c-FLIPL cDNA or a
control vector for 48 h, and p27Kip1 cDNA levels were
evaluated by real-time PCR. Interestingly, we observed a
significant reduction of p27Kip1 mRNA levels in HeLa cells
transfected with c-FLIPL but not with its mutant (Figure 4e),
suggesting that the c-FLIPL–Gsk3 pathway regulates p27
Kip1
expression levels through a transcriptional mechanism.
The effect of p27Kip1 on TRAIL-mediated apoptotic
signaling. We recently provided evidence that p27Kip1 is
involved in TRAIL resistance in non-small cell lung cancer
(NSCLC).22 We demonstrated that in TRAIL-resistant CALU-1
cells, miR-222 and miR-221 are overexpressed and target
Gsk3–cFLIP pathway and TRAIL resistance
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p27Kip1, inducing its downregulation. However, TRAIL-
sensitive H460 cells exhibited reduced levels of miR-222
and miR-221 and increased p27Kip1 expression. We
therefore investigated whether p27Kip1 modulated sensitivity
to TRAIL-mediated cell death through the regulation of the
apoptotic machinery molecules. To this aim, HeLa Tween
FLIP cells, which express p27Kip1 at very low levels, were
transfected with HA–p27 cDNA, and caspase-3 levels were
investigated by western blot analysis. We observed a
significant increase in caspase-3 levels (Figure 5a).
Furthermore, silencing of p27Kip1 using a specific siRNA in
H460 cells, which express p27Kip1 at high levels, resulted in
reduction in caspase-3 level (Figure 5b).
To further confirm the role of the FLIP–Gsk3 pathway on
TRAIL apoptotic machinery, we evaluated caspase-3 levels in
HeLa Tween c-FLIP-overexpressing cells, Gsk3 pathway of
which was inhibited either byGsk3 siRNA or by LiCl treatment.
Both inhibitions resulted in an increase in caspase-3 expres-
sion levels, whereas no differences were observed in FADD
levels (Figure 5c).
We investigated whether c-FLIPL modulated caspase-3
transcript levels through a transcriptional mechanism by
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does not affect Akt phosphorylation. (b) Western blot analysis of p-Gsk3b and Gsk3b expression in HeLa WT or transfected with different concentrations of c-FLIPL cDNA
(500 ng, 1 mg and 2 mg) for 48 h. We observed a strong reduction of Gsk3b phosphorylation. (c) HeLa cells were transfected with HA–Gsk3b cDNA, and c-FLIPL cDNA or
control vector, as indicated for 24 h. Cells were starved for 12 h and then treated with insulin (100 nM) for 15 min. Cell lysates were immunoprecipitated with anti-HA antibody
and blotted with phospho-Gsk3b antibody. (d) Western blot analysis of HeLa cells transfected with c-FLIP-WT, c-FLIP-F1, c-FLIP-R0 or c-FLIP-R1 cDNA. Total lysates were
analyzed with anti-phospho-Gsk3b, Gsk3, Flag and b-actin antibodies. c-FLIP mutants were not able to decrease phospho Gsk3b levels. (e) HeLa cells were transfected with
HA–Gsk3b and c-FLIP-R1 cDNA or with a control vector, treated with insulin (100 nM) for 15 min, immunoprecipitated with anti-HA antibodies, and blotted with p-Gsk3b
antibodies. Total lysates were analyzed with the indicated antibodies. c-FLIP mutant overexpression did not reduce Gsk3b phosphorylation. (f) HeLa cells were transfected
with HA–Gsk3b cDNA, and c-FLIPL cDNA, c-FLIPs cDNA or control vector, as indicated for 24 h. Cells were serum starved for 12 h and then treated with insulin (100 nM) for
15 min. Cell lysates were immunoprecipitated with anti-HA antibody and blotted with anti-phospho-Gsk3b antibody
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real-time PCR. Interestingly, we observed a significant
reduction in caspase-3mRNA levels in HeLa cells transfected
with c-FLIPL compared with controls, whereas this effect was
not observed in FLIP R1 mutant (Figure 5d).
Finally, we also examined the activity of caspase-3 by
the colorimetric CaspACE assay in HeLa cells transfected
with an empty vector or with c-FLIPL cDNA. The expression
of c-FLIPL induced a reduction of caspase-3 activity
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Figure 3 Role of c-FLIPL and Gsk3b signaling pathway on TRAIL-induced cell death. Cell death quantification – HeLa cells were transfected with 2 mg of c-FLIPL cDNA for
24 h, plated in 96-well plates in triplicate and then treated with SuperKiller TRAIL (500 ng/ml) and lithium chloride (20 mmol) for 48 h, as indicated. Cell viability was assessed
by Cell Vitality assay (a) or by propidium iodine staining and FACS analysis (b). (c and d) Western blot analysis of caspase-8 activation. The inhibition of Gsk3b was obtained
by transfection of HeLa cells with kinase-inactive Gsk3b cDNA or by treatment with 20 mmol lithium chloride for 24 h. Cells were incubated with 500 ng/ml TRAIL for 1 or 3 h.
The inhibition of Gsk3b induced an increase of caspase-8 activation in c-FLIP-overexpressing cells
Figure 4 c-FLIP overexpression regulates p27Kip1 levels through Gsk3b. Western blot analysis of Gsk3b, p-Gsk3b and p27Kip1 levels in different cell lines. (a) HEK-293–
Tween GFP and tween–GFP c-FLIPL; (b) HeLa cells transfected with c-FLIPL cDNA and HeLa Tween c-FLIPL. There is an inverse correlation between FLIP and p-Gsk3
levels. (c) Western blot analysis of p27Kip1 levels in HeLa cells transfected with c-FLIPL mutants F1, R0 and R1 cDNA. (d) Effects of inhibition of Gsk3b on p27
Kip1 expression.
HeLa Tween FLIP cells were transfected with Gsk3b siRNA or scrambled siRNA or treated with 20 mmol lithium chloride for 24 h. Levels of p27Kip1 and Gsk3b were analyzed
by immunoblotting. (e) Real time PCR analysis of p27Kip1 mRNA with transfection of FLIPL cDNA in HeLa cells. c-FLIP reduces p27
Kip1 levels through Gsk3b. c-FLIP deletion
mutants were not able to reduce p27Kip1 levels. (f) Total lysates of HeLa cells transfected with c-FLIPL, c-FLIPs or control vector were analyzed for p27 expression
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(Figure 5e). All these effects were reverted when c-FLIPL
endogenous levels were downregulated by a specific c-FLIPL
siRNA (Figure 5f). The effects of specific RNAi constructs for
c-FLIP on FLIP expression levels are shown in Supplemen-
tary Figure 1b.
Discussion
In this study, we provide evidence for a new role of c-FLIPL.
c-FLIPL has been identified as an inhibitor of apoptosis
triggered by the engagement of death receptors, such as Fas
or TRAIL.23,24 c-FLIPL has also been implicated in other
cellular functions, such as control of gene expression by ERK
and NF-kB.9,25
We demonstrate, to the best of our knowledge, for the first
time that Akt interacts with c-FLIPL, and that this interac-
tion functionally regulates Gsk3b activation and apoptosis.
Recently, Giampietri et al.26 described that in c-FLIP
transgenic mice, the phosphorylation of Akt and Gsk3b were
reduced compared with control animals, even though cas-
pase-3 activity was unchanged, highlighting an apoptosis-
independent role of c-FLIP on pressure overload-mediated
cardiac hypertrophy. The role of c-FLIP in heart development
has been previously described in c-FLIP ko mice that, similar
to FADD ko mice, developed severe defects of heart
development.27,28 These studies identify c-FLIP as a new
regulator of heart development and the hypertrophic re-
sponse, possibly through Gsk3 signaling.
In this study, by genetic and biochemical methodologies,
we have demonstrated that Akt is able to interact with c-FLIPL
in the region stretching from a.a. 253 to a.a. 339 of the c-FLIPL
protein. We observed that overexpression of c-FLIPL,
although does not interfere with insulin-induced Akt activation,
almost abolishes Gsk3b phosphorylation. The effects on
Gsk3b were abrogated when we overexpressed c-FLIPL
mutants that do not bind Akt. This may means that, by binding
to Akt, c-FLIPL relegates the kinase in a different cellular
compartment, and abolishes its ability to bind and phosphory-
late its substrates. It is interesting that the phosphorylation
of other Akt substrates besides Gsk3b, such as BAD, was
reduced in c-FLIPL-overexpressing cells (data not shown).
It has been reported that Gsk3b contributes both to cell
death and cell survival, depending on the cellular system and
the appropriate stimuli.19 Several studies indicated that
inhibition of Gsk3b activity in cancer cells potentates
apoptosis stimulated by death receptor.29–32 Furthermore,
knocking out Gsk3b or inhibiting Gsk3b using lithium chloride,
potentates TNF-induced apoptosis, indicating an anti-apop-
totic role for Gsk3b.30
Therefore, we asked whether c-FLIPL-mediated reduction
of Gsk3b phosphorylation, and thus increase in its kinase
activity, might be necessary for the anti-apoptotic function of
c-FLIPL. Interestingly, when we interfered with Gsk3b activity,
either using LiCl or with overexpression of a kinase-inactive
form of Gsk3, anti-apoptotic c-FLIPL effects were significantly
reduced. Thus, Gsk3b may act as an important mediator that
participates in FLIP’s anti-apoptotic function in human cancer.
We have recently demonstrated that p27 expression is
linked to TRAIL resistance in NSCLC cells overexpressing
miR-222.22 We therefore investigated the level of p27 in
different cells overexpressing c-FLIPL. Interestingly, we
observed an inverse correlation between the c-FLIPL and
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Figure 5 Role of p27Kip1 on caspase-3 expression. (a) HeLa Tween FLIP cells transfected with HA–p27Kip1 cDNA were analyzed by western blotting for caspase-3.
Loading and transfection control were analyzed with anti-p27Kip1 and anti-b-actin antibodies. p27 overexpression induced an increase in caspase-3 expression levels.
(b) Western blot analysis of caspase-3 and -8 in H460 cells on transfection of p27Kip1 siRNA. The inhibition of p27 decreases caspase-3 levels. (c) Immunoblotting of HeLa
Tween FLIP cells upon transfection of scrambled siRNA (sc-si), Gsk3b siRNA or treatment with 20 mM lithium chloride for 24 h with caspase-3, FADD or Gsk3b antibodies.
The inhibition of Gsk3 pathway resulted in an increase in expression levels of caspase-3, whereas no differences were observed in FADD and caspase-8 expression. (d) Real-
time PCR of caspase-3 mRNA on transfection in HeLa cells with Flag–FLIPL cDNA. FLIP overexpression induced a significant reduction of caspase-3 mRNA levels.
(e) Quantification of caspase-3 activity by Colorimetric CaspACE Assay System in HeLa cells transfected with an empty vector or Flag–FLIPL cDNA. (f) Total lysate of HeLa
cells expressing RNAi constructs for c-FLIP (FLIP 1003) or with a scrambled control. A total of 40 mg of proteins were loaded and blotted with the indicated antibodies. b-Actin
was used as the loading control. FLIP downregulation induced an increase of GSK3b phosphorylation, p27 and caspase-3 levels. Representative experiment was performed
in triplicates
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p27 expression levels, as well as Gsk3b phosphorylation. This
was also true in forced c-FLIPL-expressing cells (HEK-293
and HeLa). We then investigated whether c-FLIP could affect
p27 levels through the activation of Gsk3b. For this purpose,
we interfered with Gsk3b expression levels or activity in
c-FLIPL-overexpressing cells and evaluated p27 levels. We
observed that Gsk3b inhibition increased protein and mRNA
levels of p27. The effects of FLIPL on p27 depend on its
interaction with Akt, as c-FLIPLWT overexpression, but not its
Akt-binding-site deletion mutants, was able to reduce p27
mRNA level. Recently, Wang et al.21 described that Gsk3b
negatively regulates p27 protein in MLL leukemia cells, thus
being critical for the maintenance of MLL leukemia, and
prospecting Gsk3 as an interesting target for this form of
cancer. In the MLL cellular system, the effects were mainly at
the protein level because the inhibition of Gsk3b did not affect
mRNA levels. Therefore, although the final effect is similar, the
functional relationships of Gsk3b with p27 seem to be cell type
dependent. Gsk3b is a negative regulator of heart hypertro-
phy.33 Interestingly, Hauck34 recently described that silencing
p27 induced cardiomyocyte hypertrophyc growth in the absence
of growth-factor stimulation. It is interesting to speculate that
Gsk3b mediates negative regulation of hypertrophyc growth
through its effects on p27 expression levels.
Finally, we investigated the mechanisms of c-FLIP–Gsk3b
–p27-mediated inhibition of cell death, by the evaluation of
protein and mRNA levels of apoptosis-signaling molecules.
We showed that the absence of p27 induces a reduction
in caspase-3 levels. This effect was mediated by Gsk3b
because its inactivation induced an increase in caspase-3
level. The effect was specific on caspase-3 because other
apoptosis-signaling molecules, such as FADD, were not
affected. This effect occurred at the transcriptional level
because c-FLIPL overexpression, but not its mutants, was
able to reduce caspase-3 mRNA level, as assessed by
RT-PCR. The overexpression of c-FLIPL also induces a
significant reduction in the amount of the active caspase in
untreated cells. Thus, taken together these data depict a
model in which in c-FLIP-overexpressing cells, the activation
of Gsk3b induces a reduction in p27Kip1 and caspase-3
expression and activity levels, and thus a reduction in TRAIL-
induced cell death (Figure 6).
Recently, Gsk3b has been described as a protein complex
associated with death receptors, DDX3, and cellular inhibitor
of apoptosis protein-1 (cIAP-1).29 In that study, Gsk3b
inhibited apoptosis by interfering with DISC formation and
caspase-8 activation. Our data reveal other possible mechan-
isms through which Gsk3 might inhibit apoptosis, that is,
through regulation of p27 expression and that of downstream
caspase-3 (Figure 6).
Our data show that c-FLIP overexpression strongly reduces
Akt-mediatedGsk3b phosphorylation. Furthermore, it’s down-
regulation by a specific c-FLIP siRNA resulted in an increase
in Gsk3b phosphorylation, as well as in p27 and caspase-3
levels.
In conclusion, this study demonstrates that anti-apoptotic
functions of c-FLIPL are mediated by its effects on Gsk3b
activity, and p27 and caspase-3 levels. These findingsmay be
of importance in optimizing a strategy for the treatment of
TRAIL-resistant human cancer.
Materials and Methods
Materials. Media, sera and antibiotics for cell culture were purchased from Life
Technologies (Grand Island, NY, USA). Protein electrophoresis reagents were
obtained from Bio-Rad (Richmond, VA, USA). Western blotting and ECL reagents
were procured from GE Healthcare (Pixcataway, NJ, USA). All other chemicals were
from Sigma (St. Louis, MO, USA). The antibodies: anti-caspase-8 antibody (1C12),
anti-Akt, anti-P-Akt, anti-P-Gsk3b, anti-Gsk3b and anti-p27Kip1 were purchased
from Cell Signaling Technology (Danvers, MA, USA); anti-caspase-3 antibody was
obtained from Abcam (Cambridge, MA, USA); anti-c-FLIP (NF6) antibody was
purchased from Alexis (Lausen, Switzerland); anti-Flag M2 and anti-b-actin
antibodies were obtained from Sigma; anti-HA antibody was obtained from Covance
(Berkeley, CA, USA). SuperKiller TRAIL was purchased from Alexis.
Plasmids. The plasmids pcDNA3 Flag(hs)FLIPL and FLIPs were kindly provided
by Professor Pasquale Vito and Henning Walczack, respectively. Akt WT, Akt E40K
(constitutively active, HA–Akt Dþ ) and Akt K179M (dominant-negative HA–Akt D)
with an HA tag were a kind gift of Professor Gianluigi Condorelli. Gsk3b WT and
Gsk3b kinase inactive (KI) cDNAs were kindly provided by Professor Junichi
Sadoshima. p27 cDNA was kindly provided by Professor Alfredo Fusco. pRetroSuper
vectors expressing RNAi for c-FLIP were obtained from Professor Simone Fulda.
Cell culture. Human HeLa, HEK-293, K562 and A459 cell lines were grown in
DMEM containing 10% heat-inactivated FBS with 2 mM L-glutamine and 100 U/ml
penicillin–streptomycin. DU145 and H460 cell lines were grown in RPMI containing
10% heat-inactivated FBS with 2 mM L-glutamine and 100 U/ml penicillin–
streptomycin.
Yeast two-hybrid system. All experiments were performed in the yeast
reporter MaV203. The human heart cDNA library was obtained from Invitrogen
(Carlsbad, CA, USA). Screening of the library was performed essentially following
instructions for the ProQuest two-hybrid system (Life Technologies) and has been
previously described.35 The GAL4 DNA-binding domain/human Akt fusion was
obtained from Dr. Alfonso Bellacosa (Fox Chase Cancer Center, Philadelphia, PA,
USA). Subsequently, yeast pLEx4-Akt plasmid was transformed with the pPC86AD
cDNA library and plated onto plates lacking histidine in the presence of 3AT
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Figure 6 Role of cFLIP–Gsk3 signaling pathway in the regulation of cell death.
In FLIP-overexpressing cells, activation of Gsk3b induces a reduction in p27Kip1 and
caspase-3 expression levels and a reduction in TRAIL-induced cell death
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(aminotriazole; 10 mM). Approximately 1.2 106 individual clones were plated, and
about 200 grew on the selective medium. Resistant colonies were grown on a
master plate and then replica-plated onto selection plates to determine their ability
to induce three independent reporters (HIS3, URA3 and lacZ). A total of 80
independent clones were isolated after this first screening. The DNA was isolated
from each positive clone and sequenced to identify the inserts. Independent clones
were retransformed into yeast and tested for interaction with a fresh Akt clone.
c-FLIPL deletion mutants generation. We generated three deletion
mutants of c-FLIPL by PCR, using as template the plasmid pcDNA3-3 Flag-FLIPL.
c-FLIP I-DED mutant, encoding a.a. 81–480, which lacks the first DED, was
generated using the primers: Fw: 50-cccaagcttacccacctgctcaggaaccct-30 and Rv:
50-gctctagattatgtgtaggagaggata -30; c-FLIP-II-DED, encoding a.a. 1–93 and a.a.
178–480, which lacks the second DED, was generated using the primers: Fw: 50-
cccaagcttatgtctgctgaagtcatccat-30 and Rv: 50-tgtccctgcatagtccgaaacaaggtgagg-30
for amino acids 1–93 and Fw: 50-tcggactatgcagggacaagttacaggaat-30 and Rv: 50-
gctctagattatgtgtaggagaggata-30 for amino acids 178–480; FLIPL-DDED, encoding
a.a. 178–488, which lacks both DEDs, was generated using the primers: Fw: 50-
cccaagcttgcagggacaagttacaggaat-30 and Rv: 50-gctctagattatgtgtaggagaggata-30.
The amplified sequences were cloned in p3 -Flag-CMV previously linearized with
the restriction enzymes HinDIII and XbaI. The following deletion mutants were
generated: c-FLIPL-F1, encoding a.a. 1–253, was generated using the primers: Fw:
50- tgacgataaagaattcatgtctgc-30 and Rv: 50-gattcctaggggcttgctctt-30; c-FLIPL-F3,
encoding a.a. 1–339, was generated using the primers: Fw: 50-tgacgata
aagaattcatgtctgc-30 and Rv: 50-catcctcctgatgtgatgca-30; cFLIPL-F5, encoding a.a.
1–434, was generated using the primers: Fw: 50-tgacgataaagaattcatgtctgc-30 and
Rv: 50-ttcttgtctcagtttctggg-30; c-FLIPL-R0, encoding a.a. 1–177, was generated
using the primers: Fw: 50-tgacgataaagaattcatgtctgc-30 and Rv: 50-gccctcgagttatc
cagttgatctggggcaac-30; c-FLIPL-R1, encoding a.a. 1–182, was generated using the
primers: Fw: 50-tgacgataaagaattcatgtctgc-30 and Rv: 50-gccctcgagttactgtaacttgt
ccctgctcc-30. Temperature cycles used were as follows: 951C for 1 min; 951C for
50 s, 601C for 50 s, 681C for 7 min for 35 cycles; 681C for 2 min.
Production of retroviral particles and infection of HeLa andHEK-
293 cells. The c-FLIPL cDNA was cloned in PINCO vector.
36 The amphotropic
packaging cell line Phoenix was transfected by standard calcium phosphate/
chloroquine method, and culture supernatants containing retroviral particles were
collected at 48 h after transfection. Transduction was carried out by culturing (thrice)
5 105 cells in 1 ml of 0.45-mmol/l filtered supernatant containing viral particles.
Gene-transfer efficiency was evaluated by flow cytometry analysis based on the
expression of the GFP reporter. The levels of c-FLIP expression were evaluated by
immunoblot analysis using lysates of cells infected with the empty Tween vector
(HeLa Tween and HEK-293 Tween) for comparison.
Western blotting. Total proteins from cells was extracted with RIPA buffer
(0.15 mM NaCl, 0.05 mM Tris-HCl (pH 7.5), 1% Triton X-100, 0.1% SDS, 0.1%
sodium deoxycolate and 1% Nonidet P40). A total of 50 mg of sample extract were
resolved on 7.5–12% SDS-PAGE using a mini-gel apparatus (Bio-Rad
Laboratories, Richmond, CA, USA) and transferred to Hybond-C extra
nitrocellulose. Membranes were blocked for 1 h with 5% non-fat dry milk in TBS
containing 0.05% Tween-20, incubated for 2 h with primary antibody, washed and
incubated with secondary antibody, and visualized by chemiluminescence.
Phosphorylation experiments. HeLa cells were transiently transfected
with different cDNAs as indicated. After 24 h, the cells were incubated in serum-free
culture medium for 16 h at 371C. Insulin (final concentration, 100 nM) was then
added, and the cells were rapidly rinsed with ice-cold saline followed by
solubilization with 0.5 ml of RIPA buffer per dish for 1 h at 41C. Lysates were
centrifuged at 5000 g for 20 min, and solubilized proteins were precipitated with
the indicated antibodies, separated by SDS-PAGE, and revealed by western blot
with antibodies recognizing the phosphorylated proteins.
Immunoprecipitation. Cells were cultured at a final concentration of 90% in
p100 plates. The cells were collected with RIPA Buffer on a shaker for 30 min.
A total of 1 mg of total extract was immunoprecipitated using the indicated
antibodies (5mg/ml anti-Flag, 2mg/ml anti-HA, 3 mg/ml anti-Akt and 3 mg/ml anti-
Gsk3b) for 16 h on shaker. Then, A/G beads (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) were added for 2 h. The beads were washed for three times with
washing buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Triton X-100, 10%
glycerol), and then 20ml of sample buffer was added; the samples were boiled at
1001C for 5 min and then the supernatants resolved by SDS-PAGE.
Caspase assay. The assay was performed using the Colorimetric CaspACE
Assay System (Promega, Madison, WI, USA) as reported in the instruction manual.
Briefly, HeLa cells were transfected with lipofectamine 2000; 48 h after transfection,
cells were collected in caspase assay buffer and protein was quantified by Bradford
Assay. A total of 50mg of protein were used.
Cell death and cell proliferation quantification. Cells were plated in
96-well plates in triplicate and incubated at 371C in a 5%CO2 incubator. To induce
apoptosis, Superkiller TRAIL (Alexis) was used for 24 h at 500 ng/ml. Cell viability
was evaluated with the CellTiter 96 AQueous One Solution Cell Proliferation Assay
(Promega), according to the manufacturer’s protocol. Metabolically active cells were
detected by adding 20ml of MTT to each well. After 30 min of incubation, the plates
were analyzed in a Multilabel Counter (Bio-Rad, Richmond, VA, USA). Apoptosis
was also assessed using annexin V–FITC Apoptosis Detection Kit followed by flow
cytometric analysis. Cells were seeded at a density of 1.8 106 cells per 100-mm
dish, grown overnight in 10% FBS/RPMI, washed with PBS, and then treated for
24 h with 200 ng TRAIL. After incubation, cells were washed with cold PBS and
removed from the plates using very mild trypsinization conditions (0.01 % trypsin/
EDTA). The resuspended cells were washed with cold PBS and stained with FITC-
conjugated annexin V antibody and propidium iodide (PI), according to the
instructions provided by the manufacturer (Roche Applied Science, Indianapolis, IN,
USA). Cells (50 000 per sample) were then subjected to flow cytometry analysis.
Flow cytometry analysis and PI staining were performed as described previously.16
To quantify caspase activation, cells were transfected with the indicated cDNA or
treated with lithium chloride (20 mM) and then incubated with superkiller TRAIL for
the indicated times. Lysates were examined by western blotting with anti-caspase-8
antibodies.
siRNA transfection. HeLa cells were cultured to 80% confluence, kept in
antibiotic-free, serum-containing medium, and transiently transfected using
Lipofectamine 2000 with 150 nmol anti-Gsk3-b siRNA (Invitrogen), a pool of two
target-specific 20–25 nt siRNAs, or with siCONTROL oligonucleotides, as indicated.
Cells were incubated with siRNAs for the indicated times.
The siRNAs were transfected with 6 ml transfection reagent, as described in the
manufacturer’s protocol. Anti p27Kip1 siRNA was purchased from Santa Cruz
Biotechnology. siCONTROL Non-Targeting siRNA Pool #2 (D-001206–14–05) was
from obtained from Dhamarcon (Lafayette, CO, USA) and comprised four
siCONTROL Non-Targeting siRNAs. Each individual siRNA within this pool was
characterized by genome-wide microarray analysis and found to have minimal
off-target signatures.
c-FLIPL knockdown. Stable knockdown of c-FLIPL in HeLa cells was
obtained with siRNAs (complementary sense and antisense oligonucleotides):
FLIP-909 (50-GGAGCAGGGACAAGTTACA-30) and FLIP-1003 (50-GTAAAGAAC
AAAGACTTAA-30) or scrambled oligonucleotide were cloned in the pRSC retroviral
vector as described previously.37 Cells were selected with 10mg/ml puromycin.
RNA isolation and real-time PCR analysis. The RNA was extracted
using TRIzol solution (Invitrogen) followed by DNAse treatment (DNA free, Ambion,
Austin, TX, USA). The quality and quantity of RNA was determined by measuring
the absorbance of the total RNA at 260 and 280 nm, and by 1% agarose
electrophoresis under reducing conditions and visualized with ethidium bromide. For
mRNA profiling, reverse transcription (RT) was performed by using Superscript II First
Stand Synthesis Kit (Invitrogen). Real-time PCR to assay mRNA level was performed
in an iQ Real Time PCR Detection System (Bio-Rad, Hercules, CA, USA) with iQ
SYBR Green Supermix (Bio-Rad). All primers were synthesized commercially
(PRIMM, Milan, Italy). Polymerase chain reactions were performed in triplicate and
fold changes were calculated with the following formula: 2(sample 1DC t sample 2DC t),
where DCt is the difference between the amplification fluorescent thresholds of the
mRNA of interest and the mRNA of b-actin used as an internal reference. All reactions
were performed according to manufacturer’s protocol.
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Aims Contrast media (CM) induce a direct toxic effect on renal tubular cells. This toxic effect may have a role in the
pathophysiology of contrast nephropathy.
Methods
and results
We evaluated (i) the cytotoxicity of CM [both low-osmolality (LOCM) and iso-osmolality (IOCM)], of iodine alone,
and of an hyperosmolar solution (mannitol 8%) on human embryonic kidney (HEK 293), porcine proximal renal
tubular (LLC-PK1), and canine Madin–Darby distal tubular renal (MDCK) cells; and (ii) the effectiveness of
various antioxidant compounds [N-acetylcysteine (NAC), ascorbic acid and sodium bicarbonate] in preventing CM
cytotoxicity. The cytotoxicity of CM was assessed at different time points, with different methods: cell viability,
DNA laddering, flow cytometry, and caspase activation.
Both LOCM and IOCM produced a concentration- and time-dependent increase in cell death as assessed by the
different methods. On the contrary, iodine alone and hyperosmolar solution did not induce any significant cytotoxic
effect. There was not any significant difference in the cytotoxic effect between LOCM and IOCM. Furthermore, both
LOCM and IOCM caused a marked increase in caspase-3 and -9 activities and poly(ADP-ribose) fragmentation, while
no effect on caspase-8/-10 was observed, thus indicating that the CM activated apoptosis mainly through the intrinsic
pathway. Both CM induced an increase in protein expression levels of pro-apoptotic members of the Bcl2 family (Bim
and Bad). NAC and ascorbic acid but not sodium bicarbonate had a dose-dependent protective effect on renal cells
after 3 h incubation with high dose (200 mg iodine/mL) of both LOCM and IOCM.
Conclusion Both LOCM and IOCM induce a dose-dependent renal cell apoptosis. NAC and ascorbic acid but not sodium
bicarbonate prevent this contrast-induced apoptosis.
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Keywords Contrast media † Kidney † Apoptosis † Prevention
Introduction
Contrast-induced nephropathy (CIN) accounts for 10% of all
causes of hospital-acquired renal failure, causes a prolonged
in-hospital stay, and represents a powerful predictor of poor
early and late outcome.1,2 Haemodynamic changes of renal
blood flow, which lead to hypoxia of the renal medulla, and
direct toxic effects of contrast media (CM) on renal cells are
thought to contribute to the pathogenesis of CIN.3 A predominant
toxic effect of CM on renal tubules has been shown in both clinical
trials and animal experiments.4 –6 Furthermore, administration of
compounds with antioxidant properties [such as N-acetylcysteine
(NAC), ascorbic acid, and sodium bicarbonate] has emerged as
an effective strategy to prevent CIN.7– 11 Little is known about cel-
lular mechanisms underlying CIN, and, as a consequence, about the
mechanism(s) for the protective effect of compounds, such as
NAC, ascorbic acid, and sodium bicarbonate.
In the present study, we assessed the apoptotic effect of both
iso-osmolar (IOCM) and low-osmolar (LOCM) CM on human
embryonic kidney (HEK 293), porcine proximal renal tubular
(LLC-PK1), and canine Madin–Darby distal tubular renal
(MDCK) cells and determined the role of various antioxidant com-
pounds in preventing CM-induced apoptosis.
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Methods
Culture conditions and reagents
Three different cell lines were utilized: (i) human embryonic kidney
(HEK 293), which are undifferentiated human renal cells; (ii) porcine
proximal renal tubular (LLC-PK1) and canine Madin–Darby renal epi-
thelial (MDCK) cells which have the characteristics of proximal and
distal tubule cells, respectively. Cells were grown in a 5% CO2 atmo-
sphere in Dulbecco’s Modified Eagle Medium (DMEM) containing 10%
heat-inactivated FBS, 2 mM L-glutamine, and 100 U/mL penicillin–
streptomycin. Cells were routinely passaged when they reached
80–85% confluent. Media, sera, and antibiotics for cell culture were
from Life Technologies, Inc. (Grand Island, NY, USA). Protein electro-
phoresis reagents were from Bio-Rad (Richmond, VA, USA) and
western blotting and ECL reagents (GE Health care, Europe SA). All
other chemicals were from Sigma (St Louis, MO, USA).
Contrast agents
Two different CM were tested: (i) iodixanol (Visipaquew, GE Health-
care Europe; 320 mg iodine/mL) non-ionic, IOCM (290 mOsm/kg of
water) and (ii) iobitridol (Xenetixw, Guerbet, France; 250 mg iodine/
mL) non-ionic, LOCM (915 mOsm/kg of water).
Experimental design
Experiments were driven in the following phases: (i) assessment of
cytotoxicity of both LOCM (iobitridol) and IOCM (iodixanol). In
order to assess the impact of contrast dose, two different doses of
CM were tested, 100 and 200 mg iodine/mL. The cytotoxicity of CM
was tested at 15, 30, 45, 60, 90, 120, 150, 180. The osmolality of
DMEM alone was 355 mOsm/L, when compared with 395 mOsm/L
for DMEM plus IOCM and 830 mOsm/L for DMEM plus LOCM. In
order to clarify the potential major determinants of the cytotoxic
effect, we further assessed the effect of iodine alone (by incubation
with 100 and 200 mg/mL sodium iodine)12 and hyperosmolality (by
incubation in DMEM/8% mannitol, having an osmolality of
830 mOsm/L); (ii) assessment of the effectiveness of various antioxi-
dant compounds (that is, NAC, ascorbic acid, and sodium bicarbonate)
in preventing contrast cytotoxicity. Different doses of all tested com-
pounds were utilized, in order to elicit any dose-dependent effect. The
doses tested were selected according to the available data in the clini-
cal setting. NAC was tested at 1, 10, and 100 mM.13,14 Ascorbic acid
was tested at 2, 4, and 8 mM.15 Sodium bicarbonate was tested at
75, 150, and 300 mM.10 Each concentration was done in triplicate.
Protein isolation and western blotting
Cellular pellets from a singular cell line at time were washed twice with
cold PBS and resuspended in JS buffer (HEPES 50 mM, NaCl 150 nM,
1% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 5 mM EGTA) containing
Proteinase Inhibitor Cocktail (Roche). Solubilized proteins were incu-
bated for 1 h on ice. After centrifugation at 13 200 rpm for 10 min at
48C, lysates were collected as supernatants. Eighty micrograms of
sample extract were resolved on a 12% SDS-polyacrylamide gel
using a mini-gel apparatus (Bio-Rad Laboratories, Richmond, CA,
USA) and transferred to Hybond-C extra nitrocellulose (GE Health-
care Europe). Membrane was blocked for 1 h with 5% non-fat dry
milk in TBS containing 0.05% Tween-20 and incubated over night at
48C with specific antibodies. The following antibodies were used for
immunoblotting: anti-pro-caspase-3 (recognizing only the inactive
pro-caspase-3) (cell signalling), anti-beta Actin (Sigma), anti-PARP
(Sigma), anti-Bim (Santa Cruz), anti Bad (Santa cruz), and
anti-Caspase-9, -10, and -8 from Stressgen. Washed filters were then
incubated for 60 min with HRP-conjugated anti-rabbit or anti-mouse
secondary antibodies (GE Healthcare, Europe) and visualized using
chemioluminescence detection (GE Healthcare Europe). The acti-
vation of caspase was followed by the disappearance of the band
corresponding to the inactive pro-caspase enzyme, utilizing a specific
antibody that recognizes this form.
Cell-death quantification
Cell death was evaluated with the CellTiter 96w AQueous One Solution
Cell Proliferation Assay (Promega, Madison, WI, USA), according to
the manufacturer’s protocol. The assay is based on reduction of
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium, inner salt (MTS) to a coloured product that is
measured spectrophotometrically. Cells were plated in 96-well plates
in triplicate, stimulated, and incubated at 378C in a 5% CO2 incubator.
Iobitridol, iodixanol, NAC, sodium bicarbonate, and ascorbic acid were
used in vitro at the doses and time indicated. Metabolically active cells
were detected by adding 20 mL of MTS to each well. After 30 min of
incubation, the plates were analysed on a Multilabel Counter (Bio-Rad,
Richmond, VA, USA). DNA laddering was also used to confirm the
apoptotic death induced by CM. Briefly, after CM exposure, the cells
were harvested with 500 mL of DNA lysis buffer [5 mM Tris–HCl
(pH 7.5), 20 mM EDTA (pH 8.0), 0.5% NP40], and were incubated
on ice for 20 min. After centrifugation at 13 200 rpm for 30 min, the
DNA was then extracted with phenol chloroform isoamyl alcohol
and finally precipitated with the addition of 1.25 mL of cold ethanol
100% and 50 mL sodium acetate (pH 5.2) on dry ice for 20 min. The
precipitates were centrifuged (30 min, 13 200 rpm, 48C), dried at
room temperature, solubilized in 10 ml of TE, and then incubated
with RNase A for 30 min at 378C. The DNA samples were finally
separated on 1.5% agarose gel containing ethidium bromide (Sigma,
St Louis). The gel was photographed under UV light. Apoptosis was
also analysed via propidium iodide incorporation in permeabilized
cells by flow cytometry. The cells (2  105) were washed in PBS
and resuspended in 200 mL of a solution containing 0.1% sodium
citrate, 0.1% Triton X-100, and 50 mg/mL propidium iodide (Sigma).
Following incubation at 48C for 30 min in the dark, nuclei were
analysed with a Becton Dickinson FACScan flow cytometer. Cellular
debris was excluded from analyses by raising the forward scatter
threshold, and the DNA content of the nuclei was registered on a
logarithmic scale. The percentage of elements in the hypodiploid
region was calculated.
Statistical analysis
Continuous variables are expressed as mean values+ SD. We per-
formed a multiple comparison test using the information derived by
performing one-way analysis of variance (ANOVA) test on groups of
independent variables having cell viability as our dependent variable.
In an ANOVA, we compared the means of several groups to test
the hypothesis that they are all the same, against the general alternative
that they are not all the same. However, since the alternative hypoth-
esis may be too general and more information is needed about which
pairs of means are significantly different, and which are not, we used
the multiple comparison procedure, which allows us to comparing
all group mean pairs at the same time. Throughout the analysis, we
have specified a significance level a ¼ 0.001 and we performed
priori comparisons on the outputs derived from ANOVA test. Also,
main focus was given on the ANOVA outputs where the F test
resulted significantly. We performed the priori comparisons using
the Bonferroni t method for both orthogonal and non-orthogonal
comparisons to reduce multiplicity between group comparisons.
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The Bonferroni t method increases the critical F value needed for the
comparison to be declared significant. Data were analysed with SPSS
13.0 (Chicago, IL, USA) for Windows.
Results
Effects of contrast medium on cell
viability
As shown in Figure 1A, both LOCM and IOCM produced a
concentration-dependent decrease in cell viability as assessed by
MTS assay. This effect was identical in all the three renal cell
lines utilized (Figure 2). Indeed, the amount of cell death was signifi-
cantly higher with 200 mg iodine/mL than with 100 mg iodine/mL
of contrast at each time-point of the experiment (P ¼ 0.0025; by
paired t-test with a ¼ 0.001). There was a significant interaction
between time of exposure and the effect of CM on cell viability
(P ¼ 9.51  1025; F ¼ 5.93 by ANOVA model with a ¼ 0.001).
The toxic effect of CM was further evaluated by DNA laddering
(Figure 1B) and propidium staining and FACS analysis (Figure 1C).
Both methods confirmed that exposure of cells to LOCM and
IOCM induces apoptosis of renal cells.
The cytotoxic effect, although maximum at 3 h, was mostly
(85%) observed already at 15 min of incubation (Figure 1A). In
order to better clarify the time-dependency effect, we performed
a further control experiment in which cells were exposed for a
short period (only 15 min), then washed free of CM, and studied
for viability immediately or 3 h later, and compared these effects
to those observed upon 3 h of incubation. Interestingly, we
found that the cytotoxic effect induced by 15 min of high dose
(200 mg iodine/mL) of CM exposure was similar whether it was
observed immediately or 3 h later (cell viability: 12+ 6 vs. 13+
6%, respectively; P ¼ 1.0) (data not shown).
There was not any interaction between the cytotoxic effect and
the type of contrast used (P ¼ 0.22; F ¼ 1.87 by ANOVA model
with a ¼ 0.001). Furthermore, neither sodium iodine alone nor
hyperosmolar solution decreased cell viability or induced cell
apoptosis (Figure 2). All cell lines were exposed to the same con-
centrations of CM. On the contrary, in vivo, cell apoptosis was
mostly found in the more distal tubular cells (MDCK) which may
be exposed to higher concentrations of CM.
Role of caspases in contrast-induced
cytotoxicity
To test whether CM stimulate caspase activity, HEK 293 cells were
incubated in the presence of either LOCM or IOCM at different
time points and then the activation of caspases-8, -10, -3, -9 was
assessed by western blot (Figure 3A). Both LOCM and IOCM
caused a marked increase in caspase-3 and -9 activities at 7 h of
exposure, as assessed by the reduction of the pro-caspase form
(Figure 3A). No effect on caspases-8 and -10 was observed, thus
indicating that the CM activated apoptosis mainly through the
intrinsic, or ‘mitochondrial’, pathway (Figure 3A). This pathway of
apoptosis is regulated by Bcl2 family members. Hence, we
studied the expression of Bad and Bim, two pro-apoptotic
members of the Bcl2 family, after incubation with the CM.
Western blotting revealed that exposure to CM induce an increase
in both Bad and Bim expression (Figure 3B). Similar results were
obtained in the other cell types (data not shown).
Effects of NAC on contrast-induced
cytotoxicity
HEK 293, LLC-PK1, and MDCK cells were pre-incubated with
different concentrations of NAC and cell viability was assessed
with the cell proliferation assay. We observed a dose-dependent
protective effect of NAC on renal cells after 3 h incubation with
the high dose (200 mg iodine/mL) of both LOCM and IOCM
(P, 0.001; F ¼ 396.22 by ANOVA test; Figure 4A). As compared
to baseline, after 3 h of incubation, cell viability was ,10% in the
CM-treated cells, ,25% with the lowest (1 mM) dose of NAC,
,30% with the middle (10 mM), and approximately 80% with
the highest (100 mM) dose of NAC. There was not any interaction
between the protective effect of NAC (for dose 1 and 10 mM) and
the type of CM (P ¼ 0.75; F ¼ 0.12 and P ¼ 0.32; F ¼ 1.31,
Figure 1 Effects of contrast media on renal cell viability.
(A) HEK 293, LCC-PK1, and MDCK cells were incubated in the
presence of either 100 (low dose) or 200 (high dose) mg
iodine/mL of iobitridol or iodixanol for the indicated time. Cell
viability was then assessed with CellTiter Proliferation Assay. By
the ANOVA model and multiple comparison test, there was a sig-
nificant interaction between cell viability and time of exposure
(P, 0.001; F ¼ 285.02) and dose of contrast media (P, 0.001;
F ¼ 5.93). (B) HEK 293, LCC-PK1, and MDCK cells were incu-
bated in the presence of 200 mg iodine/mL of iobitridol or iodix-
anol for 3 h. DNA was extracted and loaded on 1.5% agarose gel.
(C ) HEK 293, LCC-PK1, and MDCK cells were incubated in the
presence of 100 and 200 mg iodine/mL of iobitridol or iodixanol
for 24, 48, or 72 h and then DNA fragmentation was measured
by flow cytometry. Data represent the mean+SD of two separ-
ate experiments performed in triplicate.
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respectively, both by ANOVA test with a ¼ 0.001).
However, results for NAC 100 mM with LOCM appears to be
slightly better for cell viability when compared with NAC
100 mM with IOCM (P ¼ 0.006; F ¼ 28.22). In order to clarify
the mechanism by which NAC prevented contrast-induced apop-
tosis, we analysed the effect of NAC pre-treatment on
Poly(ADP-ribose) (PARP), a final substrate of caspase-3. We
found that the CM induced the activation of PARP as assessed
by the marked reduction of the 116 kDa PARP pro-form. On
the contrary, NAC completely prevented this activation, suggesting
that NAC acts through the inhibition of the intrinsic pathway of
apoptosis (Figure 4B).
Effects of ascorbic acid on
contrast-induced cytotoxicity
We observed a dose-dependent protective effect of ascorbic acid
on renal cells exposed after 3 h of incubation with the high dose
(200 mg iodine/mL) of both LOCM (HEK 293: P ¼ 2.99  1025;
F ¼ 1552.67; LLC-PK1: P ¼ 0.04; F ¼ 10.85; MDCK: P ¼ 0.04;
F ¼ 18.57) and IOCM (HEK 293: P ¼ 6.43  1025; F ¼ 933.55;
LLC-PK1: P ¼ 0.02; F ¼ 16.29; MDCK: P ¼ 0.01; F ¼ 19.98)
(Figure 5A). When compared to baseline, at 3 h of incubation cell
viability was ,6% in the control group, ,15% with the lowest
(2 mM) dose of ascorbic acid, and ,60% with in both 4 mM and
Figure 2 Effects of contrast media, iodine, and mannitol on renal cells. HEK 293 (A), LCC-PK1 (B), and MCDK (C) cells were incubated in the
presence of 200 mg iodine/mL of iobitridol (IBT) or iodixanol (IXN), of iodine alone (sodium iodine, 100 and 200 mg) and 8% mannitol (hyper-
osmolar solution) for 3 h. Cell viability was then assessed with CellTiter Proliferation Assay. *P, 0.001 vs. all the other groups; (D) HEK 293,
LCC-PK1, and MDCK cells were incubated in the presence of 200 mg iodine/mL of iobitridol or iodixanol for 72 h and then DNA fragmentation
was measured by flow cytometry. Data represent the mean+SD of two separate experiments performed in triplicate.
Figure 3 Effect of contrast media on caspase activation and on Bcl2 family proteins expression. HEK 293 cells were incubated in the presence
of 200 mg iodine/mL of iobitridol or iodixanol for the indicated time. Eight micrograms of protein were loaded onto 12% SDS–PAGE gel.
(A) The membranes were incubated with anti-caspase-3, -8, -9, -10 antibodies and visualized by chemioluminescence detection. Contrast
media induced an activation of caspases-3 and -9 and not of caspases-8 and -10 as assessed by the reduction of the pro-caspase levels.
(B) Membranes were incubated with anti-Bim or anti-Bad antibodies and visualized by chemioluminescence detection. Loading control was con-
trolled with anti-b-actin.
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8 mM doses of ascorbic acid, respectively. There was a significant
interaction between the protective effect of ascorbic acid and
cell viability for both types of CM (Iobitridol: P ¼ 0.0017, F ¼
10.09, and Iodixanol: P ¼ 0.0002, F ¼ 16.46, both by the
ANOVA model).
Effects of sodium bicarbonate on
contrast-induced cytotoxicity
We did not find any protective effect of sodium bicarbonate
on HEK 293 (LOCM: P ¼ 0.53; F ¼ 0.78; IOCM: P ¼ 0.02;
Figure 4 Pre-treatment with NAC and contrast-induced cell death. (A) HEK 293 (open columns), LCC-PK1 (black columns), and MDCK
(grey columns) cells were pre-treated for 2 h with different concentration of N-acetylcysteine (NAC) as indicated (1, 10, and 100 mM) and
then incubated for 3 h with 200 mg iodine/mL of iobitridol or iodixanol. Cell viability was then assessed with CellTiter Proliferation Assay.
NAC protects the cells from contrast-induced cell death in a dose-dependent fashion (HEK 293: P, 0.001; F ¼ 143.51 with iobitridol;
P, 0.001; F ¼ 122.43 with iodixanol. LCC-PK1 cells: P, 0.04; F ¼ 12.9 with iobitridol; P, 0.03; F ¼ 14.79 with iodixanol; MDCK cells:
P, 0.006; F ¼ 41.19 with iobitridol; P, 0.01; F ¼ 25.24 with iodixanol). *P ¼ ,0.001 vs. baseline (CM2/NAC2) and [CMþ/NAC
100 mM]; †P, 0.05 vs. (CMþ/NAC 1 mM) and (CMþ/NAC 10 mM); ‡P ¼ 0.003 vs. (CMþ/NAC 100 mM); }P, 0.03 vs. (CMþ/NAC
100 mM); #P, 0.05 vs. baseline (CM2/NAC2). (B) HEK 293 cells were pre-incubated with NAC for 2 h and then incubated in the presence
of 200 mg iodine/mL of iobitridol or iodixanol for 3 h. Eighty microgram of protein was loaded onto 10% SDS–PAGE. The membranes were
incubated with anti-PARP antibody and visualized by chemioluminescence detection. PARP activation was detected by the reduction of the
116 kDa non-cleaved form of PARP. Loading was controlled with anti-b-actin.
Figure 5 Effects of ascorbic acid and sodium bicarbonate on contrast-induced cell death. HEK 293 (open columns), LCC-PK1 (black
columns), and MDCK (grey columns) were pre-treated for 2 h with different concentrations of ascorbic acid (AA) (2, 4, and 8 mM) or
sodium bicarbonate (75, 150, and 300 mM) as indicated and then incubated for 3 h with 200 mg iodine/mL of iobitridol or iodixanol. Cell via-
bility was then assessed with CellTiter Proliferation Assay. *P, 0.03 vs. (CMþ/AA 2 mMþ), †P, 0.001 vs. all the other groups.
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F ¼ 23.02); LCC-PK1 (LOCM: P ¼ 0.09; F ¼ 6; IOCM: P ¼ 0.94;
F ¼ 0.06); and MDCK (LOCM: P ¼ 0.88; F ¼ 0.13; IOCM: P ¼
0.71; F ¼ 0.38) after 3 h of incubation with the high dose of
either LOCM or IOCM. Cell viability was quite similar even in
the presence of high (300 mM) dose of sodium bicarbonate
(Figure 5B). This lack of any protective effect was similar with
LOCM and IOCM. There was no difference in pH in the
medium from the various groups (Table 1) and there was no
effect on cell viability (Iobitridol: P ¼ 0.72, F ¼ 0.33; Iodixanol:
P ¼ 0.49, F ¼ 0.73 by the ANOVA model).
Effects of co-incubation of NAC with
ascorbic acid or with sodium bicarbonate
The protective effect of NAC (100 mM) was greater than that of
ascorbic acid (8 mM) LOCM: P ¼ 1.25  1028, F ¼ 52.21; and
IOCM P ¼ 9.90  1029, F ¼ 54.03 by the ANOVA model;
Figure 6). We performed a further experiment to investigate the
effect on cell death of 2 h of NAC pre-treatment (100 mM), in
the presence of either ascorbic acid (8 mM), or sodium bicarbon-
ate (150 mM) on cell death after 3 h of incubation with the high
dose (200 mg iodine/mL) of either LOCM or IOCM. As shown
in Figure 6, the combination of NAC with another antioxidant
agent was less effective than NAC alone (P ¼ 0.95; F ¼ 0.54 by
the ANOVA test).
Discussion
The main conclusions of the present study are (i) CM induce dose-
and time-dependent renal cell apoptosis through the activation of
the intrisinc pathway, (ii) this cytotoxic effect does not seem to be
caused by iodine or osmolality 830 mOsm/L, and (iii) pre-
treatment with NAC and ascorbic acid but not with sodium bicar-
bonate prevents apoptosis in a dose-dependent fashion.
Contrast media and renal cell apoptosis
Our study confirms that the CM induce renal cell apoptosis.4–6,16–18
In order to strengthen this finding, we used three different renal
cell lines, namely, human epithelial cells (HEK 293) and two cell
lines with the characteristics of proximal and distal tubule cells
[porcine kidney proximal tubular epithelial cells (LLC-PK1) and
Madin–Darby canine kidney cells (MDCK)]. The activation of
caspase-9 and -3, but not of caspases-8 and -10 observed after
exposure to CM supports the concept that CM induce apoptosis
through the intrinsic, or ‘mitochondrial’, pathway. This finding
was also supported by the activation of PARP, a final substrate
of caspase-3. In a rat model of CIN, cellular injury of the renal
medulla consisted of extensive DNA fragmentation, which has
been attributed to medullary hypoxia.17,19 Yano et al.19 have
shown that CM induced apoptosis in the porcine tubular cell
line, LLC-PK-1, and that the injuries might be due to de-regulation
in Bax/Bcl-2 expression, followed by increases in caspases-9 and -3
activities. In agreement with these previous observations, we found
that CM induce an increase of at least two Bcl-2 pro-apoptotic
family members, i.e. Bim and Bad.20,21
Role of contrast dose and osmolality
CM induce renal cell apoptosis in a dose- and time-dependent
manner.18 Guidelines recommend to limit the volume of CM
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 pH in the various treatment groups
Group Iobitridol* Iodixanol**
Contrast media alone 7.34 (7.18–7.50) 7.25 (7.06–7.50)
Contrast media plus NAC 7.29 (6.97–7.60) 7.03 (6.96–7.10)
Contrast media plus AA 6.90 (6.80–7.01) 7.04 (7.06–7.10)
Contrast media plus NaHCO3 7.30 (7.21–7.40) 7.24 (7.08–7.50)
Values are expressed as median and interquartile range.
NAC, N-acetylcysteine; AA, ascorbic acid; NaHCO3, sodium bicarbonate.
*P ¼ 0.57 through the groups by ANOVA test, after transforming pH values into
proton Hþ concentrations.
**P ¼ 0.65 through the groups by ANOVA test after transforming pH values into
proton Hþ concentrations.
Figure 6 Effect of NAC, ascorbic acid, and sodium bicarbonate alone and in combinations on contrast-induced cell death. HEK 293 cells were
pre-treated for 2 h in the presence of N-acetylcysteine (NAC, 100 mM), ascorbic acid (AA, 8 mM), and sodium bicarbonate (NaHCO3,
150 mM) alone or in combination and then incubated for 3 h with 200 mg iodine/mL of iobitridol or iodixanol. Cell viability was then assessed
with CellTiter Proliferation Assay. *P , 0.001 vs. (CMþ/AAþ), (CMþ/NACþ), (CMþ/NACþ/AAþ), (CMþ/NACþ/NaHCO3þ), and
(CMþ/AAþ/NaHCO3þ); ‡ P , 0.001 vs. (CMþ/NACþ), (CMþ/NACþ/NaHCO3þ), and (CMþ/NACþ/AA).
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usage in order to prevent contrast-associated nephrotoxicity.22,23
It has been suggested that using the iodine dose/glomerular fil-
tration rate ratio may be a more expedient way of improving
risk assessment of CIN than the more common practice of esti-
mating CM dose from volume alone.23 After intravascular adminis-
tration of CM in rabbits, a urinary concentration higher than
100 mg/mL of iodine has been measured.12 However, we found
that the iodine alone does not cause renal cell apoptosis.
We observed that the cytotoxic effect, although maximum at
3 h, was mostly (85%) observed already at 15 min of incubation.
This suggests that even a short period of exposure activates the
cascade leading to apoptosis and therefore what is being observed
at the later time periods represents mostly the cumulative effect of
that initial exposure. This finding highlights the importance of strat-
egies limiting the exposure of the kidney to the toxins contained in
the contrast agent by generating high urine flow in patients.
The contribution of osmolality to contrast-induced apoptosis is
controversial.18,24,25 Although previous studies demonstrated that
the cytotoxicity of high-osmolality contrast media (HOCM) is
higher than that of LOCM,18 we did not find any difference in
the extent of cell injury between IOCM and LOCM. Furthermore,
the cytotoxic effect may be related to CM hypertonicity, since
equally hyperosmolal but less hypertonic urea solution failed to
induce DNA fragmentation.18 Factors other than osmolality may
contribute to the toxic effect. Ionicity and/or molecular structure
(monomeric or dimeric) may be of importance. Heinrich et al.26
demonstrated that at an equal iodine concentration, no significant
differences exist between the direct toxic effects of non-ionic
monomeric and dimeric CM on renal proximal tubular cells in
vitro. On the contrary, when comparing the data on a molar
basis, the dimeric CM showed a significantly stronger effect on
the tubular cells than did the non-ionic monomeric CM. This
suggests a greater cytotoxic effect of the dimeric CM molecules.
In the last generation of CM (which has a non-ionic, dimeric struc-
ture), iso-osmolality has been achieved at the price of an increased
viscosity. Indeed viscosity is inversely related to osmolality. High
viscous CM compromise renal medullary blood flux, renal medul-
lary erythrocyte concentration, and renal medullary pO2.
27 Our in
vitro experiments allow us to examine the cytotoxic effects of CM
on renal cells, eliminating the effects of confounding variables (e.g.
hypoxia due to haemodynamic changes or viscosity), which can be
found in vivo. Therefore, additional studies are necessary to assess
whether molecular structure and/or other components of the CM
may induce this cytotoxic effect.
Antioxidant compounds and
contrast-induced apoptosis
In the last few years, a number of clinical studies have suggested
that NAC may prevent CIN.7,8 Recently, two additional antioxidant
strategies have aroused considerable interest: sodium bicarbon-
ate10 and ascorbic acid.11 It has been hypothesized that all these
compounds may be effective due to their antioxidant properties.
Our study supports the clinical observation of the effectiveness
of NAC and ascorbic acid in preventing contrast-induced apopto-
sis. This effect is dose-dependent: indeed, the greater the dose, the
larger the cellular benefit. This finding supports the clinical
observation of the dose-dependency of NAC in preventing
CIN.8,28 The plasma level of NAC ranges from 10 mM (with a
dosing regimen of 600 mg/day) to 100 mM (with a dosing
regimen of 1200 mg BID).13,14 Of note, NAC was more effective
against contrast-induced apoptosis than ascorbic acid. In contrast,
sodium bicarbonate does not prevent contrast-induced apoptosis.
However, recent clinical studies suggest that the sodium bicarbon-
ate seems to be effective in preventing CIN.10 This discordance
may be explained by alternative mechanisms. We recently demon-
strated that the combined prophylactic strategy of sodium bicar-
bonate plus NAC, but not the combination of ascorbic acid and
NAC, is more effective than NAC alone in preventing CIN. We
speculated that NAC and ascorbic acid may work through
similar pathways while the protective action of bicarbonate may
be different in comparison to NAC and, therefore, additive.9 The
lack of benefit of the combination of NAC and ascorbic acid in pre-
venting contrast-induced apoptosis observed in the present study
supports this hypothesis. Free-radical formation is promoted by
an acidic environment typical of distal tubular urine, but is inhibited
by the higher pH of normal extracellular fluid.29 It has been
hypothesized that alkalinizing renal tubular fluid with bicarbonate10
may reduce injury. At physiologic concentrations, bicarbonate sca-
venges peroxynitrite and other reactive species generated from
nitric oxide.10 In the clinical setting, the higher concentration of
HCO3 in the proximal convoluted tubule may (i) buffer the higher
production of Hþ due to cellular hypoxia and (ii) facilitate Naþ reab-
sorption through the electrogenic Na/HCO3 co-transporter.
29 The
result of our in vitro study does not support the former mechanism.
It may be that NaHCO3 may facilitate Na
þ reabsorption: this would
mitigate the increase in sodium delivery to the macula densa induced
by CM, an effect that results in vasoconstriction of the afferent arter-
iola through the oricess of tubuloglomerular feedback. Furthermore,
in our in vitro model, NAHCO3 did not raise the pH of the media in
comparison to CM alone.
Study limitations
Hizoh et al.18 observed that NAC failed to reduce the DNA frag-
mentation rate caused by HOCM. This discordance may be
explained by (i) the lower dose of NAC utilized (10 mM) and (ii)
the use of a HOCM. Additional data are necessary to address
the issue of which CM component (other than iodine) and chemi-
cal property (such as viscosity) causes renal cell apoptosis. The
investigators who evaluated the cellular damage were not
blinded to the contrast type, the iodine dose, or the protective
strategy attempted.
In conclusion, CM induce apoptosis through the activation of the
intrinsic pathway. Pre-treatment with NAC and ascorbic acid but
not with sodium bicarbonate prevents apoptosis in a dose-
dependent fashion.
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PED-interacting protein. In this study we show that PED coadiuvates Rac1 activation by regulating AKT mediated Rac1-Ser71
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important for PED-regulated ERK 1/2 nuclear localization. Through specific Rac1-siRNA or its pharmacological inhibition, we
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DOI: 10.1002/jcp.22197PED, (phosphoprotein enriched in diabetes), also known as
PEA15, (phosphoprotein enriched in astrocytes), is a 15 kDa
protein involved in many cellular pathways, included
apoptosis and survival (Condorelli et al., 1999; Hao et al., 2001;
Ricci-Vitiani et al., 2004; Stassi et al., 2005; Garofalo et al., 2007;
Zanca et al., 2008; Peacock et al., 2009), senescence
(Gaumont-Leclerc et al., 2004), autophagy (Bartholomeusz
et al., 2008), proliferation and migration (Renault et al., 2003;
Renault-Mihara et al., 2006; Glading et al., 2007). PED function is
regulated by phosphorylation on two different serine residues:
Ser104, phosphorylated by PKC (Protein Kinase C) (Araujo
et al., 1993), and Ser116, phosphorylated by AKT/PKB (Protein
Kinase B) (Trencia et al., 2003) and CamKII (Calcium
Calmodulin Kinase II) (Kubes et al., 1998). PED is member of
Death Effector Domain (DED) containing protein family. These
domains regulate cell death through protein-protein
interaction (Valmiki and Ramos, 2009). PED inhibits DISC
(Death Inducing Signaling Complex) formation and caspase
8 activation upon death cytokines stimulation (FasL, TNFa,
TRAIL) in different cell types (Condorelli et al., 1999; Hao et al.,
2001; Garofalo et al., 2007; Zanca et al., 2008). We recently
demonstrated that PED expression is increased in B-CLL (B-cell
chronic lymphocytic leukemia) (Garofalo et al., 2007) and
non-small cell lung cancer (NSCLC) (Zanca et al., 2008), where
it mediates resistance to TRAIL (TNF-Related Apoptosis
Inducing Ligand) induced apoptosis. Moreover, PED can
contribute to apoptosis resistance to chemotherapies in breast
cancer (Stassi et al., 2005). 2 0 1 0 W I L E Y - L I S S , I N C .The molecular mechanisms that regulate PED expression in
human cancer are still unclear. Recent studies revealed that
PED expression can be regulated by several transcription
factors. Hepatocyte nuclear factor 4 alpha (HNF-4a), which is
involved in induction of apoptosis in pancreatic INS-1 beta-cell
line (Erdmann et al., 2007), negatively regulates PED expression
(Ungaro et al., 2008), while its expression is upregulated by
64 Z A N C A E T A L .Chicken Ovalbumin Upstream Promoter-Transcription Factor
II (COUP-TFII) (Ungaro et al., 2008), by vitamin D receptor
(VDR) upon vitamin D3 treatment (Obradovic et al., 2009) and
by IL-4 (interleukin-4) (Todaro et al., 2008). More recently we
demonstrated that PED expression levels in lung cancer are
regulated by microRNAs (Incoronato et al., 2010).
PED interacts with different molecules, among these ERK
1/2, altering their nuclear localization by sequestering them into
the cytosol, thus preventing their nuclear translocation
(Formstecher et al., 2001). PED augments ERK phosphorylation
acting as a scaffold protein for RSK2 and ERK 1/2 (Vaidyanathan
et al., 2007). In order to get further insights on the role of PED in
cancer, we aimed to find new PED interactors through the
tandem affinity purification (TAP) method (Rigaut et al., 1999)
in NSCLC. Upon mass spectrometry analysis, we identified
several new PED interactors.
In this article we describe the functional role of the
interaction between PED and Rac1, a member of mammalian
Rho GTPase protein family. Rac1 regulates a wide range of
cellular effects such as secretory processes, phagocytosis of
apoptotic cells, epithelial cell polarization, growth factor-
induced formation of membrane ruffles, ROS generation,
lamellipodia formation and cell migration (Bosco et al., 2009;
Heasman and Ridley, 2008). We investigate the downstream
effects of PED/Rac1 interaction, focusing our attention on cell
migration processes.
Materials and Methods
Reagents
Media, sera, and antibiotics for cell culture were from Life
Technologies, Inc. (Grand Island, NY). Protein electrophoresis
reagents were from Bio-Rad (Richmond, VA), and Western
blotting and ECL reagents were from GE Healthcare (Piscataway,
NJ). All other chemicals were from Sigma (St. Louis, MO).
Plasmids
Expression vectors for Rac wild type, RacQL, Rac12V, RasN17 and
Vav1 were kindly provided by Dr. Mario Chiariello. pBS1761 was
kindly provided by Dr. Ingram Iaccarino. PED-MYC expression
plasmid was previously described (Condorelli et al., 2002).
PED-MYC S104G was realized through AGT-GGT single
nucleotide substitution (QuikChange Site-Directed Mutagenesis
Kit, Stratagene, La Jolla, CA). ShRNAi-PED and shRNAi-scrambled
were from Open Biosystems (Huntsville, AL), GST-CRIB has been
previously described (Benard et al., 1999).
Virus production
We produced vector stocks by calcium phosphate transient
transfection, cotransfecting three plasmids in 293 T human
embryonic kidney cells, since these cells are good DNA recipients.
The three plasmids are: the packaging plasmid, pCMVDR8.74
designed to provide the HIV proteins needed to produce the virus
particle; the envelope-coding plasmid, pMD.G, for pseudotyping
the virion with VSV-G and TWEEN PED-TAP vector, the transgene
coding plasmid.
The calcium phosphate–DNA precipitate was allowed to stay on
the cells for 14–16 h, after which the medium was replaced,
collected 48 h later, centrifuged at 1,000 rpm for 5 min at room
temperature and filtered through 0.22 mm pore nitrocellulose
filters.
Generation of lentiviral vectors and gene transfer
For PED-TAP plasmid, we PCR-amplified PED cDNA from PED-
MYC expressing vector and subcloned into the pBS1761 plasmid
for TAP-tagging of proteins at the N-terminus. For TWEEN
PED-TAP vector, we PCR-amplified PED-TAP cDNA from PED-JOURNAL OF CELLULAR PHYSIOLOGYTAP expressing vector and subcloned into the lentiviral vector
TWEEN17 under control of the cytomegalovirus promoter.
On the day of infection, the medium was removed and replaced
with viral supernatant to which 4 mg/ml of Polybrene had been
added. Cells were then centrifuged in their plate for 45 min in a
Beckman GS-6KR centrifuge, at 1,800 rpm and 328C. After
centrifugation, cells were kept for either 1 h 15 min or ON in a
5% CO2 incubator at 32 or 378C, respectively. After exposure,
cells were washed twice with cold PBS and fresh medium added. At
either 12 or 48 h after the infection, cells were washed with PBS,
harvested with trypsin/EDTA and analyzed by FACS for GFP
expression.
Cell culture
Human A459, A459 TWEEN, A459 TWEEN PED-TAP and HeLa
cell lines were grown in DMEM containing 10% heat-inactivated
FBS and with 2 mM L-glutamine and 100 U/ml penicillin-
streptomycin. PEDshRNA A459 clones (A459 shPED#1 and A459
shPED #2) and SCRAMBLEDshRNA A459 clone (A459 shSCR)
were grown in DMEM medium containing 10% heat-inactivated
FBS, with 2 mM L-glutamine and 100 U/ml penicillin–streptomycin
and selected with 2.5mg/ml puromycin from Sigma.
Tandem affinity purification
A459 PED-TAP cells were lysed in TEB buffer (50 mM Tris–HCl,
pH 8, 150 mM NaCl, 5% glycerol, 1% Triton X-100, 1.5 mM MgCl2,
2 mM EGTA and protease inhibitors from Roche (Indianapolis, IN))
for 2 h under gently mix and cleared by centrifugation for 30 min at
13,000 rpm. The lysate was incubated with rabbit-IgG agarose
beads (Sigma) overnight at 48C. Beads were collected by
centrifugation (3,000 rpm for 5 min), and then extensively washed
firstly with TEB buffer and then with TEV-protease cleavage buffer
(TCB: 10 mM Tris–HCl (pH 8), 150 mM NaCl and 0.1% Triton
X-100, 0.5 mM EGTA). Beads were then incubated with 150ml TEV
protease in 1.5 mL of TCB overnight at 48C. The TEV-protease
cleavage products were collected and then loaded onto
Calmodulin sepharose beads (GE Healthcare) in Calmodulin
Binding Buffer (CBB: 10 mM Tris–HCl, pH 8, 150 mM NaCl, 0.1%
Triton X-100, 1 mM MgAcetate, 1 mM Imidazole, 2 mM CaCl2)
supplemented with 250 mM CaCl2 at 48C for 1.5 h. Beads were
recovered by centrifugation at 3,000 rpm for 5 min and then
extensively washed with CBB. Proteins retained on the beads were
eluted by incubation with Calmodulin Eluition Buffer (CEB: 10 mM
Tris–HCl, pH 8, 150 mM NaCl and 0.1% Triton X-100, 1 mM
MgAcetate, 1 mM Imidazole) with three different CaCl2
concentrations (2, 10, and 20 mM). The eluate was collected and
concentrated by methanol/chloroform precipitation before
loading onto a 12% SDS–PAGE.
Mass spectrometry analysis and protein identification
The gel was stained with colloidal Coomassie blue (Sigma). Protein
bands were excised from the gel, reduced, alkylated and digested
with trypsin (Zito et al., 2007). Peptide mixtures were extracted
from the gel and analyzed by nano-chromatography tandem mass
spectrometry (nanoLC–MS/MS) on a CHIP MS Ion Trap XCT Ultra
equipped with a capillary 1100 HPLC system and a chip cube
(Agilent Technologies, Palo Alto, CA). Peptide analysis was
performed using data-dependent acquisition of one MS scan (mass
range from 400 to 2,000 m/z) followed by MS/MS scans of the three
most abundant ions in each MS scan. Raw data from nanoLC–MS/
MS analyses were employed to query a non-redundant protein
database using in house MASCOT software (Matrix Science,
Boston, MA).
Western blotting
Total proteins from A459 and HeLa cells were extracted with RIPA
buffer (0.15 mM NaCl, 0.05 mM Tris–HCl, pH 7.5, 1% Triton,
0.1% SDS, 0.1% sodium deoxycolate and 1% Nonidet P40). Fifty
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SDS–polyacrilamide gels using a mini-gel apparatus (Bio-Rad
Laboratories, Richmond, CA) and transferred to Hybond-C extra
nitrocellulose. Membranes were blocked for 1 h with 5% non-fat
dry milk in TBS containing 0.05% Tween-20, incubated over night
with primary antibody, washed and incubated with secondary
antibody, and visualized by chemiluminescence. The following
primary antibodies were used: anti-PAP (Peroxidase-Anti-
Peroxidase Soluble Complex), anti-b-actin antibodies from Sigma,
anti-Rac1 antibody from Abcam (Cambridge, MA); anti-phospho
ser71 Rac1, anti-phospho ser104 PED, anti-ERK 1/2, anti-phospho
ERK 1/2, anti-ELK1, anti-phospho-ELK1, anti-MYC-tag antibodies
from Cell Signalling (Danvers, MA), anti-phospho ser116 PED
antibody from Biosource International Inc. (Camarillo, CA), anti-
PED antibody (Condorelli et al., 2002), anti-AU5, anti-HA
antibodies from Covance (Emeryville, CA), anti-Ras antibody from
Upstate (Temecula, CA).
Immunoprecipitation
Cells were cultured at a final concentration of 90% in p100 plates.
The cells were harvested with RIPA Buffer on a shaker for 30 min.
One milligram of total extract was immunoprecipitated using the
indicated antibodies (4mg/ml Anti-Rac1, 4mg/ml Anti-PED), for
16 h on shaker. Then, A/G beads (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) were added for two hrs. The beads were washed
for three times with washing buffer (50 mM Tris–HCl pH 7.5,
150 mM NaCl, 0.1% Triton, 10% glycerol), and then 20ml of sample
buffer was added; the samples were boiled at 1008C for 5 min and
then the supernatants resolved by SDS–PAGE.
siRNA and plasmid transfection
A459 cells were cultured to 80% confluence and transiently
transfected using LIPOFECTAMINE 2000 (Invitrogen, Carlsbad,
CA) with 150 nM anti-PED siRNAs and anti-Rac1 siRNAs
(Dharmacon, Lafayette, CO), or with control vector, PED, PED
S104G, Rac, RacQL, Rac12V, Vav1 cDNAs as reported in the
paper, as described in the manufacturer’s protocol.
Rac1 pull-down assay
Plates were starved for 24 h and then treated as indicated. After a
quick wash with iced-cold PBS, cells were lysed with GST-Fish
buffer (50 mM Tris–HCl ph 7.4, 2 mM MgCl2, 1% NP-40, 10%
glycerol, 100 mM NaCl, 1mg/ml leupeptin, 1mg/ml pepstatin, 1mg/
ml aprotinin, 1 mM PMSF, and 2 mM DTT). After 10 min at 48C
under agitation, cells were scraped and lysates were cleared by
centrifugation in a precooled rotor. One hundred fifty micrograms
of total protein extract was mixed with 10mg of GST-PAK-CRIB
domain coupled to glutathione-sepharose beads and incubated
30 min at 48C under agitation. Beads were then rinsed three times
rapidly with 1 ml of iced-cold GST-Fish buffer. The amounts of total
Rac and Rac-GTP were estimated by immunoblot against Rac1.
Migration assay
Transwell Permeable Supports, 6.5 mm diameter inserts, 8.0mM
pore size, polycarbonate membrane (Corning Incorporate,
Corning, NY) were used to perform migration assay. A459 and
HeLa cells were grown as indicated above, then harvested by
TrypLETM Express (Invitrogen) and 105 cells were washed three
times and then resuspended in 1% FBS containing DMEM medium
and seeded in the upper chamber. Lower chamber of the Transwell
was filled with 600ml of culture medium containing 10% FBS,
5mg/ml fibronectin, as an adhesive substrate. Cells were incubated
at 378C for 24 h. Transwell were then removed from 24-well plates
and stained with 0.1% Crystal Violet in 25% methanol.
Nonmigrated cells were scraped off on the top of the Transwell
with a cotton swab. % of migrated cells was evaluated by eluiting
crystal violet with 1% SDS and reading the absorbance at
l¼ 570 nm.JOURNAL OF CELLULAR PHYSIOLOGYInvasion assay
A similar procedure as in migration assay was used. The upper
chamber of the Transwell was filled with 100ml of BD MatrigelTM
(BD Biosciences, San Jose, CA). BD MatrigelTM was diluted to
1mg/ml in serum free culture medium and put into the top of the
Transwell. Then it was incubated for 4 h for gelling. Cells were
counted and treated as indicated above. Invaded cells were
measured as % over control cells, transfected with empty vector.
Wound healing
Cells were cultured as confluent monolayers, synchronized in
1% FBS for 24 h, and wounded by pipette tip. Wounded monolayers
were washed twice with PBS to remove nonadherent cells. Wound
healing was followed up to 24 h. For these studies, cells were
seeded in 35 mm Petri dishes and kept at 378C in a humidified
atmosphere with 5% CO2.
Adhesion assay
4 105 cells were plated onto Fibronectin coated 96-well plate and
incubated at 378C with 5% CO2 for 30 min. Then cells were fixed
with 4% PFA for 20 min at RT and stained with 0.1% Crystal Violet
in 25% methanol. % of adherent cells was evaluated by eluiting
crystal violet with 1% SDS and reading the absorbance at
l¼ 570 nm.
Microscope image acquisition
Cells were fixed with 4% PFA for 20 min, blocked with 1% BSA and
incubated with rhodamine-labeled phalloidin (Sigma). Fluorescent
images of cells were captured on Confocal Laser Scanner
Microscope LSM510 (Carl Zeiss MicroImaging, Thornwood, NY).
(Objective lens: plan-apochromat 63/1.4 oil dic).The samples
were hold at room temperature. The acquisition software was
Zeiss LSM510 Version 2.8 and the image was adapted using
Photoshop1 imaging software.
Results
PED interacts with Rac1
In order to discover new PED interactors, A459 cells were
infected with the tween PED-TAP construct or, as control,
tween vector. Total protein lysate was incubated with
immunoglobulin derivatised agarose beads (IgG) and the
retained sample eluted by hydrolysis with TEV protease. PED
containing complexes were finally purified onto Calmodulin
derivatised beads. After these two purification steps, the
sample and the control were fractionated by SDS–PAGE, the
entire lanes from the gel were cut in slices and each gel slice was
submitted to the identification procedure (Fig. 1A,B) (Pisa et al.,
2009). The resulting peptide mixtures were directly analyzed by
mass spectrometry (LC–MS/MS) and identified by MASCOT
protein database search. Proteins identified in both the control
and the sample lanes were discarded, whereas those proteins
solely identified in the sample and absent in the control were
selected as putative PED interactors.
Several new candidate proteins were identified (data not
shown) and among these we focused our attention on Rac1,
because of its involvement in cancer signaling pathways. PED
and Rac1 interaction was also confirmed by
immunoprecipitation experiments from A459-tween PED-TAP
cells (Fig. 1C), from A459 transfected with Rac1 (Fig. 1D) and
from wild type A459 cells (Fig. 1E). PED and Rac1 co-
immunoprecipitation was evident either with exogenous or
with endogenous proteins.
PED affects Rac1 activation
In order to investigate the effects of PED on Rac1 activation,
A459 cells were transfected with PED-MYC cDNA or control
Fig. 1. PED interacts with Rac1. A459 cells infected with PED-TAP cDNA has been subjected to tap purification as described in the method’s
section. A: Samples from Tandem Affinity Purification collected at each step of the protocol. Lanes: (1) 40mg of total extract; (2) 40mg of
supernatant after IgG incubation; (3) TEV cleavage control; (4) IgG beads after TEV cleavage; (5) supernatant after Calmodulin beads; (6)
Calmodulin beads before final eluition; (7,8) eluition with 2, and 10 mM EGTA. B: Coomassie staining of preparative polyacrilamide gel. Our
PED-CBP bait is indicated at 23 kDa. A459 cells infected with TWEEN vector were used as negative control. C: Co-immunoprecipitation of
endogenous Rac1 with exogenous PED-TAP. One milligram of total extract immunoprecipitated using an anti-Rac1 antibody.
Immunoprecipitatedandinputsampleswereloadedon12%SDSpolyacrilamidegelandblottedwithanantibody(PAP)toidentifytheexternalpart
of the TAP tag. As negative control (C), proteins were incubated with beads without antibody. D: Co-immunoprecipitation of endogenous PED
with exogenous Rac-AU5 tagged. E: Co-immunoprecipitation between endogenous PED and Rac1. Samples from A459 wild type cells were
immunoprecipitated with anti-PED antibody. Samples incubated with beads only were used as negative control for each immunoprecipitation.
66 Z A N C A E T A L .vector. After 24 h cells were serum starved for 16 h and then
treated with 20% FBS for 5 or 15 min. The activity of Rac1 was
assessed using the p21-binding domain (CRIB) of p21-activated
kinase 1 (PAK1) in a GST-pull down assay (Benard et al., 1999).
As shown in Figure 2A, after 5 min of stimulation, a larger
amount of Rac1-GTP could be observed in PED overexpressing
cells, compared to the control cells, transfected with an empty
vector. This activation decreased after 15 min. Similar results
have been obtained upon EGF stimulation, a Rac1 specific
activator (Dise et al., 2008), with a similar kinetics
(Supplementary Data, Fig. S1).
Mechanisms of PED-mediated Rac1 activation
The removal of bound GDP and the subsequent GTP loading
are catalyzed by guanine nucleotide exchange factors (GEFs
proteins) (Bernards and Settleman, 2007). We therefore asked
whether PED could act as a scaffold protein in Rac1 activation
by promoting the interaction between Rac1 and its GEFs. A459
cells were transfected with PED-MYC cDNA, starved for 24 h
and then incubated for 16 h with 100mM of NSC23766, a Rac1
GTPase specific inhibitor that inhibits GEFs binding to Rac1
(Gao et al., 2004). Subsequently cells were treated with 20%
FBS for 5 min and Rac1-GTP pull down assay was performed. As
shown in Figure 2A, PED overexpression increased Rac1JOURNAL OF CELLULAR PHYSIOLOGYactivation upon serum stimulation. However, this effect was
inhibited by pretreating cells with NSC23766 (Fig. 2B),
suggesting that Rac1 is activated by PED through a mechanism
involving GEFs action. Since PED can stimulate Ras activation,
thereby promoting Rac activation, A459 were transfected with
empty vector, PED or RasN17 dominant negative cDNAs,
starved for 24 h and then Rac1-GTP pull down assay was
performed as shown in Figure 2C. RasN17 transfection did not
alter PED-induced Rac1 activation.
Role of PED in AKT-mediated Rac1 phosphorylation
AKT is serine/threonine kinase downstream PTEN/PI3K
pathway involved in many cellular processes, for example,
survival, apoptosis and migration (Tokunaga et al., 2008). AKT
phosphorylates Rac1 on Ser71 and thus inhibits its GTP-loading
(Kwon et al., 2000). Because PED interferes the Rac1-GTP
loading, we asked whether this effect was mediated through the
regulation of Rac1 phosphorylation on Ser71. To this aim, A459
cells were transfected with control vector or PED-MYC cDNA.
After 24 h, the cells were serum starved and then treated for
5 min with 20% FBS. As shown in Figure 2D, PED
overexpression resulted in a strong reduction of serum
mediated Rac1 phosphorylation on Ser71. Similar results were
obtained with EGF stimulation (Supplementary Data, Fig. S2).
Fig. 2. PED regulates Rac1-GTP loading. A–C: Rac pull down experiments. A: A459 cells were transfected with 2mg empty vector as control or
2mgPED-MYC cDNAas indicated. After24 hcells wereserumstarvedandthentreated for5and15 minwith20% FBSrespectively. Rac1-GTP pull
down assay was performed as described in Materials and Methods Section. The amounts of total Rac1 and Rac1-GTP were estimated by
immunoblotting with Rac1. B: Cells were transfected as described and then treated with 20% FBS stimulation, with or without 100mM NSC23766
pretreatment for 16 h as indicated. C: A459 cells were transfected with 2mg of PED, Ras17N cDNAs or control vector, then starved for 24 h and
treatedwith20%FBS.Then150mgoftotal lysatewassubjectedtoRac1-GTPpulldownassay.D:A459cellsweretransfectedwith2mgofPEDcDNA
or control vector, then starved for 16 h and treated as indicated. The phosphorylation of Rac1 was evaluated by immunoblotting with specific
phospho Ser71 Rac1antibody. E: Evaluation ofRac1phosphorylation levels upon transfection with 2mgof PED-MYC or AKT DR.The total amount
of transfected plasmids is normalized with co-transfection of empty vector. PED cDNA expression inhibits AKT-induced Ser71 Rac1
phosphorylation upon serum stimulation.
C E L L M O T I L I T Y A N D P E D / E r k / R a c 1 P A T H W A Y 67To further confirm this observation, we evaluated basal Rac1
phosphorylation levels in A459 cells transfected with a
constitutive active AKT (AKT Dþ) (Stassi et al., 2005) and
PED-MYC cDNAs (Fig. 2E). AKT Dþ increased Rac1-Ser71
phosphorylation, while co-transfection of AKT Dþ and PED-
MYC cDNAs resulted in a reduction of Rac1 phosphorylation
levels. These results suggest that PED can enhance Rac1-GTP
bound state by interfering with AKT-mediated Rac1
phosphorylation.
Effects of Rac1 activation on PED phosphorylation status
We also asked whether Rac/PED interaction could result in a
Rac-1 modulation of PED cellular function. In order to be
recruited to the DISC and inhibit the apoptotic process, PED
needs to be phosphorylated in Ser104 and Ser116 (Condorelli
et al., 1999; Trencia et al., 2003). On the other hand, in its
non-phosphorylated status PED can bind and sequester ERK
1/2 into the cytosol (Renganathan et al., 2005; Glading et al.,
2007). Therefore we asked whether Rac1 could alter PED
phosphorylation status and thus its function. To this aim, we
transfected A459 cells with wild type Rac or constitutively
active Rac (RacQL) cDNAs. Interestingly, PED-Ser104
phosphorylation was increased upon transfection of wild type
Rac and more strongly by RacQL compared to control, while
Serine116 phosphorylation was not modified (supplementaryJOURNAL OF CELLULAR PHYSIOLOGYdata, Fig. S3). Furthermore, Ser104-PED phosphorylation was
also increased by transfection with another constitutively active
Rac (Rac12V) and with Vav1 overexpression, one of Rac1 GEFs
(Crespo et al., 1997; Fig. 3A). Because PKC is the major kinase
involved in PED-Ser104 phosphorylation (Araujo et al., 1993;
Renganathan et al., 2005), we investigated whether Rac1 may
regulate PED phosphorylation through PKC. To this aim, A459
cells were transfected with constitutively active Rac and then
treated with 108 nM Ro-32-0432, a cell-permeable and
selective PKC inhibitor. PED phosphorylation levels on
serine 104 were evaluated by blotting with specific anti-
phospho-serine 104 PED antibody. As shown in
Figure 3B, RacQL-mediated PED phosphorylation was
completely abolished when the cells were treated with the PKC
inhibitor. These results suggest that Rac1 augments PED
phosphorylation on serine 104 by regulating PKC activity.
Role of PED and Rac1 interaction on ERK 1/2 activation
In order to investigate the downstream effects of PED and Rac1
interaction, we investigated ERK 1/2 pathway. PED can
promote ERK 1/2 phosphorylation and is able to retain them
into cytosol and thus avoiding their nuclear translocation and
thus their transcriptional effects (Renganathan et al., 2005;
Glading et al., 2007). The mechanism by which PED allows ERK
1/2 phosphorylation is not clear yet. Rac1 activation leads to
Fig. 3. Rac1 activation induces PED-Ser104 phosphorylation. A:
A459 cells were transfected with control vector, Rac, RacQL, Rac12V
or Vav1 respectively. Expression of constitutively active Rac resulted
in a strong increase of Ser104–PED phosphorylation, as attested by
immunoblotting with specific Ser104–PED antibody, compared to
empty vector and wild type Rac. B: A459 cells were transfected with
2mg of RacQL and then treated with 108 nM PKC inhibitor Ro-32-
0432 for 16 h. PKC inhibition resulted in abolishment of Rac-induced
Ser104–PED phosphorylation. C: A459 cells were transfected with
control vector, PED, PED S104G or RacQL. Then cells were starved
for 16 h and treated with 20% FBS. Expression of PED and Rac-QL
resulted in an increase of ERK 1/2 phosphorylation and ELK1
activation upon serum stimulation.
68 Z A N C A E T A L .ERK 1/2 phosphorylation through a pathway involving PAK1-
MEK1-ERK1/2 (Eblen et al., 2002; Alahari, 2003). To determine
the effect of PED and Rac1 interaction on ERK 1/2 activation, we
transfected A459 cells with control vector, PED-MYC or
RacQL cDNAs and then evaluated the downstream effects on
ERK 1/2 phosphorylation. PED and RacQL alone were able to
activate ERK 1/2. Interestingly, when PED and RacQL were
co-transfected the levels of ERK 1/2 phosphorylation were
even stronger (Fig. 3C). As previously described (Glading et al.,
2007), we found that PED transfection resulted in an inhibitory
effect on ERK 1/2 nuclear translocation, as attested by the
reduction of the phosphorylation of their nuclear substrate
ELK1 (Hill and Treisman, 1995; Reddy et al., 2003; Fig. 3C). On
the contrary, when PED was overexpressed together with
RacQL, ELK1 phosphorylation was stronger compared to
control. In order to evaluate whether this effect was due to
Rac1-induced phosphorylation on PED Serine 104, we
generated a mutant PED protein which could not be
phosphorylated in Ser104 (S104G PED). Interestingly,
transfection of S104G PED mutant, alone or co-transfected
with RacQL, abolished the phosphorylation of ELK1 (Fig. 3C).
These results suggest that PED, upon Rac-induced Ser104
phosphorylation, loses its capability to retain ERK 1/2 into
cytosol and thus to phosphorylate ELK1, while itsJOURNAL OF CELLULAR PHYSIOLOGYunphosphorylable mutant S104G retains ERK 1/2 into cytosol,
even in the presence of constitutively active Rac.
Role of PED on cell migration
One of the most important effects of the activation of ERK1/2
pathway is regulation of cellular migration and invasion (Reddy
et al., 2003). For this reason we asked whether PED/Rac1
interaction was involved in these phenomena. Overexpression
of PED-MYC resulted in increased migration and invasion of
A459 cells. The effect was similar to that obtained with
constitutive active Rac (Fig. 4A). When PED-MYC and RacQL
were cotransfected, the effects on cell migration and invasion
were even stronger. Similar results were obtained by
transfecting the same constructs into HeLa cells (data not
shown). Moreover, unphosphorylable S104G PED mutant was
able to inhibit both cell migration and invasion, even when
co-transfected with constitutively active Rac (Fig. 4A). These
results suggest that RacQL effects on PED phosphorylation may
regulate its effects on migration/invasion.
To determine the pathway involved in the regulation of
PED-mediated migration and invasion, PED overexpressing
A459 cells were treated with Rac1 inhibitor NSC23766, PKC
inhibitor Ro-32-0432 or MEK1 inhibitor U0126 for 16 h.
PED-MYC transfected cells lost their capability to migrate and
invade upon treatment with all the inhibitors used (Fig. 4B),
suggesting that PED requires either Rac1, PKC and MEK1
activity to promote migration and invasion. To confirm Rac1
involvement in PED-mediated cell migration and invasion, we
down-regulated Rac1 by transfection of specific siRNAs and
then we tested cell migration and invasion in A459 cells. Upon
Rac1 downregulation, PED lost its effects on cell migration and
invasion (Fig. 4C). These results show for the first time that PED
expression promotes cell migration and invasion through a
mechanism involving the activation of Rac1, PKC and MEK1.
Effects of PED downregulation on cell migration
In order to evaluate the direct effect of PED on cell migration
and invasion processes, we performed migration assays on PED
knock down clones A459 ShPED#1 and A459 ShPED#2. As
attested by western blotting analysis, we obtained a strong
reduction of PED expression upon silencing, compared to the
scrambled ShRNA clone (A459 ShSCR; Fig. 5A). PED silencing
resulted in a reduction of cell capability for adhering, migrating
and invading compared to control cells (Fig. 5A). Interestingly,
PED knock down clones failed in Rac1-activation upon serum
stimulation, as shown in Figure 5B.
Moreover, reduction of migration capability was also
confirmed by wound healing assay, where the cells were
induced to repair upon serum stimulation (Fig. 5C). We next
analyzed F-actin structures in PED knock down clones using
Rhodamine-conjugated phalloidin. Interestingly, as show in
Figure 5D, cellular morphology of PED knock down clones was
strongly altered, with the increase of cortical actin structures
and rounder, less elongated phenotype. These data support the
pivotal role of PED in regulating cell shape and migration
processes in A459 cells.
Discussion
Several observations support the important role of PED in
human cancer. PED, being a member of DED protein family
(Valmiki and Ramos, 2009), induces resistance to TRAIL, FasL,
TNFa-mediated death in cancer cells (Condorelli et al., 1999;
Hao et al., 2001; Ricci-Vitiani et al., 2004; Garofalo et al., 2007;
Zanca et al., 2008; Valmiki and Ramos, 2009), making therapy
often ineffective. PED is overexpressed in many types of human
cancer, among which lung cancers. The ability of PED to bind
ERK 1/2 was the focus of many studies indicating that PED
Fig. 4. Pathways of PED-mediated migration and invasion. A: A459 cells were transfected with control vector, PED, PED S104G or mutant
RacQL, and Transwell migration and invasion assay was performed as described in Materials and Methods Section. Percentage of migrated cells is
indicated as increase/decrease compared to control sample. B: A459 cells were transfected with control vector or PED cDNA. Then cells were
plated on Transwell chambers to perform migration and invasion assays and treatedwith Rac1, PKC and MEK1 inhibitors (NSC23766, Ro-32-0432
andU0126respectively).Migratedcellswereevaluated24 hlater.Cellswerestainedin25%methanoland0.1%crystalviolet.Thenitwaselutedwith
1%SDSandthemigrationratewasestablishedbyreadingabsorbanceatlU 570 nm.(C)A459cellsweretransfectedwithcontrolvector,PED-MYC
and Rac1-siRNAs. Rac1 downregulation was evaluated by immunoblotting with Rac1 antibody. Transwell chambers were used to perform
migration and invasion assays. 105 cells were plated onto the upper chamber of Transwell and cells were incubated for 24 h. Rac1 downregulation
blocked PED-mediated migration and invasion. Each assay was performed three times in independent experiments (n U 3). Error bars indicate
standard deviation.
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translocation and thus ERKs nuclear effects, included
transcription, migration, invasion (Ramos et al., 2000;
Formstecher et al., 2001; Condorelli et al., 2002; Gaumont-
Leclerc et al., 2004; Renganathan et al., 2005; Glading et al.,
2007). PED is also able to bind RSK2 in a phosphorylation-
regulated manner and act as a scaffold protein to strengthen its
role in ERK activation (Vaidyanathan et al., 2007). In order to
give new insights in PED’s role in cancer, in this article we aimed
to find new PED interactors. We performed a two steps
purification method, the tandem affinity purification method for
protein complexes characterization (Rigaut et al., 1999) and
identified several new candidate partners of PED, one of which
was Rac1. We first confirmed the interaction between PED and
Rac1 through independent immunoprecipitation experiments,
using both exogenous and endogenous proteins. In order to
investigate the effect of PED on Rac1 GDP/GTP bound state, we
performed a GST-pull down assay using the p21-binding domain
(CRIB) of p21-activated kinase 1 (PAK1) to isolate the active
GTP-bound Rac1 from the total extract (Benard et al., 1999).JOURNAL OF CELLULAR PHYSIOLOGYWe demonstrated that PED augmented GTP-bound state upon
stimulation with both 20% serum and specific Rac1 activator as
EGF (Supplementary Data, Fig. S1) in a mechanism probably
involving GEFs action. Even though our data show that GEFs
action is necessary for Rac activation, we suggest that PED does
not act as a scaffold protein in promoting GEFs-Rac1 binding,
since in co-immunoprecipitation experiments, PED could not
bind neither Tiam1 nor TrioN, two of the most abundant Rac1
GEFs (Bernards and Settleman, 2007). Moreover, we did not
identify any GEFs from tandem affinity purification analysis and
mass spectrometry experiments that bind to PED. Therefore,
the mechanism of GEF involvement needs to be clarified. Since
it was reported that AKT inhibits Rac1 activation (Kwon et al.,
2000), we hypothesize that PED promotes GTP loading to Rac1
by reducing AKT inhibitory effects on Rac1, thus allowing its
binding with GEFs. Our data are supported by the finding that
PED downregulation in two stable knock down clones resulted
in 30% increase in Rac1 phosphorylation, compared to control
cells (Supplementary Data, Fig. S4). PED is AKT substrate
(Trencia et al., 2003) and reduces AKT-mediated
Fig. 5. Effects of PED downregulation on cell migration and cell morphology. A: A459-PED KO clones, obtained with transfection of specific
PEDshRNA vector and then selected with 2.5mg/ml of Puromycin. PED downregulation was evaluated by immunoblot against PED. Two clones
wereobtainedandareindicatedasShPED#1andShPED#2.ControlShRNAcells is indicatedasShSCR.A459-PEDKOclonesshowedareductionof
migration, invasion and adhesion upon serum stimulation, compared to control cells expressing Scrambled shRNA (ShSCR). Each assay was
performedthreetimes in independentexperiments(n U 3).Errorbars indicatestandarddeviation.B:ShSCR,ShPED#1andShPED#2A459clones
were serum starved for 24 h and then treated with 20% FBS for 5 min. Cells were subjected to Rac1-GTP pull down assay in order to evaluate the
amount of activated Rac1. Rac1-GTP was detected by blotting with Rac1 antibody. Total lysate was examined by western blotting to exclude
variations in the total amount of Rac1. C: Wound healing assay of A459 ShSCR cells and PED shRNA clones (ShPED#1 and ShPED#2). Cells were
grown to confluence and then wound was performed using a pipette tip. Then cells were incubated and grown for 24 h. D: Analysis of cell
morphology. Cells were fixed with 4% PFA for 20 min, blocked with 1% BSA and incubated with rhodamine-labeled phalloidin.
70 Z A N C A E T A L .phosphorylation of Rac1 probably competing with Rac1 for
AKT binding or through a direct binding to the AKT binding site
of Rac1. Many evidences show that AKT and its regulatory
pathway can sustain migration process of tumor cells
(Tokunaga et al., 2008; Garofalo et al., 2009) and then it was also
found to be activated in vivo in human lung cancers (Mukohara
et al., 2003; Balsara et al., 2004). Our observations, coupled
with the AKT-mediated increased stability of PED (Trencia
et al., 2003), gives new insights of the mechanism by which AKT
augments cell migration/invasion: that is, increasing PED levels
which promotes Rac1 activation.
Moreover, PED and Rac1 interfered with each other’s
function once bound together. In facts, when Rac1 is active,
promotes PED Ser104 phosphorylation, through a mechanism
involving PKC activation. The mechanism through which Rac1
promotes PKC-dependent PED phosphorylation is under
investigation in our lab.
PED and Rac1 are involved in many cellular processes. To
understand the biological meaning of their interaction we
focused on the regulation of ERK 1/2 activation status as well as
their cellular localization. We observed that co-expression of
PED and constitutively active Rac induced a strong ERKs
activation as well as Elk-1 phosphorylation (Hill and Treisman,JOURNAL OF CELLULAR PHYSIOLOGY1995), indicating that ERKs were able to translocate from the
cytosol into the nucleus. We propose that PED alone
coadiuvates Rac1-mediated ERKs activation and the expression
of active Rac facilitates PED phosphorylation on Ser104 and the
consequent release of ERKs. In fact, PED Ser104 mutant
blocked ELK phosphorylation when co-expressed with RacQL.
Interestingly, EGFR/K-Ras activating mutations, an upstream
regulator of Rac1 (Yip et al., 2007), often found in human
NSCLC (Slebos et al., 1990; Mukohara et al., 2003), can
contribute to the activation of Rac1 and thus promote the
Rac1-mediated PED phosphorylation.
In this article we demonstrated that PED is involved in
promoting cell migration and invasion. Previous findings
described that PED mediated inhibition of cell migration/
invasion (Renault-Mihara et al., 2006; Glading et al., 2007). Our
data suggest that Rac1’s effects on PED phosphorylation
determine a reduction of PED’s inhibitory role of ERK 1/2
nuclear translocation, which is required to promote migration/
invasion (Hill and Treisman, 1995; Reddy et al., 2003). The
importance of PED in controlling of ERK 1/2 localization was
recently highlighted in a study in which PED, according to its
phosphorylation status, is one of the main regulator of ERK 1/2
activity in response to treatment of EGF or NGF during
C E L L M O T I L I T Y A N D P E D / E r k / R a c 1 P A T H W A Y 71neuronal differentiation (von Kriegsheim et al., 2009).
Moreover Haling et al. proposed that PED could sustain ERK
1/2 activation by regulating FRS2alpha phosphorylation status
by retaining ERK 1/2 within the cytosol and preventing their
localization to plasma membrane (Haling et al., 2009). Ramos
et al. previously reported that PED activates ERK MAP Kinase
through a Ras-dependent pathway (Ramos et al., 2000). In our
experiment we found that PED-mediated Rac1-activation is
independent from Ras activity. PED-Rac1 interaction gives a
new explanation of how PED can mediate its effects on MAPK
signaling.
In order to clarify PED role in migration and invasion
processes, we generated two stable A459 PED knock down
clones and evaluated the adhesion, migration and invasion
capabilities of the cells. We found that PED silencing reduced
these phenomena. Cell shape of PED knock down clones was
strongly altered compared to control cells. In fact, cell showed a
rounder and less elongated shape, as well as cortical actin
structures, in accordance with a reduced migratory capability.
Cells need multiple protrusions and well-organized lamellipodia
structures to migrate (Petrie et al., 2009). The actin based
cytoskeleton structures are dynamically controlled by several
stimuli and Rac1 is one of the main effectors of this process,
acting in the generation of focal adhesions and lamellipodia
(Ridley et al., 1992; Machesky, 1997; Nobes and Hall, 1999;
Heasman and Ridley, 2008; Bosco et al., 2009). The lost of these
structures in PED knock down cells correspond to a reduced
Rac1 activity. Furthermore, similar phenotypes can be observed
in Rac1 deficient fibrosarcoma cells HT1080, endothelial cells
or platelets, that show an impairment in lamellipodia formation
(McCarty et al., 2005; Heasman and Ridley, 2008; Tan et al.,
2008; Niggli et al., 2009) supporting the role of Rac1 in
migration process.
Our findings about PED interactome demonstrate that PED
overexpression is linked to cancer not only because of its anti-
apoptotic role but also because this promotes migration and
invasion of malignant cells.
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